



Vineet Laboratories Limited

**9th Annual Report
2024-25**

Corporate Information

<p>CIN L24304TG2016PLC112888</p> <p>BOARD OF DIRECTORS</p> <p>Mr. Dilip Vishnu Acharekar (DIN: 08849689) - Non-Executive - Independent Director - Chairman</p> <p>Mr Gaddam Venkata Ramana (DIN: 00031873) - Managing Director</p> <p>Mr Satyanarayana Raju Bhupathiraju (DIN: 02697880) - CFO & Whole-time Director</p> <p>Mr. Bhaskara Reddy Karna (DIN: 08961904) - Non-Executive - Independent Director - <i>Resigned w.e.f. November 14, 2024</i></p> <p>Ms. Hari Priya Yerukalapudi (DIN: 09690829) - Non-Executive - Independent Director</p> <p>Mr. Alluri Ranga Raju (DIN: 10044882) - Non-Executive Director</p> <p>Mr. Satish Pandurang Samant (DIN: 10294920) - Executive Director & CEO - <i>Appointed w.e.f October 16, 2023; Resigned w.e.f. May 29, 2024</i></p> <p>COMPANY SECRETARY</p> <p>CS Ramesh Kumar Bandari</p> <p>REGISTERED OFFICE</p> <p>Sy. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500 074</p> <p>CORPORATE OFFICE</p> <p>5-5-160, Malleswari Nilayam, Opp. Vishnu Theatre, Chintalkunta, L.B Nagar, Hyderabad, Telangana-500 074</p> <p>CONTACT DETAILS</p> <p>040-24128833; cs@vineetlabs.co.in</p>	<p>WEBSITE https://www.vineetlabs.co.in</p> <p>MANUFACTURING & PRODUCTION FACILITY (WORK UNIT)</p> <p>Sy.No.300, Malkapur Village, Choutuppall Mandal, Yadadri Bhuvangir Dist, Telangana - 508252</p> <p>STATUTORY AUDITORS M/s. NSVR & Associates LLP Chartered Accountants Hyderabad</p> <p>SECRETARIAL AUDITORS M/s. P. S. Rao & Associates Company Secretaries Hyderabad</p> <p>INTERNAL AUDITORS M/s. V D P & Co Chartered Accountants Hyderabad</p> <p>BANKER</p> <p>HDFC Bank Limited</p> <p>REGISTRAR AND SHARE TRANSFER AGENTS</p> <p>Venture Capital and Corporate Investments Private Limited</p> <p>Address: "AURUM", D No.4-50/P-II/57/4F & 5F, 4th & 5th Floors, Plot No.57, Jayabheri Enclave, Phase - II, Gachibowli, Serilingampally, Hyderabad - 500 032. Ranga Reddy Dist., Telangana.</p> <p>LISTED WITH</p> <p>BSE Limited (BSE); National Stock Exchange of India Limited (NSE)</p>
---	--

NOTICE

Notice is hereby given that the 9th Annual General Meeting (“AGM”) of Vineet Laboratories Limited will be held on Thursday, September 25, 2025 at 11:00 A.M. at SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana – 500 074 (IST) through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”) to transact the following businesses:

ORDINARY BUSINESS:

1. To receive, consider, and adopt the Audited Financial Statement for the financial year ended on March 31, 2025

To receive, consider, and adopt the Audited Financial Statement of the Company for the financial year ended on March 31, 2025 together with the Reports of the Board of Directors and the Auditors thereon and, in this regard, to consider and if thought fit, to pass the following resolution as Ordinary Resolution:

“RESOLVED THAT the audited financial statement (standalone) of the Company for the financial year ended on March 31, 2025 and the reports of the Board of Directors and the Auditors thereon, as circulated to the members, be and are hereby considered and adopted.”

2. To appoint Gaddam Venkata Ramana (DIN: 00031873), who retires by rotation as a director

In this regard, to consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

“RESOLVED THAT Gaddam Venkata Ramana (DIN: 00031873) be and is hereby appointed as a Director of the Company, liable to retire by rotation.”

SPECIAL BUSINESS:

3. To ratify the remuneration of Cost Auditors for the financial year 2025-26

To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 and all the other applicable provisions of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of Rs.60,000/- (Rupees Sixty Thousand Only) excluding applicable taxes and out-of-pocket expenses, as approved by the Board of Directors of the Company, to be paid to M/s KJU & Associates., Cost Accountants (Registration No. 000474), the Cost Auditors appointed by the Board of Directors, to conduct the audit of cost records of the Company for the financial year ending March 31, 2026, be and is hereby ratified.”

4. To appoint Secretarial Auditors of the company

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to Section 204 and other applicable provisions, if any, of the Companies Act, 2013, Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Regulation 24A of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements)

Regulations, 2015, other applicable laws/statutory provisions, if any, as amended from time to time, P S Rao & Associates, Practising Company Secretaries (Unique Identification Number P200ITL078000) be and is hereby appointed as the Secretarial Auditors of the Company for term of five consecutive years commencing from financial year 2025-26 till financial year 2029-30, at such fees, plus applicable taxes and other out-of-pocket expenses as may be mutually agreed upon between the Board of Directors of the Company and the Secretarial Auditors."

5. To approve material related party transactions with Vineet Life Sciences Private Limited and Organo Metallics Private Limited

To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, ("SEBI Listing Regulations"), the applicable provisions of the Companies Act, 2013 ("Act") read with Rules made thereunder, other applicable laws/statutory provisions, if any, (including any statutory modification(s) or amendment(s) or re-enactment(s) thereof, for the time being in force), the Company's Policy on Related Party Transactions, and subject to such approval(s), consent(s), permission(s) as may be necessary from time to time and basis the approval and recommendation of the Audit Committee and the Board of Directors of the Company, the approval of the Members of the Company be and is hereby accorded to the Company to enter into and/or continue the Material Related Party Transaction(s)/Contract(s)/Arrangement(s)/Agreement(s) (whether by way of an individual transaction or transactions taken together or series of transactions or otherwise) with entities falling within the definition of 'Related Party' under Section 2(76) of the Act and Regulation 2(1)(zb) of the SEBI Listing Regulations, on such material terms and conditions as detailed in the explanatory statement to this Resolution and as may be mutually agreed between related parties and the Company, for financial year 2025-26, such that the maximum value of the Related Party Transactions with such parties, in aggregate, does not exceed value as specified under each category for each financial year, provided that the said contract(s)/arrangement(s)/ transaction(s) shall be carried out in the ordinary course of business of the Company and in respect of transactions with related parties under Section 2(76) of the Act, on an arm's length basis."

"RESOLVED FURTHER THAT the Board of Directors of the Company (hereinafter referred to as 'Board' which term shall be deemed to include the Audit Committee of the Company and any duly constituted/to be constituted Committee of Directors thereof to exercise its powers including powers conferred under this resolution) be and is hereby authorised to do all such acts, deeds, matters, and things as it may deem fit at its absolute discretion and to take all such steps as may be required in this connection including finalizing and executing necessary documents, contract(s), scheme(s), agreement(s) and such other documents as may be required, seeking all necessary approvals to give effect to this resolution, for and on behalf of the Company and settling all such issues, questions, difficulties or doubts whatsoever that may arise and to take all such decisions from powers herein conferred to, without being required to seek further consent or approval of the Members and that the Members shall be deemed to have given their approval thereto expressly by the authority of this resolution."

"RESOLVED FURTHER THAT all actions taken by the Board in connection with any matter referred to or contemplated in this resolution, be and are hereby approved, ratified and confirmed in all respects."

6. To re-appoint Dilip Vishnu Acharekar (DIN:08849689) as an Independent Director of the Company

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

“RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 150, 152 and other applicable provisions, if any, of the Companies Act (“the Act”) read with Schedule IV of the Act and the Companies (Appointment and Qualification of Directors) Rules, 2014, Regulations 17, 17(1A) and 25 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) as amended from time to time, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board based on the performance evaluation, Dilip Vishnu Acharekar (DIN:08849689), who is eligible to be re-appointed for another term of five (5) consecutive years and who has submitted a declaration that he meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from November 16, 2025 to November 15, 2030 including the period from December 07, 2027 when he shall attain the age of 75 years of age.”

By order of the Board
For Vineet Laboratories Limited

Place: Hyderabad

Date: May 12, 2025

Ramesh Kumar Bandari
Company Secretary & Compliance Officer

NOTES:

1. The Ministry of Corporate Affairs (“MCA”) has vide its General Circular Nos. 14/2020 dated April 8, 2020 and 17/2020 dated April 13, 2020, in relation to “Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder on account of the threat posed by “COVID-19”, General Circular Nos. 20/2020 dated May 5, 2020, 10/2022 dated December 28, 2022, 09/2023 dated September 25, 2023 and subsequent circulars issued in this regard, the latest being 09/2024 dated September 19, 2024 in relation to “Clarification on holding of Annual General Meeting (“AGM”) through Video Conferencing (VC) or Other Audio Visual Means (OAVM)”, (collectively referred to as “MCA Circulars”) permitted the holding of the AGM through VC/OAVM, without the physical presence of the Members at a common venue. In compliance with the MCA Circulars, the AGM of the Company is being held through VC /OAVM. The registered office of the Company shall be deemed to be the venue for the AGM.
2. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (“Act”) setting out material facts concerning the business under Item Nos. 3 to 6 of the Notice, is annexed hereto. Further, the relevant details with respect to Item Nos. 2 & 6 pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking re-appointment at this AGM are also annexed.
3. In accordance with the aforesaid MCA Circulars and Circular Nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022, SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 7, 2023 issued by Securities Exchange Board of India (collectively referred to as “SEBI Circulars”), Notice of the AGM along with the Annual Report 2024-25 is being sent only through electronic mode to those Members whose e-mail address is registered with the Company/Depository Participants. Members may note that the Notice and the Annual Report 2024-25 will also be available on the Company’s website www.vineetlabs.co.in , websites of the Stock Exchanges, that is, BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com , respectively, and on the website of Company’s Registrar and Transfer Agent, Venture Capital and Corporate Investments Private Limited (“VCC”) at <https://www.vccipl.com/> and on the website of CDSL <https://www.evotingindia.com/>.
4. For receiving all communication (including Annual Report) from the Company electronically:
 - a) Members holding shares in physical mode and who have not registered / updated their email address and phone number with the Company are requested to register / update the same by writing to the Company with details of folio number and attaching a self-attested copy of PAN card at investorcomplaints@vineetlabs.co.in or to VCC at investor.relations@vccipl.com .
 - b) Members holding shares in dematerialised mode are requested to register / update their email addresses and Phone numbers with the relevant Depository Participant.
 - c) Members can also update their email addresses and Phone numbers by following the procedure mentioned below:
 - Click on the URL: <https://www.vccipl.com/CustomerContactUpdate.html>
 - Select the Name of the Company from dropdown: Vineet Laboratories Limited
 - Enter DP and Client ID (if shares held in electronic form)/Folio number (if shares held in physical form) and Permanent Account Number (“PAN”). In the event PAN details are not registered for physical folio, Member to enter one of the Share Certificate numbers.
 - Enter Mobile number and e-mail ID.
 - System generated One Time Password (“OTP”) to be sent on mobile number and e-mail ID

- Enter OTP received on mobile number and e-mail ID.
 - Click on Submit button.
 - On completing the above process your request will be accepted and request ID will be generated.
5. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through VC/OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxy(ies) by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and route map of AGM are not annexed to this Notice.
 6. Institutional shareholders / corporate shareholders (i.e. other than individuals, HUFs, NRIs, etc.) are required to send a scanned copy (PDF/JPG Format) of their respective Board or governing body Resolution/Authorization etc., authorizing their representative to attend the AGM through VC/OAVM on their behalf and to vote through remote e-voting. The said Resolution/Authorization shall be sent to the Scrutinizer by e-mail to jinesh211@gmail.com with a copy marked to helpdesk.evoting@cDSLindia.com. Institutional shareholders (i.e. other than individuals, HUFs, NRIs etc.) can also upload their Board Resolution/Power of Attorney/Authority Letter, etc. by clicking on "Upload Board Resolution/Authority Letter" displayed under "e-Voting" tab in their login.
 - 7. Record Date / Book Closure Date for the purpose of AGM: from September 19, 2025 to September 25, 2025 (both days included).**
 8. The members, who were allotted shares at the time of demerger from Ortin Laboratories Limited, and whose share certificates were returned back to the company are held in the dematerialized form for the benefit of such shareholders. The list of such members is available at https://vineetlabs.co.in/images/pdf/other-information/VINEET_SUSPENCE_SHAREHOLDERS_FY%202025.pdf
 9. Members may please note that SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022 has mandated the Listed Companies to issue securities in dematerialized form only while processing service requests viz. Issue of duplicate securities certificate; claim from unclaimed suspense account; renewal/exchange of securities certificate; endorsement; sub-division/splitting of securities certificate; consolidation of securities certificates/folios; transmission and transposition. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the Company's website at <http://vineetlabs.co.in/images/pdf/other-information/Form%20ISR-4.pdf> and on the website of the Company's RTA, Venture Capital and Corporate Investments Private Limited at <https://www.vccipl.com/index.html>. It may be noted that any service request can be processed only after the folio is KYC Compliant.
 10. In terms of Regulation 40(1) of SEBI Listing Regulations, as amended from time to time, transfer, transmission and transposition of securities shall be affected only in dematerialized form. In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company or Venture and Corporate Investments Private Limited (RTA), for assistance in this regard.
 11. Members holding shares in physical form, in identical order of names, in more than one folio are requested to send to the Company or VCC, the details of such folios together with the share certificates along with the requisite KYC Documents for consolidating their holdings in one folio. Requests for consolidation of share certificates shall be processed in dematerialized form.
 12. As per the provisions of Section 72 of the Act, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13, which is available on the company's website at http://vineetlabs.co.in/images/pdf/other-information/SH-13%20_Reg%20of%20Nomination.pdf. If a member

desires to opt out or cancel the earlier nomination and record a fresh nomination, he/she may submit the same in Form ISR-3 or SH-14 as the case may be, which are available on the company's website at <http://vineetlabs.co.in/images/pdf/other-information/Form%20ISR-3.pdf> or http://vineetlabs.co.in/images/pdf/other-information/SH-14_requestforcancellation.pdf. And, the same are available on the website of the Company's RTA, Venture Capital and Corporate Investments Private Limited at <https://www.vccipl.com/index.html>. Members are requested to submit the said details to their DP in case the shares are held by them in dematerialized form and to Venture and Corporate Investments Private Limited in case the shares are held in physical form.

13. For updating the signature of the securities holder, the holder / claimant shall furnish original cancelled cheque and banker's attestation of the signature in Form ISR-2. The same is available on the company's website at <http://vineetlabs.co.in/images/pdf/other-information/FormISR-2.pdf>, and, the same is available on the website of the Company's RTA, Venture Capital and Corporate Investments Private Limited at <https://www.vccipl.com/index.html>.
14. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company as on the cut-off date will be entitled to vote during the AGM.
15. SEBI vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/ CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/135 dated August 4, 2023, read with Master Circular No. SEBI/HO/ OIAE/OIAE_IAD-1/P/ CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market. Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the RTA/ Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (<https://smartodr.in/login>) and the same can also be accessed through the Company's website at <https://vineetlabs.co.in/other-information.html>.
16. The Board of Directors has appointed Jineshwar Kumar Sankhala, Practicing Company Secretary (M.No. A21697; C P No. 18365), as the scrutinizer of the company to scrutinize the remote e-voting and voting at the AGM in a fair and transparent manner.
17. Members are requested to note that dividends, if not encashed for a period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). Further, all the shares in respect of which dividend has remained unclaimed for 7 consecutive years or more from the date of transfer to unpaid dividend account shall also be transferred to IEPF. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline.

The Members whose unclaimed dividends and/or shares have been transferred to IEPF, may contact the Company or RTA and submit the required documents for issue of Entitlement Letter. The Members can attach the Entitlement Letter and other required documents and file the IEPF-5 form for claiming the dividend and/ or shares available on www.iepf.gov.in. The details of the shareholders, who did not claim their dividend are available on the website of the company at https://vineetlabs.co.in/images/pdf/Unpaid-UnclaimedDividend_FY%202025.pdf

18. INSTRUCTIONS FOR E-VOTING AND JOINING THE AGM ARE AS FOLLOWS:

1. As you are aware, in view of the situation arising due to COVID-19 global pandemic, the general meetings of the companies shall be conducted as per the guidelines issued by the Ministry of Corporate Affairs (MCA) vide Circular No. 14/2020 dated April 8, 2020, Circular No.17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 05, 2020. The forthcoming AGM will thus be held through video conferencing (VC) or other audio-visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM.

2. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
5. Pursuant to MCA Circular No. 14/2020 dated April 08, 2020, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.
6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at <https://vineetlabs.co.in/images/pdf/FY2024-2025.pdf> . The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.
7. The AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 8, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
8. In continuation to this Ministry's General Circular No. 20/2020 dated 05.05.2020, General Circular No. 02/2022 dated 05.05.2022, General Circular No. 10/2022 dated 28.12.2022 and General Circular No. 9/2023 dated 25.09.2023 after due examination, it has been decided to allow companies whose AGMs are due in the Year 2024 or 2025, to conduct their AGMs through VC or OAVM on or before 30th September, 2025 in accordance with the requirements laid down in Para 3 and Para 4 of the General Circular No. 20/2020 dated 05.05.2020.

THE INTRUCTIONS OF SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (i) **The voting period begins on Monday, September 22, 2025 from 09:00 A.M. and ends on Wednesday, September 24, 2025 at 05:00 P.M. During this period, shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of Thursday, September 18, 2025** may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020**, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to **all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

- (iv) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to above said SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL Depository	<ol style="list-style-type: none"> 1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsi website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.

	<p>3) If the user is not registered for Easi/Easiest, option to register is available at cdsi website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option.</p> <p>4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
<p>Individual Shareholders holding securities in demat mode with NSDL Depository</p>	<p>1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p> <p>2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting</p> <p>4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>
<p>Individual Shareholders (holding securities in demat mode) login through their Depository Participants (DP)</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

- (v) Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individual holding in Demat form.**
- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
 - 2) Click on "Shareholders" module.
 - 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.
 - 4) Next enter the Image Verification as displayed and Click on Login.
 - 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
 - 6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10-digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ol style="list-style-type: none"> 1. If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- (vi) After entering these details appropriately, click on "SUBMIT" tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <Company Name> on which you choose to vote.
- (x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xiii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.
- (xvii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
 - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; jinesh211@gmail.com / cs@vineetlabs.co.in, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / iPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least **five days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@vineetlabs.co.in . The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance **five days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at cs@vineetlabs.co.in . These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders may be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to Company/RTA email id.

2. For Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 1800 21 09911.

19. The members who have cast their vote(s) by remote e-voting may also attend the Meeting but shall not be entitled to cast their vote(s) again at the Meeting. Once the vote on a resolution is cast by a member, whether partially or otherwise, the member shall not be allowed to change it subsequently or cast the vote again.

20. A member can opt for only single mode of voting per EVSN, i.e., through remote e-voting or voting at the Meeting. If member casts vote(s) by both modes, then voting done through remote e-voting shall prevail and vote(s) cast at the Meeting shall be treated as "INVALID".

A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the **cut-off date, i.e., Thursday, September 18, 2025** only shall be entitled to avail the facility of remote e-voting or for participation at the AGM and voting at AGM.

21. Non-Resident Indian members are requested to inform VCC / respective DPs, immediately of:

- Change in their residential status on return to India for permanent settlement.
- Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.

Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 and additional information as required under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Circulars issued thereunder:

The following statement sets out all material facts relating to the businesses mentioned under Item Nos. 3 to 6 in the Notice:

Item No. 3:

The Board of Directors has, on the recommendation of the Audit Committee, approved the appointment and remuneration of the Cost Auditors to conduct the audit of the cost records of the Company, for the financial year ending March 31, 2026.

In accordance with the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the remuneration of Rs. 60,000/- payable to the Cost Auditors, as recommended by the Audit Committee and approved by the Board of Directors of the Company, has to be ratified by the Members of the Company.

Accordingly, ratification by the Members is sought by the Board for the remuneration payable to the Cost Auditors for the financial year ending March 31, 2026 by passing an Ordinary Resolution as set out at Item No. 3 of the Notice.

None of the Directors, Key Managerial Personnel or their relatives, beyond the shares held by them, is concerned or interested, financially or otherwise, in the said resolution.

Item No. 4:

The Board at its meeting held on May 29, 2025, based on the recommendation of the Audit Committee, after evaluating and considering various factors such as industry experience, competency of the audit team, efficiency in conduct of audit, independence, etc., has approved the appointment of P S Rao & Associates, Practising Company Secretaries, a peer reviewed firm (Unique Identification Number P200ITL078000) as Secretarial Auditors of the Company for a term of five consecutive years commencing from FY 2025-26 till FY 2029-30, subject to approval of the Members.

The appointment of Secretarial Auditors shall be in terms of the amended Regulation 24A of the SEBI Listing Regulations vide SEBI Notification dated December 12, 2024 and provisions of Section 204 of the Act and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

P S Rao & Associates is a well-known firm of Practising Company Secretaries founded in 2003 and based in Hyderabad. Renowned for its commitment to quality and precision, the firm has been Peer Reviewed and Quality Reviewed by the Institute of Company Secretaries of India (ICSI), ensuring the highest standards in professional practices.

P S Rao & Associates has a team of 40 members including 6 partners and focussed on providing comprehensive professional services in corporate law, SEBI regulations, FEMA compliance, and allied fields, delivering strategic solutions to ensure regulatory adherence and operational efficiency.

The firm provides its services to various prominent companies and its expertise has earned the trust of industry leaders across sectors like manufacturing, pharmaceuticals, Information Technology, Textile, Telecommunication, FMCG, Defence etc.,

P S Rao & Associates has confirmed that the firm is not disqualified and is eligible to be appointed as Secretarial Auditors in terms of Regulation 24A of the SEBI Listing Regulations. The services to be rendered by P S Rao & Associates as Secretarial Auditors is within the purview of the said regulation read with SEBI Circular No. SEBI/ HO / CFD / CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.

The proposed fees in connection with the secretarial audit shall be Rs.1,50,000/- (Rupees One Lakh Fifty Thousand only) plus applicable taxes and other out-of-pocket expenses for FY 2026, and for subsequent year(s) of its term, such fees as may be mutually agreed between the Board of Directors and P S Rao & Associates.

In addition to the secretarial audit, P S Rao & Associates shall provide such other services in the nature of certifications and other professional work, as approved by the Board of Directors. The relevant fees will be determined by the Board, as recommended by the Audit Committee in consultation with the Secretarial Auditors.

The Board recommends the Ordinary Resolution as set out in Item No. 4 of this Notice for approval of the Members.

None of the Directors, Key Managerial Personnel or their relatives, beyond the shares held by them, is concerned or interested, financially or otherwise, in the said resolution.

Item No. 5:

Pursuant to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the threshold limit for determination of material Related Party Transactions is the lower of Rs.1,000 Crores (Rupees One Thousand Crores) or 10% (Ten Percent) of the annual consolidated turnover of the listed entity as per the last audited financial statements of the listed entity and such material related party transactions exceeding the limits, would require prior approval of Members by means of an ordinary resolution.

Vineet Laboratories Limited ("the Company" or "Vineet") is an ISO 9001:2015 certified company specialized in pharmaceutical intermediates & fine chemicals. Vineet is widely acknowledged for its abilities in product development & process technology and therefore is the preferred source for many multinational companies for their outsourcing requirements.

In terms of the revised thresholds prescribed under the applicable provisions of law for determining the related party transactions that require prior approval of shareholders, and considering that the list of related parties may vary from time to time without any specific action on the part of the Company, the Company seeks the consent of the shareholders for entering into contracts/arrangements within the limits and conditions specified in the resolution. This approval will facilitate seamless contracting and efficient rendering/availing of products and services between the Company and its related parties. All such contracts/arrangements and transactions with related parties are placed before and reviewed by the Audit Committee, in accordance with the applicable provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015. All the contracts/arrangements and the transactions with "related parties" are reviewed and approved by the Audit Committee.

Transactions with Vineet Life Sciences Private Limited:

Sr. No	Description	Particulars
1.	Name of the related party	Vineet Life Sciences Private Limited
2.	Nature of relationship [including nature of its interest (financial or otherwise)]	Related Party as per the Companies Act, 2013, Accounting Standards and Listing Regulations
3.	Name of the Director or Key Managerial Personnel, who is related, if any	Gaddam Venkata Ramana, Satyanarayana Raju Bhupathiraju
4.	Type of the proposed transaction	Sale and Purchase of goods / services
5.	Nature, duration/tenure, material terms, monetary value and particulars of contract/arrangement	Transactions proposed to be entered into in the ordinary course of business

		and on arm's length basis, with terms and conditions generally prevailing in the industry in which the Company operates. The monetary value of transactions with any single related party shall not exceed Rs.50 Crores per annum, for contracts/arrangements entered into / undertaken during FY 2025-26.
6.	Particulars of the proposed transaction	Sale and Purchase of goods / services
7.	Tenure of the transaction	For 1 year
8.	Value of the proposed transaction	maximum of Rs.50 Crores per annum
9.	Percentage of the company's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction	66.67%
10.	Benefits of the proposed transaction	In carrying out such transactions, the Company relies on the niche skills and competencies of partner entities
11.	Details of the valuation report or external party report (if any) enclosed with the Notice	All contracts and arrangements with related parties, as defined under the SEBI Listing Regulations, are entered into in compliance with the Company's governance policies relating to negotiations with third parties, and are reviewed and approved by the Audit Committee on a quarterly basis.
12.	Following additional disclosures to be made in case loans, inter-corporate deposits, advances or investments made or given	
A.	Source of funds	Not Applicable
B.	In case any financial indebtedness is incurred to make or give loans, intercorporate deposits, advances or investment: • Nature of indebtedness • cost of funds and • tenure of the indebtedness	Not Applicable
C.	Terms of the loan, inter-corporate deposits, advances or investment made or given (including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security)	Not Applicable
D.	The purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the RPT	Not Applicable
13.	Any other relevant information	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Act, forming part of this Notice.

Transactions with Organo Metallica Private Limited:

Sr. No	Description	Particulars
1.	Name of the related party	Organo Metallica Private Limited
2.	Nature of relationship [including nature of its interest (financial or otherwise)]	Related Party as per the Companies Act, 2013, Accounting Standards and Listing Regulations
3.	Name of the Director or Key Managerial Personnel, who is related, if any	Gaddam Venkata Ramana

4.	Type of the proposed transaction	Sale and Purchase of goods / services
5.	Nature, duration/tenure, material terms, monetary value and particulars of contract/arrangement	Transactions proposed to be entered into in the ordinary course of business and on arm's length basis, with terms and conditions generally prevailing in the industry in which the Company operates. The monetary value of transactions with any single related party shall not exceed Rs.50 Crores per annum, for contracts/arrangements entered into / undertaken during FY 2025-26.
6.	Particulars of the proposed transaction	Sale and Purchase of goods / services
7.	Tenure of the transaction	For 1 year
8.	Value of the proposed transaction	maximum of Rs.50 Crores
9.	Percentage of the company's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction	66.67%
10.	Benefits of the proposed transaction	In carrying out such transactions, the Company relies on the niche skills and competencies of partner entities
11.	Details of the valuation report or external party report (if any), enclosed with the Notice	All contracts and arrangements with related parties, as defined under the SEBI Listing Regulations, are entered into in compliance with the Company's governance policies relating to negotiations with third parties, and are reviewed and approved by the Audit Committee on a quarterly basis.
12.	Following additional disclosures to be made in case loans, inter-corporate deposits, advances or investments made or given	
A.	Source of funds	Not Applicable
B.	In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investment: <ul style="list-style-type: none"> • Nature of indebtedness • cost of funds and • tenure of the indebtedness 	Not Applicable
C.	Terms of the loan, inter-corporate deposits, advances or investment made or given (including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security)	Not Applicable

D.	The purpose for which the funds will be utilized by the ultimate beneficiary of such funds pursuant to the RPT	Not Applicable
13.	Any other relevant information	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Act, forming part of this Notice.

The material related party transactions as set out in Item No. 5 of this Notice have been unanimously approved by the Independent Directors on the Audit Committee.

Basis the consideration and approval of the Audit Committee, the Board recommends the Ordinary Resolutions as set out in Item No. 5 of this Notice for approval of the Members.

The approval of the shareholders sought for the material Related Party Transactions entered during FY 2025-26 as given in Item No.5 shall be valid up to the date of the next AGM.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives, other than as mentioned above, are concerned or interested in the respective resolutions.

The Members may note that as per the provisions of the SEBI Listing Regulations, all related parties (whether such related party is a party to the above-mentioned transactions or not), shall not vote to approve the Resolutions as set out in Item No. 5.

Item No. 6:

Dilip Vishnu Acharekar (DIN:08849689) was appointed as an Independent Director of the Company by the shareholders in the Annual General Meeting (AGM) held on December 19, 2020 for a term of five (5) consecutive years from November 16, 2020 to November 15, 2025.

Since the tenure of Dilip Vishnu Achrekar (DIN:08849689) is going to conclude, he has consented to get re-appointed for a second term of another five (5) consecutive years. In this context, he has submitted a declaration that he is not disqualified to get appointed as a director and also, he meets the criteria of independence as under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI LODR Regulations.

The Board, pursuant to the recommendation of the Nomination and Remuneration Committee, at its meeting held on May 12, 2025, approved the re-appointment of Dilip Vishnu Acharekar (DIN:08849689) as an Independent Director of the Company, not liable to retire by rotation, for a second term of five (5) consecutive years commencing from November 16, 2025 to November 15, 2030, subject to approval of the shareholders.

Moreover, pursuant to Regulation 17(1A) of the SEBI LODR Regulations, no listed entity shall appoint a person or continue the directorship of any person as a non-executive director who has attained the age of seventy-five years unless a prior approval from the shareholders is obtained.

Incidentally, Dilip Vishnu Achrekar will attain the age of Seventy-Five (75) years by December 07, 2027.

Accordingly, the Board of Directors in its meeting held on May 12, 2025 approved the continuation of Dilip Vishnu Acharekar as Independent Director of the Company till the expiry of his term of office and the same is required to be approved by shareholders by passing special resolution.

Dilip Vishnu Acharekar holds a B.E (Chemical) degree from the Institute of Chemical Technology (formerly, University Department of Chemical Technology (UDCT), Mumbai). He is approved as an expert staff for manufacture of Bulk drugs / fine chemicals by Food & Drugs Administration under Drugs & Cosmetic Rules, 1944

and has more than four decades of extensive experience across all sectors in chemical industry, driven by a profound passion for innovation and the creation of novel solutions.

In the opinion of the Board and based on the performance evaluation, Acharekar is a person of integrity, possesses relevant expertise, experience and fulfils the conditions specified in the Act and the SEBI Listing Regulations for re-appointment as an Independent Director and is independent of the management.

Given his vast experience and being the man behind the policy decisions during his tenure, the Board considers - in the interest of the Company - to have him on the Board of the Company as an Independent Director.

The terms and conditions of appointment of the independent director of the Company is open for inspection by the Members in electronic form 21 days before the Annual General Meeting and can be viewed on the Company's website at <https://vineetlabs.co.in/terms-and-conditions-appointment.html>.

The Board recommends the Special Resolution set out at Item No. 6 of the Notice for approval by the Members.

Save and except the above, none of the other Directors or Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in the resolution.

DETAILS OF DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT IN THE FORTHCOMING ANNUAL GENERAL MEETING

[Pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 on General Meetings]

Name of the director	Gaddam Venkata Ramana	Dilip Vishnu Acharekar
Director Identification Number	00031873	08849689
Date of Birth (Age)	18-08-1968 (56 years)	07-12-1952 (72 Years)
Date of first appointment on the Board	01-01-2021	16-11-2020
Educational Qualification	Post Graduate in Chemistry	B.E (Chemical) degree from Institute of Chemical Technology
Experience (including expertise in specific functional areas) / Brief Resume	He has more than 3 decades of experience in Pharma and Bulk Drug Industry. He has good knowledge and is very familiar with the industry and having good relations with top management of the pharma giants.	He is approved as an expert staff for manufacture of Bulk drugs / fine chemicals by Food & Drugs Administration under Drugs & Cosmetic Rules, 1944 and has more than four decades of extensive experience across all sectors of the chemical industry, driven by a profound passion for innovation and the creation of novel solutions.
Directorships held in other companies (excluding foreign companies)	1. Vineet Life Sciences Private Limited 2. Wohler Laboratories Private Limited 3. Satyadeva Organosys Private Limited 4. Vineet Chem Trade Private Limited	Nil
Membership / Chairmanships of committees across companies (excluding foreign companies)	Nil	Nil
Relationship with other Directors, Manager and other Key Managerial Personnel of the Company	Nil	Nil
No. of shares held in the Company either by self or as a beneficial owner	8,30,207	Nil
Terms and Conditions of appointment / re-appointment	As per the Ordinary Resolution set forth at Item No. 2 of this Notice	As per the special resolution and explanatory statement set forth at Item No. 6 of this Notice
Name of listed entities from which the person has resigned in the past three years	Ortin Global Limited (ceased w.e.f 30-09-2022)	Nil

For other details such as number of meetings of the Board attended during the year; remuneration last drawn & sought to be paid; and the manner in which the person proposed to be appointed / re-appointed meets such requirements, etc. please refer to the Corporate Governance Report which is a part of the Annual Report.

DIRECTORS' REPORT

Dear Members,

Your directors have great pleasure in presenting the report on the Business and Operations of your Company ('the Company' or 'Vineet Laboratories Limited'), along with the audited financial statements, for the financial year ended on 31st March, 2025.

FINANCIAL HIGHLIGHTS

The financial highlights of the Company are as follows:

Particulars	Rs. In Lakhs	
	2024-25	2023-24
Revenue from Operations	7,499.50	15,059.13
Other Income (Including Exceptional Items)	198.68	46.32
Total Expenses	9,775.73	15,069.11
Profit Before Tax	(2,077.55)	36.34
Less: Provision for Taxation	(58.45)	(66.37)
Profit / (Loss) After Tax	(2,019.10)	102.71
Other Comprehensive Income	11.44	1.38
Total Comprehensive Income	(2,007.67)	104.09
Earning per Equity Share		
Basic	(21.90)	1.11
Diluted (in Rs.)	(21.90)	1.11

STATE OF THE COMPANY'S AFFAIRS

During the year under review, your Company achieved total income of Rs. 7,499.50 Lakhs as against the previous year's Rs. 15,059.13 Lakhs. The Net profit after tax stood at Rs. -2,019.10 Lakhs as against Rs. 102.71 Lakhs for the previous year.

DIVIDEND

No dividend was recommended by the Board of Directors for the FY 2024-25.

TRANSFER TO RESERVES

Your Company did not transfer any amount to reserves for the financial year 2024-25.

CHANGE IN THE NATURE OF THE BUSINESS

There has been no change in the nature of business of the Company during the year under review.

SHARE CAPITAL

The Paid-up Equity Share Capital of the Company stood at Rs. 9,21,90,080/- comprising of 92,19,008 equity shares of Rs. 10/- each as on March 31, 2025.

The Company has paid Listing Fees for the Financial Year 2025-26 to each of the Stock Exchanges, where its equity shares are listed.

ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3) (a) of the Act, the Annual Return as on March 31, 2024 is available on the Company's website at https://vineetlabs.co.in/images/pdf/MGT-7_2025.pdf

NUMBER OF MEETINGS OF THE BOARD

The Board met Four (4) times during the year 2024-2025 viz on May 29, 2024; August 13, 2024; November 13, 2024 and February 12, 2025.

The details of the composition of the Board and its Committees and the number of meetings held and attendance of Directors at such meetings are provided in the Corporate Governance Report, which forms part of the Annual Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirements under Section 134, sub-section 3(c) and sub-section 5 of the Companies Act, 2013, the Board of Directors, to the best of its knowledge and ability, states and confirms that:

- a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) the Directors had selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that period;
- c) the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) the Directors had prepared the annual accounts on a going concern basis;
- e) the Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
- f) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SECTION 149

As required under Section 149 of the Companies Act, 2013, the Independent Directors have submitted the declaration affirming that they meet the criteria of independence as provided in Section 149(6) of the Act and Regulation 25(8) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. There has been no change in the circumstances affecting their status as independent directors of the Company.

The Board is of the opinion that all the Independent Directors appointed during the year under review are persons of integrity and possess relevant expertise and experience to act as Independent Director of the Company. The Independent Directors of the Company have confirmed that they have registered themselves with the Indian Institute of Corporate Affairs, Manesar and have included their name in the databank of Independent Directors within the statutory timeline and they have also appeared and qualified for the online proficiency test, wherever applicable.

POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION AND OTHER DETAILS

The policy of the Company relating to the remuneration of the Directors, Key Managerial Personnel and other employees, including criteria for determining qualifications, positive attributes, independence of a Director and other matters, as required under sub-section (3) of Section 178 of the Companies Act, 2013, is governed by the Nomination and Remuneration Policy.

The Company's policy relating to the appointment of directors and remuneration including other matters provided in Section 178(3) of the Act has been disclosed in the Corporate Governance Report forming part of this Report and is also available on <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/nomination-remuneration-policy.pdf>

INSURANCE

The assets/ properties of the Company are adequately insured against loss due to fire, riots, earthquake, terrorism, etc., and against other perils that are considered necessary by the management.

LOANS, GUARANTEES, OR INVESTMENTS

Particulars of loans given, guarantees provided and investments made by the Company during the year 2024-25, as required under the provisions of Section 186 of the Companies Act, 2013 read with Companies (Meetings of Board and its Powers) Rules, 2014, are disclosed in the notes to Financial Statements which may be read as a part of this Report.

CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All Related Party Transactions (RPT) that were entered into during the financial year were at arm's length basis and in the ordinary course of business.

All Related Party Transactions were placed before the Audit Committee and the Board for approval. The Board of Directors has framed a policy on Related Party Transactions to ensure a process for approval and reporting of transactions between the Company and its related parties. The policy is posted under the Investors section of the Company's website at <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/related-party-transactions-policy.pdf>

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 in the prescribed **Form AOC-2** is appended as **Annexure I** which forms part of this Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars as prescribed under Section 134(3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 with respect to Conservation of Energy, Technology Absorption, and Foreign Exchange Earnings and Outgo are provided in **Annexure II** to this Report.

DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY

We have developed and are implementing Risk Management Policy. Accordingly, we have a risk management framework for the identification and management of risks. The Company has formulated Risk Management Policy, which guides the Board in (a) approving the Company's Risk Management Framework and (b) overseeing all the

risks that the organization faces such as strategic, financial, liquidity, security, regulatory, legal, reputational and other risks that have been identified and assessed to ensure that there is a sound Risk Management Policy in place to address such concerns / risks. The Risk Management process covers risk identification, assessment, analysis and mitigation. Incorporating sustainability in the process also helps to align potential exposures with the risk appetite and highlight risks associated with chosen strategies.

The Audit Committee has additional oversight in the area of financial risks and controls. Major risks identified by the business and functions are systematically addressed through mitigating actions on a continuing basis.

The Company has adopted a Risk Management Policy in accordance with the provisions of the Act and Regulation 21 of the Listing Regulations. The Risk Management Policy is also posted under the Investors' section of the Company's website at <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/risk-management-policy.pdf>

CORPORATE SOCIAL RESPONSIBILITY (CSR)

The provisions of Section 135 of the Act are not applicable to the company for the financial year 2024-25. Since, the Company's Unspent Corporate Social Responsibility Account has a balance of Rs.8,92,849/- pertaining to the FY 2022-23, the Board is continuing with the constitution of Corporate Social Responsibility Committee (CSR Committee) as required under Rule 3 of Companies (Corporate Social Responsibility Policy) Rules, 2014. The Committee was initially constituted on May 28, 2022 and then re-constituted on August 14, 2024 and November 14, 2024.

The CSR Committee constituted by the Board has reviewed the existing Corporate Social Responsibility Policy (CSR Policy) in its meeting held on February 12, 2025, amending the policy in accordance with latest provisions, statues and legislations indicating the activities to be undertaken by the Company. The CSR Committee monitors the CSR Policy and recommends the amount of expenditure to be incurred on the activities mentioned in the CSR Policy.

The category and composition of the committee is as follows: -

Name	Designation	Category	Tenure
Bhaskar Reddy Karna #	Chairman	Independent Non-Executive	Till 13-08-2024
Satyanarayana Raju Bhupathiraju	Chairman	Non-Independent Executive	w.e.f 14-08-2024
Gaddam Venkata Ramana	Member	Non-Independent Executive	
Dilip Vishnu Acharekar	Member	Independent Non-Executive	w.e.f 14-11-2024

Resigned from the Board w.e.f 14-11-2024 and ceased to be a member of Committee

A CSR meeting was held on February 12, 2025 during the FY 2024-25, in which Satyanarayana Raju Bhupathiraju and Dilip Vishnu Acharekar were present.

The Corporate Social Responsibility Policy is posted under the Investors section of the Company's website at: <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/CSR-policy.pdf>

The Annual Report on CSR activities is appended as **Annexure-III**, which forms part of this report.

BOARD EVALUATION

The Board of Directors has carried out an annual evaluation of its own performance, its Committees and the directors individually, in accordance with the provisions of the Companies Act, 2013 and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), with specific focus on the performance and effective functioning of the Board and individual directors.

A separate meeting of Independent Directors was held on February 12, 2025 to review the performance of the Non-Independent Directors and the Board as a whole, review the performance of Chairperson of the Company and assess the quality, quantity, and timeliness of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties. All the Independent Directors were present at the meeting.

CRITERIA FOR PERFORMANCE EVALUATION

- a. Ability of the candidate to devote sufficient time and attention to his professional obligations as Independent Director for informed and balanced decision making.
- b. Adherence to the Code of Conduct in letter and in spirit by the Independent Directors.
- c. Bringing objectivity and independence of view to the Board's discussions in relation to the Company's strategy, performance, and risk management.
- d. Statutory compliance and ensuring high standards of financial probity and Corporate Governance.
- e. Responsibility towards requirements under the Companies Act, 2013, responsibilities of the Board and accountability under the Director's Responsibility Statement.

FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTORS

The Independent Directors attend a Familiarization /Orientation Program on being inducted into the Board. Further, various other programmes are conducted for the benefit of Independent Directors to provide periodical updates on regulatory front, industry developments and any other significant matters of importance. The Company issues a formal letter of appointment to the Independent Directors, outlining their role, function, duties and responsibilities, the format of which is available on the Company's Website.

The details of training and familiarization program are available on the website at https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/familiarisation-programme_independent-directors.pdf.

DIRECTORS

The Board of Directors as on March 31, 2025 consists of five (5) directors, two (2) of whom are Independent Directors including a woman Director, remaining two (2) are Executive Directors and the balance one (1) is a Non-Executive Director.

In accordance with the provisions of Companies Act, 2013 and the Articles of Association of the Company, Gaddam Venkata Ramana (DIN: 00031873), Director, retires by rotation at the ensuing Annual General Meeting and, being eligible, offers himself for re-appointment. The Board recommends his re-appointment as a Director for the approval of the members.

Further, Mr. Dilip Vishnu Acharekar (DIN:08849689) was appointed as an Independent Director of the Company by the shareholders in the 4th Annual General Meeting (AGM) of the Company held on December 19, 2020 for a term of Five (5) consecutive years from November 16, 2020 to November 15, 2025.

Mr. Dilip Vishnu Achrekar who is eligible to be re- appointed for another term of Five (5) consecutive years, has submitted a declaration that he meets the criteria of independence under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations.

Further Mr. Dilip Vishnu Achrekar will attain the age of Seventy-Five (75) years on December 07, 2027 and pursuant to Regulation 17(1A) of the SEBI Listing Regulations, approval of the Shareholders is required to allow him to continue as an Independent director of the Company after the age of 75 Years.

In this regard, the Board recommends the re-appointment of Dilip Vishnu Acharekar (DIN: 08849689) as an Independent Director and continue as an Independent Director after the age of 75 years for the approval of the members and the same is made part of the notice.

In compliance with Regulation 36(3) of the Listing Regulations and Secretarial Standard-2 on General Meetings, brief resume of the directors proposed to be re-appointed is attached along with the Notice of the ensuing AGM.

Moreover, the Directors have devised proper systems and processes for complying with the requirements of applicable Secretarial Standards issued by the Institute of Company Secretaries of India and that such systems were adequate and operating effectively.

CHANGES IN THE DIRECTORS OR KEY MANAGERIAL PERSONNEL (KMP)

Board of Directors:

The Board is duly constituted.

During the year under review, Satish Pandurang Samant (DIN: 10294920) has resigned from the office of Executive Director and Chief Executive Officer w.e.f. May 29, 2024; and Bhaskara Reddy Karna (DIN: 08961904) has resigned from the office of Independent Director w.e.f. November 14, 2024.

Moreover, the Board appointed Rajesh Kumar Kathulla (DIN: 05349717) as an Additional Director, designated as Whole Time Director for a period of 3 (Three) years commencing from May 14, 2025 and ending on May 13, 2028. His appointment was placed before the shareholders via postal ballot through e-voting between May 27, 2025 and June 25, 2025. However, the resolution was defeated by the shareholders and he ceased to be a director w.e.f. June 26, 2025.

Company Secretary and Compliance Officer:

Ramesh Kumar Bandari (M.No: A24519), an Associate member of The Institute of Company Secretaries of India (ICSI) was appointed as Company Secretary and Compliance Officer of the Company w.e.f. November 10, 2023.

Key Managerial Personnel (KMP):

In terms of Section 203 of the Act, the following are the Key Managerial Personnel of the Company as on March 31, 2025:

Gaddam Venkata Ramana	-	Managing Director
Satyanarayana Raju Bhupathiraju	-	Whole-Time Director and Chief Financial Officer
Ramesh Kumar Bandari	-	Company Secretary and Compliance Officer

Apart from the above, there were no other changes in the office of Directors and KMP.

SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES

The Company did not have a Subsidiary / Associate/ Joint Venture Company as on the beginning of the financial year or close of financial year under report and even as on date. Further, no Company has become or ceased to become the Subsidiary/ Associate/ Joint Venture of the Company during the financial year.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

No significant or material orders were passed by the Regulators or Courts or Tribunals that impact the going concern status and Company's operations in future.

DETAILS IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

Your Company has established and maintained a framework of internal financial controls and compliance systems. Based on the framework of internal financial controls and compliance systems established and maintained by the Company, the work performed by the internal, statutory and secretarial auditors and external consultants, including the audit of internal financial controls over financial reporting by the statutory auditors and the reviews performed by management and the relevant board committees, including the audit committee, the Board is of the opinion that the Company's internal financial controls were adequate and your Company is constantly endeavouring to improve the standards of internal control in various areas and taking steps to strengthen the internal control system to make it commensurate and effective with the nature of its business.

Further, the statutory auditors of your Company have also issued an attestation report on internal control over financial reporting (as defined in section 143 of Companies Act, 2013) for the financial year ended on March 31, 2025, which forms part to the Statutory Auditor's Report.

VIGIL MECHANISM

The Board of Directors, on the recommendation of the Audit Committee, established a vigil mechanism for directors and employees called "Whistle Blower Policy", pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, to report genuine concerns or grievances about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or Ethics Policy and to provide adequate safeguards against victimization of persons who use such mechanism and to provide direct access to the Chairperson of the Audit Committee in appropriate or exceptional cases.

The Whistle Blower Policy is posted under the Investors section of the Company's website at <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/whistle%20blower-policy.pdf>

ANTI-SEXUAL HARASSMENT POLICY

The Company has adopted a policy on Prevention of Sexual Harassment of Women at Workplace in accordance with The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company has taken several initiatives across the organization to build awareness amongst employees about the Policy and the provisions of the Prevention of Sexual Harassment of Women at Workplace Act. The Company has constituted Internal Complaints Committee as required under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Further details follow:

Particulars	Number of Complaints / cases
Number of complaints of sexual harassment received in the year	0
Number of complaints disposed off during the year	0
Number of cases pending for more than ninety days	0

STATEMENT ON COMPLIANCE WITH THE PROVISIONS OF MATERNITY BENEFITS ACT, 1961

The company is fully compliant with the provisions of the Maternity Benefit Act, 1961, ensuring all eligible employees receive the mandated maternity benefit.

CODE OF CONDUCT FOR PREVENTION OF INSIDER TRADING

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed and disclosures to be made while in possession of Unpublished Price Sensitive Information and while dealing in the shares of the Company, as well as the consequences of violations. The Policy has been formulated to regulate, monitor and ensure reporting of trading by insiders by employees and to maintain the highest ethical standards while dealing in the company's securities.

The Insider Trading Policy of the Company, covering the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information and Code of Conduct for prevention of insider trading is available on our website at https://vineetlabs.co.in/images/pdf/2025.06.10code-practices-procedures-fair-disclosure-UPSIVLL_F.pdf and <https://vineetlabs.co.in/images/pdf/2025.06.10code-conduct-forprohibition-insider-trading.pdf>

MANAGEMENT DISCUSSION & ANALYSIS REPORT

A report on Management Discussion & Analysis forms part of the Annual Report as per the requirements of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.

INVESTOR EDUCATION AND PROTECTION FUND

Pursuant to the applicable provisions of the Companies Act, 2013, read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ('the Rules'), all unpaid or unclaimed dividend are required to be transferred by the Company to the IEPF established by the Central Government, after the completion of seven years. Further, according to the Rules, the shares in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more shall also be transferred to the demat account created by the IEPF Authority.

STATUTORY AUDITORS

The Members of your Company in the 6th Annual General Meeting held on September 28, 2022 appointed NSVR & Associates LLP, Chartered Accountants (Registration No. 0088015/S200060) as the Statutory Auditors of the Company for a term of 5 (five) consecutive financial years from the conclusion of the 6th Annual General Meeting till the conclusion of the 11th Annual General Meeting i.e from the FY 2022-23 to FY 2026-27.

AUDITORS' QUALIFICATION AND REMARKS

There are no qualifications and remarks from the Auditors of the Company.

However, the Auditors brought to the notice of the members that there are certain delays in depositing undisputed statutory dues i.e., taxes deducted at source. To which, the Board explained that the delay was because of insufficient cash flows and shortage of working capital.

SECRETARIAL AUDITORS

M/s. P S Rao & Associates, Practicing Company Secretaries were appointed as the Secretarial Auditors for the financial year 2024-2025. Pursuant to Section 204 of the Companies Act, 2013 and the Rules made thereunder, the Secretarial Audit Report for the financial year ended on March 31, 2025, in **Form MR-3**, is annexed to this Annual Report as **Annexure IV**.

Pursuant to sub-regulation 1(b) of Regulation 24A of the SEBI Listing Regulations, the Board in its meeting held on May 12, 2025 has recommended the appointment of M/s P S Rao & Associates, Practicing Company Secretaries, as the Secretarial Auditor of the Company for a term of 5 (five) years from FY 2025-26 to FY 2029-30, subject to the approval of shareholders in the ensuing AGM.

AUDITORS' QUALIFICATION AND REMARKS

Auditor's qualification / adverse remark / reservation	Explanations or comments by the Board
As required under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Company transferred the unspent CSR amount pertaining to the financial year 2022-23 to a separate bank account on August 25, 2023. The unspent CSR amount is required to be spent by March 31, 2026.	The unspent CSR funds are parked in a separate bank account and will be utilized for the proposed village road project near the factory after obtaining all required clearances.
In a few instances, the forms were filed with the Registrar of Companies after the prescribed time.	The Company ensures timely filing of all forms within the prescribed due dates

COST AUDITORS

Pursuant to the provisions of Section 148(3) of the Companies Act, 2013, the Board in its meeting held on May 29, 2024 has appointed KJU & Associates, Cost Accountant (Registration No.000474) as the Cost Auditor for the Financial Year 2024-25 who has carried out the Cost Audit for the applicable business for the year under review. The company is maintaining cost accounts and records as specified under sub-section (1) of Section 148 of the Companies Act, 2013.

Yet again, the Board of Directors has appointed KJU & Associates, Cost Accountant (Registration No.000474) as Cost Auditor of the Company for the financial year 2025-26 at a remuneration of Rs. 60,000/- in its meeting held on May 12, 2025. The remuneration payable shall be ratified by the members at the ensuing AGM that was made part of the notice.

INTERNAL AUDITORS

V D P & Co, Chartered Accountants (Firm Regd No.024607S) are the Internal Auditors of the Company for the financial year 2024-25. The Internal Auditors carry out audit as per the audit plan defined by the Audit Committee and regularly updates the committee on their internal audit findings at the Committee's meetings. The Internal

Auditors were satisfied with the management response on the observation and recommendations made by them during the course of their audit.

The same Chartered Accountants were appointed as the Internal Auditors of the Company for the financial year 2025-26 by the Board in its meeting held on May 12, 2025.

AUDIT COMMITTEE

The details of the composition of the Audit Committee as required under the provisions of Section 177(8) of the Companies Act, 2013 is given in the Corporate Governance Report furnished as part of the Annual Report. There have been no instances during the year where recommendations of the Audit Committee were not accepted by the Board.

NOMINATION AND REMUNERATION COMMITTEE

The details of the composition of the Nomination and Remuneration Committee are given in the Corporate Governance Report furnished as a part of the Annual Report.

STAKEHOLDERS' RELATIONSHIP COMMITTEE

The details of the composition of the Stakeholders' Relationship Committee are given in the Corporate Governance Report furnished as part of the Annual Report.

PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES

The remuneration paid to your directors is in accordance with the Nomination and Remuneration Policy formulated in accordance with Section 178 of the Companies Act, 2013 and Regulation 19 of the Listing Regulations.

The information required under Section 197 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) in respect of directors/employees of the Company is appended as **Annexure – V** to this Report.

CORPORATE GOVERNANCE

Your Company is committed to maintain high standards of corporate governance and adhere to the corporate governance requirements set out by Securities and Exchange Board of India.

The Report on Corporate Governance as stipulated under the Listing Regulations, forms part of the Annual Report.

The detailed report on Corporate Governance as per the format prescribed by Securities and Exchange Board of India under Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with a certificate from P S Rao & Associates, Practicing Company Secretaries, confirming compliance with the requirements of Corporate Governance is attached with this report as **Annexure VI**. There are no observations or adverse remarks in the said certificate.

As required by Listing Regulations, a certificate from P S Rao & Associates, Practicing Company Secretaries confirming that none of the directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of the companies is attached to this report as **Annexure VII**.

SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards issued by the Institute of Company Secretaries of India.

DEPOSITS

The Company did not accept any deposits within the meaning of provisions of Chapter V – Acceptance of Deposits by Companies of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY

There were no material changes and commitments affecting the financial position of your Company that have occurred between the end of the financial year (March 31, 2025) of the company to which the financial statements relate and the date of the report (May 12, 2025).

REPORTING OF FRAUDS BY AUDITOR

During the year under review, neither the Statutory Auditors nor the Internal Auditors has reported to the Audit committee under Section 143(12) of the Companies Act 2013, any instances or fraud committed against the company by its officers or employees, the details of which need to be mentioned in the Board's report.

DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016

No applications were made and no proceedings were pending under the Insolvency and Bankruptcy Code, 2016 during the year under the review.

DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF

No one time settlement took place during the year under review.

ACKNOWLEDGMENTS

Your Directors thank the Company's employees, customers, vendors, and investors for their continuous support. The Directors also thank the Government of India, Governments of various states in India, and concerned Government departments and agencies for their co-operation.

For and on behalf of the Board
Vineet Laboratories Limited

Place: Hyderabad
Date: May 12, 2025

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Satyanarayana Raju Bhupathiraju
Whole-time Director & CFO
DIN: 02697880

MANAGEMENT DISCUSSION AND ANALYSIS

a) Industry structure and developments.

The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume and the thirteenth largest by value in the world, producing more than 60,000 generic drugs across 60 therapeutic categories.

Indian pharmaceutical industry plays significant role globally, supplying affordable and low cost generic drugs to millions of people across the globe. The sector offers lower cost without compromising on quality as is reflected by the fact India has the highest number of United States Food and Drug Administration (USFDA) approved pharmaceutical plants outside the US and also a significant number of World Health Organization (WHO) Good Manufacturing Practices (GMP)-compliant plants as well as plants approved by regulatory authority of other countries. India's pharmaceutical sector forms a major component of the country's foreign trade and has been consistently making trade surplus.

India's pharmaceutical exports have demonstrated robust and consistent growth in recent years, underscoring the country's prominent role as the "Pharmacy of the World." During the financial year 2023-24, the exports of drugs and pharmaceuticals reached approximately \$27.85 billion, marking a significant growth of 9.67% compared to the previous year's \$25.39 billion, which itself was a moderate 3.25% increase over the \$24.59 billion recorded in FY 2022-23. This upward trajectory continued into FY 2024-25, when India's pharmaceutical exports surged further to about \$30.47 billion, reflecting a strong growth rate of around 9.4% year-over-year. In currency terms, the exports in FY 2023-24 stood at Rs. 2.30 lakh crore, representing a 13% increase over the Rs. 2.04 lakh crore posted in FY 2022-23. The month of March witnessed particularly strong export performance, with March 2024 exports totalling \$2.80 billion (a 12.73% increase over March 2023), followed by an even more impressive 31.2% growth in March 2025, reaching approximately \$3.68 billion. These exports span over 200 countries, with the United States remaining the largest market, accounting for nearly 30% of total exports, followed by the UK, South Africa, Brazil, and the Netherlands among others. The bulk of the export value derives from drug formulations and biologicals, which constitute roughly 75% of total pharma exports, followed by active pharmaceutical ingredients (APIs) and vaccines. India's pharmaceutical sector benefits from its extensive network of US FDA-compliant manufacturing plants, high-quality and affordable generic medicines, and its leadership role in global vaccine supply. This sustained export growth reflects India's strategic focus on maintaining high quality, regulatory compliance, and expanding market reach to highly regulated economies, positioning it for continued expansion and a growing share of the global pharmaceutical market.

During the fiscal year 2023-24, India's imports of medicinal and pharmaceutical products grew modestly by 2.02 percent to reach \$8.27 billion, up from \$8.10 billion in the previous fiscal year. However, the month of March 2024 saw a decline in imports by 2.85 percent, dropping to \$681.18 million compared to \$701.19 million in March 2023. Despite this dip in imports, the export side exhibited strong growth, with pharmaceutical exports in February 2024 increasing significantly by 22.24 percent to \$2.51 billion from \$2.05 billion in the same month the previous year. This positive export trend continued into FY 2024-25, with India's pharmaceutical exports surpassing \$30.47 billion, marking an impressive growth of about 9.4 percent over the previous year. The March 2025 exports especially highlighted the sector's strength, surging by over 31 percent to \$3.68 billion. These figures underscore India's growing dominance as a global pharmaceutical supplier, sustained by its cost-efficient production, high-quality generic drugs, and a skilled workforce, even as import growth remains relatively modest and volatile in specific months.

The top five export markets, for the sector during the last fiscal, are the US, the UK, the Netherlands, the United Kingdom, South Africa and Brazil. In 2024-25, the outbound shipments also entered new geographies like Montenegro, South Sudan, Chad, Comoros, Brunei, Latvia, Ireland, Chad, Sweden, Haiti and Ethiopia. An industry expert said that increasing market opportunities and healthy demand in countries like the US are helping exports to record healthy growth rates month after month. Experts have said that India's pharmaceutical business may exceed USD 130 billion by 2030, supported by expanding market opportunities and heightened demand in the overseas markets.

Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics.

The Pharma sector has seen a lot of investments and developments in the recent past:

- Up to 100%, FDI has been allowed through automatic route for Greenfield pharmaceuticals projects. For Brownfield pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval.
- The cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is US\$ 22.38 billion during the period April 2000–December 2025, constituting almost 3.4% of the total inflow received across sectors.
- In August 2024, Union Minister for Labour & Employment and Environment, Forest and Climate Change Bhupender Yadav launched Chemotherapy Services in 30 ESIC Hospitals across the country.
- An MoU was signed on June 4, 2023, between the Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India and Ministry of Health, Government of Suriname for Recognition of Indian Pharmacopoeia (IP) in Suriname.
- The Department of Pharmaceuticals will soon launch the Scheme for the Promotion of Research and Innovation in Pharma (PRIP) MedTech Sector. The scheme has been approved by the Union Cabinet for a period of five years starting from 2023–24 to 2027–28 with a total outlay of Rs. 5,000 crore (US\$ 604.5 million).
- Implementation of Production Linked Incentive (PLI) schemes with a total outlay of over ₹15,000 crore to boost high-value drug manufacturing, including cancer and diabetes treatments, and reduce import dependence on critical raw materials like Penicillin G.
- Promotion of Bulk Drug Parks scheme allocating ₹3,000 crore to develop mega pharma manufacturing hubs in Gujarat, Himachal Pradesh, and Andhra Pradesh to enhance production efficiency and cost-effectiveness.
- Strengthening of Pharmaceuticals Industry (SPI) scheme with ₹500 crore funding for upgrading labs, boosting research and development (R&D), and improving productivity and global competitiveness across pharma MSMEs and clusters.
- Liberalization of Foreign Direct Investment (FDI) policies allowing 100% FDI through the automatic route for greenfield pharma projects, boosting foreign investments that reached ₹12,822 crore in FY 2023–24 alone.
- Significant focus on innovation with increased R&D spending by top Indian pharma companies, advancing pipelines in biosimilars, biologics, CAR-T therapies, and mRNA vaccines, shifting towards high-value, specialty drugs.
- Expansion of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) to leverage India's skilled workforce and technology adoption in drug discovery and development.
- Government's Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) scheme operating 15,479 Kendras, providing affordable generic medicines up to 80% cheaper than branded drugs, enhancing domestic healthcare accessibility.
- India's pharma exports continuing strong growth, with incentives supporting diversification and reducing geographic and product concentration risks.
- Strategic partnerships and global alliances expanding India's market reach in the US, Europe, and emerging markets.

Some of the initiatives taken by the Government to promote the pharmaceutical sector in India are as follows:

In the Interim Budget 2025–26:

- Exemption of customs duties on three critical cancer medicines—Trastuzumab Deruxtecan, Osimertinib, and Durvalumab—reducing costs and improving patient access to these life-saving drugs.
- Extension of customs duty waiver on drugs and medicines imported under Patient Assistance Programmes (PAP) till March 31, 2029, supporting wider availability of essential medicines.
- Operationalisation of the Anusandhan National Research Fund and a financing pool of Rs. 1 lakh crore to spur private sector-driven pharmaceutical research and innovation in India.
- Increase in allocation to the Department of Pharmaceuticals to Rs. 5,268.72 crore (approximately \$603 million), a 28.8% increase over the previous fiscal year, aimed at supporting various schemes for pharma clusters, MSMEs, and R&D.

- Continued implementation and increased disbursement under the Production Linked Incentive (PLI) scheme for pharmaceuticals with a total outlay of Rs. 15,000 crores to boost domestic drug manufacturing capacity and investment.
- Increased budget allocation for biotechnology research and development from Rs. 500 crores in 2023-24 to Rs. 1,100 crores in 2024-25 to enhance innovation capabilities.
- Initiatives to streamline regulatory processes including proposals for a single-window clearance system for pharmaceuticals and medical devices to improve ease of doing business.
- Proposed multi-year transfer pricing assessments and expanded safe harbour rules to reduce litigation and provide clarity in cross-border pharma transactions and collaborations.
- Increased funding to healthcare schemes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), with a 7% increase in budget allocation for better healthcare coverage.
- Promotion of research and development focusing on novel drugs, biosimilars, bio-pharmaceuticals, and enhanced support for contract research organizations (CROs) and contract manufacturing organizations (CMOs).
- Emphasis on improving medical infrastructure, expanding medical education, and boosting medical tourism through campaigns like "Heal in India" in partnership with the private sector.
- As per the Union Budget 2024-25:
 - A mission to eliminate sickle cell anaemia by 2047 will be launched. It would involve raising awareness, conducting a comprehensive screening of seven crore individuals in the impacted tribal regions between the ages of 0 and 40, and providing counselling through coordinated efforts.
 - For innovation in the pharmaceutical sector, through centres of excellence, a new initiative to encourage pharmaceutical research and innovation will be implemented. The government persuades business to spend money on R&D in a few chosen priority fields. At the grassroots level, government has also announced on building 157 nursing colleges in co-location with government medical colleges.

b) Opportunities and Threats.

Opportunities:

Market Size: Often hailed as the 'pharmacy of the world', the Indian pharmaceutical industry is booming. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India's domestic pharmaceutical market expected to reach US\$ 120-130 billion by 2030. India's biotechnology industry comprises biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics. Beyond just keeping up with the demand at home, the Indian pharma industry commands over 20% of the global pharma supply chain and addresses approximately 60% of the worldwide demand for vaccines. It meets 40% of the generic demand in the US and provides a quarter of all medicines in the UK.

Financially speaking, the pharma sector is expected to grow. A report by EY and FICCI recently stated that the Indian Pharmaceutical market is expected to reach a value of USD 130 billion by the end of 2030. The global Pharmaceutical market is estimated at an astronomical USD 1 trillion in value.

In the Pharmaceutical industry, AI and big data technologies will allow companies to restructure their business models. They will rationalize biopharma manufacturing, improve financial decisions, reduce human error, increase performance and accelerate time-to-market. The power of AI is already being leveraged to create pipelines of precision-engineered oncological and immunological treatments.

Overall, the pharma and healthcare industry in India presents tremendous potential for growth especially in innovation, research, early detection, and futuristic solutions like robotics-assisted surgery. By leveraging its strengths, embracing technological advancements, and fostering collaboration, the Indian pharmaceutical industry can continue to play a pivotal role in shaping the future of healthcare delivery both domestically and internationally.

Exports: India is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries in the world, with US being the key market. Generic drugs account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US\$ 24.60 billion in FY22 and US\$ 24.44 billion in FY21.

Road Ahead: Medicine spending in India is projected to grow 9–12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers, which are on the rise. The Indian Government has taken many steps to reduce costs and bring down healthcare expenses. Speedy introduction of generic drugs into the market has remained in focus and is expected to benefit the Indian pharmaceutical companies. In addition, the thrust on rural health programmes, lifesaving drugs and preventive vaccines also augurs well for the pharmaceutical companies.

Threats:

The issue that Indian Pharma is facing today is the govt. stringent control over the pricing of drugs. If one can see the other perspective then it seems fine as Citizens are getting good quality drugs at cheaper prices but it becomes a hurdle in the innovation capabilities of Pharma companies. If there is not much of the surety of getting the investment back that is already spent on R&D then the pharma companies will hesitate to invest respectable amounts in their R&D departments for drug discovery.

Counterfeiting is viewed as a serious public health menace promoted by criminals with little regard for the health and safety of patients which requires a combined public –private sector response. The counterfeit medicine market is more lucrative than the narcotics business with the World Health Organization estimating that counterfeiting costs the global pharma industry \$75 billion USD a year. The Criminal Intelligence Service Canada says that “Most estimates range in the billions annually for global losses.”

With that in mind, it’s unsurprising that the majority of pharmaceutical companies believe that the illegal use of their brand name on these counterfeit products threatens the integrity of the company that they are trying to represent.

In addition to lost revenue, counterfeiting imposes other costs including increased costs to secure the supply chain, investments in anti-counterfeiting technologies, potential reputational damage and risk of liability.

Indian Pharma market is heavily dependent on China for its API needs. Currently, about 80% of the Indian Pharma Market APIs requirement is fulfilled by the Chinese Pharma Market. Occasionally there is an increase in API pricing due to policy changes & geo-political reasons. For example, to curb pollution, China closed many of the API manufacturing units which led to a shortage of API supply. Ultimately the prices of APIs were increased.

Pharma companies also need to be aware of threats from their employees. This often occurs because of disgruntled employees trying to disrupt day-to-day operations or sell customer data to a third party or competitor. Threats can also be caused by well-intentioned users not following corporate policies or through human error.

c) Segment-wise or product-wise performance.

Pharmaceutical Intermediates Market - Segment-wise performance:

The Pharmaceutical Intermediates Market is Segmented by Type (Chemical Intermediate, Bulk Drug Intermediate, and Others), Application (Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, and Others), End-User (Biotech and Pharma Companies, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America).

The pharmaceutical intermediates market studied is anticipated to grow with a CAGR of nearly 5.3%, during the forecast period (2022 - 2027).

According to a study that was published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 were discovered using a combined virtual and experimental screening strategy. Furthermore, they choose among the medications that were already in use and were examined to check for structural similarity against a library of almost 4,000 medications that were already in use, with hydroxychloroquine (HCQ) serving as a reference medication. The study suggested remdesivir and favipiravir therapies as prospective adjuvants in COVID-19 treatment and zuclopenthixol, nebivolol, and amodiaquine as

potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection. Thus, the pharmaceutical intermediates market is likely to increase both during and after a covid pandemic. As a result, market growth is anticipated in the coming years.

Given that these pharma intermediates are used in the treatment for cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the World Health Organization's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification. The discovery and development of novel drugs to treat, prevent, or cure a number of diseases, including cancer, diabetes, cardiovascular disorders, and chronic kidney disease, has been hampered by the significant rise in disease incidence rates around the world.

Additionally, increased investments in R&D are a significant driver of market expansion. Hence, owing to the rising R&D activities in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to observe a steady growth as well.

Product-Wise Performance

Our Company Vineet Laboratories has been involved in developing and manufacturing of API Intermediates through innovative technology. We are an expert in designing, developing, and manufacturing API Intermediates which are key ingredients for manufacturing drugs for saving human race. Our products are cost-effective, and they cater to customers across the nation and overseas.

Name of the Product	No. of batches	Quantity dispatched kgs	Sales In Rs.	Remarks
(2S,3S,5S)-2-Amino-3-hydroxy-5-(tert-butyloxy carbonyl) amino-1,6-diphenyl hemi succinic acid salt. (BDH)	19	4641	5,45,65,000	Intermediate of Ritonavir API, for treating HIV patients, it works by decreasing the amount of HIV in the blood.
Carbonic acid, 4-Nitro phenyl-5-thiazolyl methyl ester (NCT)	49	6867.35	5,22,69,840	
N-((N-Methyl-N-((2-iso propyl -4-thiazolyl) methyl) carbonyl)-L-valine (MTA)	8	166.40	18,83,400	
Octyl Methoxy Cinnamate	5	6810	54,76,900	Cosmetic product used in UV absorption creams.
Empa Lactone Solution in MDC: CAN (MCT)	3	379.00	52,25,460	Raw material used in various reactions.
Trans-4-Methycyclohexyl isocyanate (ICY)	17	2513.00	2,26,99,605	Intermediate of Glimepiride, which is used to treat high blood sugar levels caused by type 2 diabetes
Phenyl ethyl Isocyanate (PCY)	2	284.5	6,51,000	Reagent used for making Glimepiride
DHHB	4	285.00	6,15,000	Cosmetic product used in sun screens as UV absorption.

1-Hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)-pyridone ethanol ammonium salt (CNT)	61	26571.4	7,06,23,340	Piroctone Olamine is a cosmetic product used as anti-dandruff.
(2S,3S,5S)-2-Amino-3-hydroxy-5-(1-(tetrahydro pyrimidin-2-onyl)-3-methyl butanoyl) amino-1,6-diphenyl hexane-S-pyroglytamate (THP)	8	2737.5	2,35,31,100	Intermediate of Lopinavir API, for treating HIV patients, It works by decreasing the amount of HIV in the blood.
Lopinavir (DPC) OR 2,6-DimethylPhenoxy Acetyl Chloride	6	2801.0	35,67,600	Intermediate of Lopinavir API, for treating HIV patients, it works by decreasing the amount of HIV in the blood.
IsoPropyl-B- {D}-ThioGlactoPyranoside(IPTG)	3	136	44,97,500	Fine chemical. It's a molecular biology reagent.
E-2(2 ETHYLEXYLP-AMINO BENZOATE) (EHT-II)	3	2335.80	23,35,800	Intermediate of Cosmetic product - CI, it is an organic compound used in sunscreens to absorb UVB radiation.
EthylhexylTriazone (EHT-III)	0	410.00	6,48,000	Cosmetic product - CI, it is an organic compound used in sunscreens to absorb UVB radiation
N-Butyl Lithium (NBL) 100% Active Basis	75	41636.83	14,71,75,685	Reagent - used in various types of reactions
1-Methyl-1-Phenyl-1(2-pyridyl) Methanol Hydrochloride (DHN)	7	1251	52,06,000	Intermediates of Nadolol API - it is a medication used to treat angina and hypertension, which are significant risk factors for the development of coronary artery disease, heart failure, stroke, and a host of other cardiovascular conditions. Nadolol belongs to the class of beta-blocker medications
Boron Trichloride 1.0 M Solution in Hexane/ Toluene	2	210 Ltr	3,09,120	Fine chemical
2-Acetyl Thiophene	0	1	2,000	It is a Raw material used in the synthesis of various anti-inflammatory drugs.
2-Benzoylpyridine (2-BOP)	1	104	2,28,000	Raw material for Doxylamine, which is an antihistamine medication which is used in the treatment of insomnia and allergies
Methyl magnesium chloride solution (3 M THF) (MMC)	1	7	1,890	Reagent - used in various types of reactions

2-Phenyl-1H-benzo[d]imidazole-5-sulfonic acid - Phenyl Benzimidazole Sulfonic Acid (PBSA)	177	101922.60	9,46,49,605	Cosmetic product – CI, it is an organic compound used in sunscreens to absorb UVB radiation.
G-5285	1	60.9	91,36,043	Reagent – used in various types of reactions
2-chlorothiophene (2-CT)	8	1075.00	11,45,000	Reagent – used in various types of reactions
Boron Tribromide 1. M in MDC	2	270.00	4,40,100	Reagent – used in various types of reactions
Lithium Chloride Salt	28	15200.00	1,44,70000	Inorganic compound, No Therapeutic use
Lithium Chloride	77	33500.00	1,30,87500	Inorganic compound, No Therapeutic use
Lithium Chloride Crude	34	14682.00	14,68,200	Inorganic compound, No Therapeutic use
4-Nitrophenyl phosphate disodium salt (PNPP (DSPP)	1	30	3,60,000	Fine Chemical
Lithium bis (tri methyl silyl) amide in THF (Li HMDS)	2	1025	5,55,375	Reagent – used in various types of reactions
Trans-4-Amino Cyclohexanol (TAC)	1	541.10	12,98,640	Intermediate used in the ambroxol API Used for Cough syrup
(4S,6S)-4-(ACETYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO[2,3-B]-THIOPYRAN-7,7-DIOXIDE (DZE-VIII)	1	6.0	2,42,000	Dorzolamide intermediate, which is used to treat Glaucoma
BTZ-III	2	355.00	15,60,000	Cosmetic product – CI, it is an organic compound used in sunscreens to absorb UVB radiation.
AVOBENZONE	0	910.00	9,38,875	Cosmetic product – CI, it is an organic compound used in sunscreens to absorb UVB radiation
4-NPCF	0	3.0	21000	Reagent – used in various types of reactions
HSA	10	5050.00	50,24,000	Reagent – used in various types of reactions
Vitride	0	3.0	12,000	Reagent – used in various types of reactions
NBL(HP)	0	1.4	4620	Reagent – used in various types of reactions
(3R,4S,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(HYDROXYMETHYL)-2-METHOXY TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL (TBR)	2	184.00	25,62,321.44	Reagent – used in various types of reactions
E-2(2-ETHYLEXYLP-AMINO BENZOATE) (EHT-I)	1	1570.00	7,85,000	Intermediate of Cosmetic product – CI, it is an organic compound used in sunscreens to absorb UVB radiation.
Dibenzoyl-L-Tartaric Acid Monohydrate	34	25255.00	1,12,88,985	Raw material used for various reactions

4-Methoxy-3,5-Dimethyl-2-Pyridinemethanol Hydrochloride	10	17800.00	3,08,80,000	Raw material used for various reactions
RCMH R-(-)-3-(Carbamoylmethyl)-5-methylhexanoic acid	4	1500.00	22,42,500	Raw material used for various reactions
2-Amino-5-(S)-N,N-Dibenzyl Amino-3-Oxo-1,6-Diphenylhex-2-Ene (DAH-II)	1	135.00	3,91,500	Raw material used for Lopinavir API, Anti-HIV drug
5-Hydroxy Methyl Thiazole	0	979.75	48,00,775	Raw material used for Ritonavir API, Anti-HIV drug

Our Company achieved a turnover of Rs. 7,499.50 Lakhs in FY 2024-2025 as against Rs. 15,059.13 Lakhs in FY 2023-2024. Our Profit after tax in FY 2024-2025 stood at Rs. (2,019.10) Lakhs as against Rs.102.71 Lakhs in FY 2023-2024. Sales of API intermediates carry a potential of generating up to 100% of the product sale value. Revenues will continue to grow as the demand for products are increasing.

As per Annual Quality Review, we have identified that all products being manufactured are improved in quality and obtaining improved yields.

d) Outlook

The rapidly increasing prevalence of chronic diseases and growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the prevention of chronic diseases. For instance, as per the International Diabetes Federation Diabetes, the global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030, and the number is rising rapidly. Pharmaceutical drugs have remained key to management of chronic diseases and other diseases. The pharmaceutical supply chain in India has undergone significant transformation, spurred by globalization, technological advancements, regulatory shifts, and rising healthcare product demand. The focus has shifted from manual and transactional processes to automation and strategic innovation.

For instance, according to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases. According to FMI's analysis, pharmaceutical intermediates sales have grown at 3.7% CAGR between 2015 and 2019.

Various small- and medium-scale companies are also focusing on enhancing their production capacity, which is another factor that is expected to fuel growth of the pharmaceutical intermediates demand. Hence, demand for pharmaceutical intermediate is increasing and sales are set to grow significantly through 2030.

Moreover, major pharma companies are increasingly relying on contract manufacturing organizations for the manufacturing of pharmaceutical intermediates and final formulations. These companies are focusing on enhancing the capacities of their manufacturing plants in various countries of the world, such as India and China, where the cost of production is comparatively lower. These developments present a positive outlook for growth. FMI expects global pharmaceutical intermediates market to grow at 4.3% CAGR through 2030.

e) Risks and concerns.

- **Highly Regulated Industry:** The pharmaceutical industry is a tightly regulated industry where all production must comply with good manufacturing practices (GMP) and quality requirements should be strictly satisfied. Historically, manufacturing in the pharmaceutical industry has been carried out in batch mode which potentially results in expensive, inefficient and poorly controlled processes. Recently, both pharmaceutical industries and regulatory authorities have recognized that continuous manufacturing has significant potential to improve product quality. Moreover, environmental, health and safety issues are driving the industry towards more efficient and more predictive manufacturing.
- **Liquid damage and contamination:** Manufacturing medicines and drugs requires a complex process with different equipment and ancillary systems. Each equipment and system possess a contamination risk. A few of the common sources are pathogens and physical contamination. Other contaminants include smoke and liquid damage. Power outages and issues beyond an organization's control can cause contamination of process or batches of drugs, which can affect the business. Liquid damage from water

lines used for fire protection, or for cooling is often over looked contaminants. These have caused large damage to many companies in the industry. Similarly, smoke damage due to a controlled fire in one area can spread to other areas, if the plant is poorly designed. An effective equipment maintenance program together with proper building materials can minimize this risk.

- Equipment breakdown: Pharmaceutical companies use reactors, dryers, and sterilizers in their plants, a breakdown in one of them can stop production. The lack of an effective maintenance system can lead to:
 - Excessive machine breakdowns.
 - Shortened life-span of the facility.
 - Sub-standard products.
 - Delay in delivery dates.
 - Disproportionate investment in spare parts and maintenance materials.
- Pharmaceutical fraud
Pharmaceutical fraud remains a major challenge for the industry – and it was possibly even worse during COVID-19. Globally and in the U.S. in particular, pharmaceutical fraud account for a large number out of all crimes in health care, which result into severe costs to the society.
- Qualified workforce
In order to define qualified workforce, we can say that it concerns people who carry out technical or intellectual work that requires thorough knowledge in a particular field of its discipline. It should be noted that work productivity within an industry depends on the qualification of the employed workforce. Relying on qualified workforce is all the more one of the essential elements that ensures a promising future in the pharmaceutical industry. In fact, the pharmaceutical industry needs workforce that has significant knowledge, experience and skills. The pharmaceutical sector has to increase its investment in highly-qualified workforce to continue progress.

f) Internal control systems and their adequacy.

The internal audit and other internal checks implemented in the Company are adequate and commensurate with the size and nature of operations providing sufficient assurance and safe guarding all assets, authorizing all transactions and its recording and timely reporting. The Audit Committee of the Board of Directors regularly reviews the internal audit reports and the adequacy and effectiveness of internal controls.

g) Discussion on financial performance with respect to operational performance.

The Revenue from Operations for the current year is at Rs. 7,499.50 lakhs compared to Rs. 15,059.13 lakhs in the previous year. The Profit before tax was Rs. (2,077.55) Lakhs against the previous Profit of Rs. 36.34 Lakhs. The Profit after Tax was Rs. (2,019.10) Lakhs vis-a-vis Rs. 102.71 Lakhs in the previous year.

h) Material developments in Human Resources / Industrial Relations front, including number of people employed.

Industrial relations are harmonious. People form the foundation of organisations and their growth. The company recognized the importance and contribution of the human resources for its growth and development. As on 31st March, 2025, the Company has total strength of 57 employees.

i) Key Financial Ratios:

S. No	Financial Ratios	FY 2025	FY 2024
i	Debtors Turnover	3.34	4.51
ii	Inventory Turnover	1.41	2.38
iii	Interest Coverage Ratio	-4.72	1.28
iv	Current Ratio	0.91	1.16
v	Debt Equity Ratio	2.73	1.28
vi	Operating Profit Margin (%)	-0.25	0.68
vii	Net Profit Margin (%)	-26.92	0.68
viii	Return on Net Worth (%)	-81.79	3.00

Since the Net profit of the Company has decreased from Rs. 102.71 lakhs FY 2024 to Rs. (2019.10) lakhs FY 2025, there is a decrease in the Return on Net Worth Ratio.

Cautionary Statement:

The Statement in this section describes the Company's objectives, projections, estimates, expectations and predictions which may be "forward looking statements" within the meaning of the applicable laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could make difference to the Company's operations include economic conditions affecting demand/supply and price conditions in the domestic and overseas markets in which the Company operates changes in the Government regulations, tax laws and other incidental factors.

Disclosure of Accounting Treatment:

Where in the preparation of financial statements, a treatment different from that prescribed in an Accounting Standard has been followed, the fact shall be disclosed in the financial statements, together with the management's explanation as to why it believes such alternative treatment is more representative of the true and fair view of the underlying business transaction. – Not Applicable

The Company has not followed any treatment different from that prescribed in an Accounting Standard.

Annexure I**FORM NO. AOC.2**

(Pursuant to clause (h) of Sub-section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in Sub-section (1) of Section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

- 1) Details of contracts or arrangements or transactions not at arm's length basis.

All the contracts or arrangements or transactions entered into by the Company with related parties during the financial year 2024-25 were at arm's length basis.

- 2) Details of material contracts or arrangement or transactions at arm's length basis

Name(s) of the related party and nature of relationship	Nature of contracts/arrangements/transactions:	Duration of the contracts /arrangement s/transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Date(s) of approval by the Board, if any	Amount paid as advance, if any Rs.
Vineet Life Sciences Private Limited Entities owned by common Promoters	Sale and Purchase of goods and services	Ongoing	The Company has entered into specific arrangements with Vineet Life Sciences for intermediate raw material supplies. Transactions are in line with such arrangements.	Appropriate approvals have been taken for RPT	Nil
Organo Metallics Private Limited Enterprise having director, who is a relative of Promoter of Listed Company	Sale and Purchase of goods and services	Ongoing	The Company has entered into specific arrangements with Organo Metallics for intermediate raw material supplies. Transactions are in line with such arrangements.	Appropriate approvals have been taken for RPT	Nil

The above contracts were entered into in ordinary course of business.

For and on behalf of the Board
Vineet Laboratories Limited

Place: Hyderabad

Date : May 12, 2025

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Satyanarayana Raju Bhupathiraju
Whole Time Director & CFO
DIN: 02697880

ANNEXURE II**CONSERVATION OF ENERGY, RESEARCH & DEVELOPMENT, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS/ OUTGO:**

The particulars as prescribed under Section 134 (3) (m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 are as follows:

A. Conservation of Energy:

- i. the steps taken or impact on conservation of energy;
-All regular CFL & MV lamps were replaced with LED bulbs. All reactors and centrifuges were equipped with VFD (variable frequency drive). Cutoff system installed for vacuum pumps. Temperature controllers installed to chilling plants and cooling towers.
- ii. the steps taken by the company for utilizing alternate sources of energy;
-625KV & 500 KV diesel generators are in place for alternative source of energy
- iii. the capital investment on energy conservation equipments;
-investing amounts as required sufficiently for energy conservation equipment

B. Technology Absorption:

- i. the efforts made towards technology absorption;
-Recruited efficient candidates in R&D Department
- ii. the benefits derived like product improvement, cost reduction, product development or import substitution;
-Improved quality and yield of products. Customer satisfaction. Procurement of raw materials increased due to cost reduction.
- iii. in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)- No imported technology.
 - (a) the details of technology imported; - NA
 - (b) the year of import; -NA
 - (c) whether the technology been fully absorbed; -NA
 - (d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof; and - NA
- iv. the expenditure incurred on Research and Development - Nil

C. Foreign Exchange Earnings and Outgo during the year:

- i. Foreign Exchange Earned : Nil
- ii. Foreign Exchange Outgo : Rs.47,23,164/-

For and on behalf of the Board
Vineet Laboratories limited

Place: Hyderabad
Date: May 12, 2025

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Satyanarayana Raju Bhupathiraju
Whole -Time Director & CFO
DIN: 02697880

ANNUAL REPORT ON CSR ACTIVITIES FOR THE FY ENDED 31-03-2025
(Pursuant to Sec 135 of the Companies Act, 2013 read with Rule 8 of Companies (Corporate Social Responsibility Policy) Rules, 2014)

1. A brief outline on CSR policy of the Company: As per Sec 135 read with Schedule VII to the Companies Act, 2013, a CSR policy was adopted by the Company. The detailed policy is mentioned in the Directors' Report under the head Corporate Social Responsibility and the same is available on the website of the Company at <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/CSR-policy.pdf>

In the aforesaid backdrop, policy on Corporate Social Responsibility of the Company is broadly framed taking into account the following measures:

1. Actively contribute to the community in which we operate and provide high quality solutions to the issues impacting their lives, which results in the overall development of the society.
2. Ensure welfare & sustainable development of the community at large.
3. Innovate for our society, deliver high quality services and impactful interventions over a long period of time and ensure sustained relations with the society.
4. Ensure making decisions based not only on financial or operational factors, but also on the social and environmental consequences.
5. Uplift the communities around its areas of operation, there by create a positive impact in the community.
6. Identify interventions to ensure sustainable social development after considering the immediate and long-term socio environmental consequences.
7. Setting high standards of quality in providing interventions and support to meet the needs of the community.
8. Practice its corporate values through its commitment to grow in a socially and environmentally responsible way, while meeting the interests of its stakeholders.

2. The Composition of the CSR Committee:

Name of the Director	Designation / Nature of Directorship	No. of meetings of CSR committee held during the year	No. of meetings of CSR committee attended during the year
Satyanarayana Raju Bhupathiraju	Chairman - Whole-time Director cum CFO	1	1
Gaddam Venkata Ramana	Member - Managing Director	1	0
Dilip Vishnu Achrekar	Member - Independent Director	1	1

3. Web-link where Composition of CSR Committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the Company:

Committee: <https://vineetlabs.co.in/committee-board-directors.html>

Policy: <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/CSR-policy.pdf>

Project: <http://vineetlabs.co.in/csr.html>

4. Executive Summary along with web-link of Impact assessment of CSR projects carried out in pursuance of Sub-rule (3) of Rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014: Not Applicable
- 5.
- Average net profit of the company as per Section 135(5): Nil
 - Two percent of average net profit of the company as per Section 135(5): Nil
 - Surplus arising out of the CSR projects or programmes or activities of the previous financial years: Nil
 - Amount required to be set off for the financial year, if any: Nil
 - Total CSR obligation for the financial year [(b)+(c)-(d)] : Nil
- 6.
- Amount spent on CSR Projects (both Ongoing project and other than Ongoing project): Nil
 - Amount spent in Administrative Overheads : Nil
 - Amount spent on Impact Assessment, if applicable – Not Applicable
 - Total amount spent for the Financial Year [(a)+(b)+(c)] – Nil
 - CSR amount spent or unspent for the financial year: Nil

Total Amount spent for the Financial Year (In Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per Section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount	Date of Transfer	Name of the Fund	Amount	Date of transfer
N.A.	N.A.	N.A.	N.A.	N.A.	N.A.

f) Excess amount for set-off, if any:

Sl.No.	Particulars	Amount (in Rs.)
(i)	Two percent of average net profit of the company as per sub-section (5) of section 135	0
(ii)	Total amount spent for the Financial Year	0
(iii)	Excess amount spent for the Financial Year [(ii)-(i)]	0
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	0
(v)	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	0

7. Details of Unspent CSR amount for the preceding three financial years.

1	2	3	4	5	6		7	8
Sl.No	Preceding financial year(s)	Amount transferred to Unspent CSR Account under sub-section (6) of section 135 (in Rs.)	Balance Amount in Unspent CSR Account under sub-section (6) of section 135 (in Rs.)	Amount spent in the financial year (in Rs.)	Amount transferred to a Fund as specified under Schedule VII as per second provision to sub section (5) of section 135, if any.		Amount remaining to be spent in succeeding financial year(s)	Deficiency, if any
					Amount (in Rs.)	Date of Transfer		
1	2022-23	8,92,849	8,92,849	-	0	N.A	8,92,849	-

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

Yes No

If yes, enter the number of Capital assets created/acquired

Furnish the details relating to such assets(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

1	2	3	4	5	6		
Sl.No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Pin code of the property or asset(s)	Date of creation	Amount of CSR amount spent	Details of entity/ Authority/ beneficiary of the registered owner		
					CSR Registration number	Name	Registered address
Not Applicable							

9. Specify the reasons(s), if the company has failed to spend two percent of the average net profits as per section 135(5): The company is not required to spend for any CSR activities for the FY 2024-25. However, the unspent CSR funds kept in a separate bank account shall be utilized post receipt of necessary approvals for laying of village road near factory.

10. Responsibility Statement of the CSR Committee that the implementation and monitoring of CSR Policy, is in compliance with CSR objectives and policy of the Company:

The Company has framed a suitable CSR policy as per the provisions of the Companies Act, 2013 but because of delay in obtaining necessary approvals, the implementation and monitoring of CSR activities got delayed.

For and on behalf of the Board
Vineet Laboratories limited

Place: Hyderabad
Date: May 12, 2025

Satyanarayana Raju Bhupathiraju
Chairman of CSR Committee
DIN: 02697880

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Annexure IV

Form MR-3

Secretarial Audit Report

for the financial year ended March 31, 2025

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

To
The Members,
Vineet Laboratories Limited,
Hyderabad.

We, P.S.Rao & Associates, Company Secretaries have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Vineet Laboratories Limited** (hereinafter called "the company") bearing Corporate Identification Number **L24304TG2016PLC112888** for the financial year ended on **31st March 2025**. Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March 2025, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2025 according to the provisions of:

- (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings – *Not Applicable for the year under review*;

The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-

- (i) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (ii) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
- (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;

- (iv) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 - *Not Applicable as the Company did not issue shares either under ESOPS / ESPS during the financial year under review;*
- (v) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 - *Not Applicable as the Company did not issue any debt securities during the financial year under review;*
- (vi) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; *Not Applicable as the Company is not registered as Registrar to an issue and Share Transfer Agent during the financial year under review;*
- (vii) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 - *Not Applicable as the Company did not delist equity shares from any stock exchange during the financial year under review;*
- (viii) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998 - *Not Applicable as the Company did not buyback equity shares during the financial year under review;*
- (ix) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015;

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The Listing Agreements entered into by the Company with National Stock Exchange of India Limited and BSE Limited

We further report that the applicable financial laws, such as Direct and Indirect Tax Laws, have not been reviewed under our audit as the same falls under the review of statutory auditor and by other designated professionals.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above *except:*

- *As required under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Company transferred the unspent CSR amount pertaining to the financial year 2022-23 to a separate bank account and is required to be spent by March 31, 2026.*
- *In a few instances, the e-forms were filed with the Registrar of Companies after the prescribed time limit.*

We further report that:

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice is given to all the directors to schedule the Board Meetings. Agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

- As a general practice of the Board, decisions were taken on unanimous consent.
- Based on our verifications and the declarations received from the respective directors, the directors were not disqualified to act as such as per the provisions of Companies Act, Rules, Orders/ Circulars/ Regulations issued by SEBI or such other acts for the time being enforceable.
- No prosecutions were initiated and no fines or penalties were imposed during the year under the Companies Act, SEBI Act, SCRA Act or other SEBI Regulations on the Company or its Directors and officers of the Company.

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For P S Rao & Associates
Company Secretaries

Date: May 12, 2025
Place: Hyderabad

P S Rao
Sr. Partner
FCS No: 10322;
C P No: 3829
PR. No:6678/2025
UDIN: F010322G000316749

*This report is to be read with our testimony of even date, which is annexed as '**Annexure A**' and forms an integral part of this report.*

Annexure A

To
The Members,
Vineet Laboratories Limited,
Hyderabad.

Our report of even date is to be read along with this letter:

- 1) Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- 2) We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the process and practices, we have followed provide a reasonable basis for my opinion.
- 3) We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- 4) Wherever required, we have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
- 5) The Compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.

The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For P S Rao & Associates
Company Secretaries

Date : May 12, 2025
Place: Hyderabad

P S Rao
Sr. Partner
FCS No: 10322;
C P No: 3829
PR. No: 6678/2025
UDIN: F010322G000316749

Annexure V

Details in accordance with the provisions of Section 197(12) of the Companies Act, 2013, read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

- i. The ratio of remuneration of each director to the median remuneration of the employees and the percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary of the Company in the financial year:

S. No	Name of the Director/KMP, Designation	Ratio of remuneration to the median remuneration of the employees	Percentage increase / decrease in remuneration
1.	Mr Gaddam Venkata Ramana, Managing Director	10.19:1	-
2.	Mr Satyanarayana Raju Bhupathiraju, CFO & Whole-time Director	7.79:1	-
3.	Mr. Alluri Ranga Raju, Non-Executive Director	0.20:1	-
4.	**Mr. Satish Pandurang Samant, Executive Director and CEO	^	-
5.	Mr. Dilip Vishnu Acharekar, Independent Director	0.20:1	-
6.	***Mr. Bhaskara Reddy Karna, Independent Director	0.15:1	-
7.	Ms. Yerukalapudi Hari Priya, Independent Director	0.20:1	-
8.	Mr. Ramesh Kumar Bandari, Company Secretary	0.60:1	-

Note: **Resigned w.e.f May 29, 2024

*** Attended only 3 meetings, since resigned w.e.f. November 14, 2024.

^ Remuneration received in FY 2025 (for part of the year) is not comparable with median remuneration and hence not stated.

- ii. The percentage increase/~~decrease~~ in the median remuneration of employees in the financial year: 12.58%
- iii. The number of permanent employees on the rolls of company: 57
- iv. Average percentile increase/~~decrease~~ already made in the salaries of employees other than the managerial personnel in the last financial year: 21%
- v. Percentile increases in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration: No change
- vi. The key parameters for any variable component of remuneration availed by the directors: Not Applicable
- vii. It is hereby affirmed that the remuneration paid is as per the Remuneration Policy, applicable for Directors, Key Managerial Personnel and other employees, adopted by the Company.
- (vi) Particulars of Employees in accordance with the provisions of Section 197(12) of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014:

S. No	Employee Name	Designation & Nature of Employment	Educational Qualifications	Age	Experience	Date of Joining	Gross Remuneration Paid (Rs. In Lacs)	Previous Employment and Designation, if any	% of share held, if any	Whether any such employee is a relative of any director / manager of the company
1	G. Venkata Ramana	Managing Director Permanent	M. Sc	57 yrs	34 yrs	01, April 2006	51.00	Siris Limited	9.01	-
2	Bh. Satyanarayana Raju	Whole Time Director & CFO Permanent	Graduation	75 yrs	43 yrs	01, March 2009	39.00	Govt. Employee	5.63	-
3	B V Ramakrishna	Manager Accounts & Finance Permanent	M.Com	60 yrs	39 yrs	01, April 2010	13.85	Siris Limited	-	-
4	P. Anjaneya Raju	Manager – QA Permanent	M.Sc	47 yrs	23 yrs	07, October 2015	12.10	GVKBIO – Tech	-	-
5	A Prabhakar Raju	Manager Warehouse Permanent	Graduation	50 yrs	24 yrs	01, April 2006	11.90	Business	3.87	Related to Satyanarayana Raju
6	M Lakshman Rao	Production Manager Permanent	Graduation	52 yrs	25 yrs	21, November 2002	11.78	Sainor Organics	-	-
7	A Srinivasa Raju	Manager Purchase Permanent	Graduation	46 yrs	22 yrs	01, April 2006	11.72	Business	2.77	Related to Satyanarayana Raju
8	K Kiran Kumar	Manager – RD Permanent	Graduation	45 yrs	26 yrs	01, October 2021	10.82	Suvin Life Sciences Limited	-	-
9	Gadde Ravi Kumar	Manager – Plant Maintenance	Diploma	46 yrs	22 yrs	28, September 2020	9.38	I 10 Laboratories Private Limited	-	-
10	J Venkata Ramana Reddy	Manager – Electrical Maintenance	Diploma	47 yrs	26 yrs	10 December, 2010	9.02	Cirex Pharmaceuticals Private Limited	-	-

For and on behalf of the Board
Vineet Laboratories Limited

Place: Hyderabad
Date: May 12, 2025

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Satyanarayana Raju Bhupathiraju
Whole-time Director & CFO
DIN: 02697880

CORPORATE GOVERNANCE REPORT

This report is prepared in accordance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and the report contains the details of Corporate Governance systems and processes at Vineet Laboratories Limited ('Vineet or 'the Company').

Corporate governance is the set of processes, customs, policies, laws and institutions affecting the way a company is directed, administered or controlled. It is a system of structuring, operating and controlling a company with a view to achieve long term strategic goals to satisfy shareholders, creditors, employees, customers and suppliers.

Corporate governance is based on principles such as conducting the business with all integrity and fairness, being transparent with regard to all transactions, making all the necessary disclosures and decisions, complying with all the laws of the land, accountability and responsibility towards the stakeholders and commitment to conducting business in an ethical manner.

The detailed report on Corporate Governance as per the format prescribed by Securities and Exchange Board of India under Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") is set out below:

1) Company's Philosophy on Code of Governance

Vineet is committed to good corporate governance. Vineet aims to achieve the objective of enhancing the shareholders' value by ensuring effective relationship with stakeholders and protecting their interests. Vineet believes that the Company's business strategy and plans should be consistent with the welfare of all its stakeholders that will bring sustained corporate growth and long-term benefit to all.

Effective corporate governance practices constitute the strong foundation on which successful commercial enterprises are built to last. The Company's philosophy on corporate governance oversees business strategies and ensures fiscal accountability, ethical corporate behaviour and fairness to all stakeholders comprising regulators, employees, customers, vendors, investors, our environment and the society at large.

Vineet has been practising the principles of good corporate governance with a great zeal of commitment and sincerity. Vineet's principle of corporate governance comes from the belief that the high standards of ethics, timely disclosures, accountability and transparency go a long way in preserving shareholders' trust and creating wealth.

The compliance with the corporate governance provisions as specified in Regulations 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, 26A, 27 and clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V are not applicable to the Company pursuant to the provisions of Regulation 15(2) of Listing Regulations.

However, the Company is in compliance with most of the exempted Regulations and the Guidance Note on Board Evaluation as prescribed by the Securities and Exchange Board of India (SEBI).

2) Board of Directors

The Company believes that an active, well-informed and independent Board is necessary to ensure the highest standards of corporate governance.

a) Composition and Category of Directors

The Board of Directors along with its committees provide leadership and guidance to the Management and directs and supervises the performance of the Company, thereby enhancing stakeholders' value. The Board has a fiduciary relationship in ensuring that the rights of all the stakeholders are protected. Your Company has an engaged and well-informed Board with qualifications and experience in diverse areas. The Board composition is in conformity with Section 149 of the Companies Act, 2013 ("the Act").

The Company's Board has an optimum combination of Executive and Non-Executive Directors including a Woman Director. The Board of Directors of the Company consists of five (5) Directors as on March 31, 2025. To ensure transparent and professional conduct of Board procedures in all aspects and related thereto 2 out of 5 Directors are Independent. The Chairman of the Board is a Non-Executive Independent Director.

The Composition of the Board as of 31st March 2025 is given below:

DIN	Name of the Director	Designation	Category
08849689	Dilip Vishnu Acharekar	Chairman & Independent Director	Non-Executive
00031873	Gaddam Venkata Ramana	Managing Director	Promoter Executive
02697880	Satyanarayana Raju Bhupathiraju	CFO & Whole-time Director	Promoter Executive
09690829	Hari Priya Yerukalapudi	Independent Director	Non-Executive
10044882	Alluri Ranga Raju	Non - Executive Director	Non-Executive

b) Attendance of each Director at the Board Meetings and the last AGM

The table hereunder gives the attendance record of the Directors at the four (4) Board Meetings held during the year 2024-25 and the last Annual General Meeting (AGM) held on 27th September 2024:

Name of the Directors	No. of Board Meeting entitled to attend	No. of Board Meetings attended	Attendance at AGM
Gaddam Venkata Ramana	4	3	Yes
Satyanarayana Raju Bhupathiraju	4	4	Yes
Hari Priya Yerukalapudi	4	4	Yes
Dilip Vishnu Acharekar	4	4	Yes
Alluri Ranga Raju	4	4	Yes

c) Number of other Boards or Board Committees in which the director of the company is a member or Chairperson.

S.No	Name of Director	No. of other directorships held *	No. of other Board Committees**		Directorship in other listed entity
			As a Member	As a Chairman	
1	Gaddam Venkata Ramana	-	-	-	-
2	Satyanarayana Raju Bhupathiraju	-	-	-	-
3	Hari Priya Yerukalapudi	-	-	-	-
4	Dilip Vishnu Acharekar	-	-	-	-
5	Alluri Ranga Raju	-	-	-	-

Note: * Excluding Private Limited Companies, Foreign Companies and Section 8 Companies.

** Only membership of Audit and Shareholders' Grievances Committees are considered.

None of the Directors on the Board is a Director in more than 7 listed entities. None of the Non – Executive Directors is an Independent Director in more than 7 listed entities as required under the Listing Regulations. Further, the Managing Director and the Executive Directors do not serve as Independent Directors in any listed company. None of the Directors held Directorships in more than 20 Indian companies, with more than 10 public limited companies. None of the Directors on the Board is a member of more than ten Committees or Chairperson of more than five Committees (committees being Audit Committee and Stakeholders' Relationship Committee) across all Public Companies in India, in which he/she is a Director. Necessary disclosures regarding their Committee positions have been made by all the Directors.

All Directors are in compliance with the limit on Directorships /Independent Directorships of listed companies as prescribed under Regulation 17A of the Listing Regulations.

The Company has received declarations on criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1)(b) of the Listing Regulations from the Directors of the Company who have been classified as Independent Directors as on March 31, 2024.

d) Number of Board meetings held, dates on which held.

Four (4) Board Meetings were held during the financial year ended 31st March 2025. The maximum gap between any two consecutive meetings did not exceed 120 days.

The dates on which the Board meetings were held are May 29, 2024, August 13, 2024, November 13, 2024 and February 12, 2025. The necessary quorum was present for all the meetings. Minutes of the meetings of all the Board and the Committees are circulated to all the Directors.

During the FY 2025, information as mentioned in Part A of Schedule II of the SEBI Listing Regulations, has been placed before the Board for its consideration.

The Board periodically reviews the compliance reports of all laws applicable to the Company.

e) Meeting of Independent Directors.

A separate meeting of Independent Directors was held on February 12, 2025, inter-alia to review the performance of the Non-Independent Directors and the Board of Directors as a whole, review the performance of Chairperson of the Company and assess the quality, quantity and timeliness of flow of information between the management of the company and the Board that is necessary for the Board to effectively and reasonably perform their duties.

All the Independent Directors were present at the meeting. The Independent Directors expressed their satisfaction to the desired level on the governance of the Board.

f) Disclosure of relationship between Directors inter-se.

None of the other Directors are related to each other.

g) Shares and Convertible Instruments held by Non-Executive Directors.

Name of the Director	Number of Equity Shares held in the Company
Dilip Vishnu Acharekar	Nil
Hari Priya Yerukalapudi	Nil
Alluri Ranga Raju	1,92,093
Bhaskara Reddy Karna ^	Nil

^ Resigned w.e.f 14-11-2024

h) Details of Familiarization programmes imparted to Independent Directors is given below.

The details of programs for familiarization of the Independent Directors with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company and related matters are available on the website of the Company at the weblink <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/familiarisation-programme-independent-directors.pdf>.

i) Skills/expertise/competence of the Board of Directors for the effective functioning of the Company which are currently available with the Board:

As required under the Listing Regulations, the list of core skills/expertise/competencies as identified by the Board of Directors in the context of its business and sector for it to function effectively and those available with the Board are as under:

Matrix of skills/expertise/competencies:

Knowledge	Understanding of the Company's business, policies and culture (including its mission, vision, values, goals, current strategic plan, governance structure, major risks and threats and potential opportunities) and knowledge of the industry in which the Company operates.
Pharma	A significant background in pharma industry, resulting in knowledge, generate disruptive markets, and extend or create new business models.
Behavioural Skills	Attributes and competencies to use their knowledge and skills to function well as team-members and to interact with key stakeholders.
Strategic thinking and Planning	Appreciation of long-term trends, strategic choices, and experience in guiding and leading management teams to make decisions in uncertain environments.
Leadership	Leadership Skill to ensure effective guidance to and monitoring of the management and to set a corporate culture and the values by which executives throughout the group should behave.
Sales and marketing	Experience in developing strategies to grow sales and market share, build brand awareness and equity, and enhance enterprise reputation
Financial Discipline and Risk Oversight	Understanding of Financial Management, Financial Reporting Process and Financial & Operational controls. Ensuring focus on returns.

	Understand and oversee internal and external risks associated with the Business and to put in place appropriate policies and procedures to effectively manage such risks.
Corporate Governance	Experience in implementation of the statutory laws, rules, regulations etc. for effective implementation and ensuring proper corporate governance.

The Board of the Company is highly structured to ensure a high degree of diversity by age, education/qualifications, professional background, sector expertise and special skills.

The eligibility of a person to be appointed as a Director of the Company is dependent on whether the person possesses the requisite skill sets identified by the Board as above and whether the person is a proven leader in running a business that is relevant to the Company's business or is a proven academician in the field relevant to the Company's business. The Directors so appointed are drawn from diverse backgrounds and possess special skills with regard to the industries / fields from where they come.

The details of Directors of the Company who possess the above referred skills/expertise/competencies are as given below:

Director	Knowledge of the Company's business	Behavioural Skills	Strategic thinking and Planning	Financial Skills	Sales and marketing	Governance Skills	Technical/ Professional skills and specialized Knowledge
Gaddam Venkata Ramana	#	#	#	#	#	#	#
Satyanarayana Raju Bhupathiraju	#	#	#	#	#	#	#
Hari Priya Yerukalapudi	#	#	#	#	-	#	#
Dilip Vishnu Acharekar	#	#	#	-	#	#	#
Bhaskara Reddy Karna ^	#	#	#	#	#	#	#
Alluri Ranga Raju	#	#	#	-	#	#	#
Satish Pandurang Samant #	#	#	#	#	#	#	#

^ Resigned w.e.f 14-11-2024. # Resigned w.e.f 29-05-2024

j) Confirmation about Independent Directors in the opinion of the Board

Independent Directors are non-executive directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Act along with rules framed thereunder. In terms of Regulation 25(8) of SEBI Listing Regulations, they have confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties. Based on the declarations received from the Independent Directors, the Board of Directors has confirmed that they meet the criteria of independence with an objective independent judgment and without any external influence as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations and that they are independent of the management.

In terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment & Qualification of Directors) Rules, 2014, the Independent Directors have confirmed that they have enrolled themselves in the Independent Directors' Databank maintained with the Indian Institute of Corporate Affairs.

k) Detailed reasons for the resignation of an independent director who resigns before the expiry of his tenure along with a confirmation by such director that there are no other material reasons other than those provided

Bhaskara Reddy Karna (DIN:08961904) was appointed as Independent Director for a term of five (5) consecutive financial years w.e.f November 16, 2020 to November 15, 2025. However, he has resigned from the Board w.e.f November 14, 2024 without assigning any material reasons therefor expect due to personal commitments.

l) Code of Conduct

The Board has laid down two separate Codes of Conduct, one for all the Board Members and the other for Senior Management of the Company. These Codes have been posted on the Company's website <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/code-of-conduct-for-board-of-directors.pdf> and <https://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/code-of-conduct-for-senior-management.pdf> respectively. All the Board Members and Senior Management Personnel have affirmed compliance with these Codes. A declaration signed by the Chairman and Managing Director to this effect is enclosed at the end of this Report as **Annexure VIII**. The Code of Conduct for the Board Members of the Company is in line with the provisions of the Companies Act, 2013, which includes Code for Independent Directors, which is a guide to professional conduct for Independent Directors of the Company pursuant to Section 149(8) and Schedule IV of the Companies Act, 2013.

m) MD and CFO Certification.

As required under the Listing Regulations, the MD and the CFO of the Company have certified the Financial Statements for the year ended 31st March 2025 before their submission to the Board. The Chairman and Managing Director and CFO also furnish quarterly certification on Financial Statements while placing the Financial Statements before the Board in terms of Regulation 17(8). The Annual Certificate given by the Managing Director and CFO forms part of the Annual Report as **Annexure IX**.

3) Audit Committee.

(a) Brief description of terms of reference.

The Committee is empowered with the role and powers as prescribed under Regulation 18 of the Listing Regulations and Section 177 of the Companies Act, 2013. The Committee also acts in terms of reference and directions of the Board from time to time.

Terms of reference of the Audit Committee, inter alia, includes the following:

- Oversight of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible.
- Recommend for appointment, remuneration and terms of appointment of auditors
- Approval of payment to statutory auditors for any other services rendered by the statutory auditors
- Review, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to

- matters required to be included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013
- changes, if any, in accounting policies and practices and reasons for the same
- major accounting entries involving estimates based on the exercise of judgment by management
- significant adjustments made in the financial statements arising out of audit findings
- compliance with listing and other legal requirements relating to financial statements
- disclosure of any related party transactions
- modified opinion(s) in the draft audit report
- review, with the management, the quarterly financial statements before submission to the board for approval
- review, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public or rights issue or preferential issue or qualified institutions placement , and making appropriate recommendations to the board to take up steps in this matter
- review and monitor the auditor's independence and performance, and effectiveness of audit process
- approval or any subsequent modification of transactions of the listed entity with related parties
- scrutiny of inter-corporate loans and investments
- valuation of undertakings or assets of the listed entity, wherever it is necessary
- evaluation of internal financial controls and risk management systems
- review, with the management, performance of statutory and internal auditors, adequacy of the internal control systems
- review the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit
- discussion with internal auditors of any significant findings and follow up there on
- review the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board
- discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern
- to look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors
- to review the functioning of the whistle blower mechanism
- approval of appointment of chief financial officer after assessing the qualifications, experience and background, etc. of the candidate
- Carrying out any other function as is mentioned in the terms of reference of the audit committee.
- review the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision
- consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders
- management discussion and analysis of financial condition and results of operations
- management letters / letters of internal control weaknesses issued by the statutory auditors
- internal audit reports relating to internal control weaknesses
- the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee
- statement of deviations – quarterly and annual

In addition, the Committee is also required to discharge such other roles / functions as may be decided from time to time.

(b) Composition, Name of Members and Chairperson including meetings and attendance

The Audit Committee of the Board is constituted with Three (3) Directors. All of the members of the Committee are financially literate and have adequate accounting knowledge. Accordingly, the Composition of the Audit Committee is in conformity with Regulation 18 of the Listing Regulations.

The Composition, Meetings and Attendance of Members of Audit Committee, is given below:

Name of Director	Designation	No. of Meetings Held	No. of Meetings attended
Yerukalapudi Hari Priya	Chairperson	4	4
Dilip Vishnu Acharekar	Member	4	4
Bhaskara Reddy Karna ^	Member	3	3
Satyanarayana Raju Bhupathiraju #	Member	1	1

^ Chairman till 13-08-2024. Member w.e.f 14-08-2024 till resignation 14-11-2024.

Member w.e.f 14-11-2024

During the Financial Year 2024-25, the Audit Committee met 4 (Four) times on the following dates:

May 29, 2024, August 13, 2024, November 13, 2024 and February 12, 2025.

The Statutory Auditor, Internal Auditor, Chief Financial Officer and Senior Manager (Finance and Accounts) were invited to the meetings of the Audit Committee. The Company Secretary acts as the Secretary to the Audit Committee.

All the recommendations of the Audit Committee have been accepted by the Board of Directors.

4) Nomination and Remuneration Committee (NRC)**(a) Brief description of terms of reference**

The Committee is empowered with the role and powers as prescribed under Regulation 19 of the Listing Regulations, Section 178 of the Companies Act, 2013 and in Nomination & Remuneration Policy of the Company. The Committee also acts in terms of reference and directions of the Board from time to time.

Terms of reference of the Nomination and Remuneration Committee, inter alia, includes the following:

- Formulate the criteria for determining qualifications, positive attributes and independence of a director and recommend to the board of directors a policy relating to, the remuneration of the directors, key managerial personnel and other employees;
 - For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:
 - use the services of an external agencies, if required;
 - consider candidates from a wide range of backgrounds, having due regard to diversity; and
 - consider the time commitments of the candidates.
- Formulate the criteria for evaluation of performance of independent directors and the board of directors;

- Devise a policy on diversity of board of directors;
- Identify persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the board of directors their appointment and removal.
- Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors.
- Recommend to the board, all remuneration, in whatever form, payable to senior management.

(b) Composition, name of members and Chairperson including meetings and attendance

The Nomination and Remuneration Committee of the Board is constituted with three Non-Executive Directors. During the financial year 2024-25, Nomination and Remuneration committee met once i.e., on February 12, 2025.

The Composition, Meetings and Attendance of Members of Nomination and Remuneration Committee, is given below:

Name of the Director	Designation	No of Meetings Held	No. of meetings attended
Yerukalapudi Hari Priya *	Chairperson	1	1
Dilip Vishnu Acharekar	Member	1	1
Bhaskara Reddy Karna ^	Member	0	0
Alluri Ranga Raju #	Member	1	1

*Chairperson w.e.f 14-08-2024.

^ Chairperson till 13-08-2024 and Member till his resignation w.e.f 14-11-2024.

Member w.e.f 14-11-2024

(c) Nomination and Remuneration policy.

The Committee recommends the compensation package to the directors of the Company. The remuneration will include salary, perquisite, allowances and commission. The remuneration policy is directed towards rewarding performance based on review of achievements. It is aimed at attracting and retaining high calibre talent. The Nomination and Remuneration Policy is available on the Company's website at <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/nomination-remuneration-policy.pdf>.

The Policy ensures that:

- The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors of the quality required to run the Company successfully.
- Relationship of remuneration to performance is clear and meets appropriate performance benchmarks and
- Remuneration to Directors, Key Managerial Personnel and Senior Management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the Company and its goals.

(d) Performance Evaluation criteria for independent directors

The performance evaluation criteria for Independent directors are determined by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation was carried out includes participation and contribution by a director, commitment, effective deployment of knowledge and expertise, integrity and maintenance of confidentiality and independence of behaviour and judgement.

5) Stakeholders' Relationship Committee.

(a) Brief description of terms of reference

The Committee is empowered with the role and powers as prescribed under Regulation 20 of the Listing Regulations and Section 178(5) of the Companies Act, 2013. The Committee also acts in terms of reference and directions of the Board from time to time.

Terms of reference of the Stakeholders Relationship Committee, inter alia, includes the following:

- Resolve the grievances of the security holders of the listed entity including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc.
- Review of measures taken for effective exercise of voting rights by shareholders.
- Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent.
- Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company.
- Resolving grievances of debenture holders related to creation of charge, payment of interest/principal, maintenance of security cover and any other covenants.

(b) Composition, name of members and Chairperson including meetings and attendance

The Stakeholders' Relationship Committee (SRC) of the Board is constituted with three Directors. During the financial year 2024-25, SRC met only once on 12th February 2025.

The Composition, Meetings and Attendance of Members of Stakeholders' Relationship Committee, is given below:

Name of Director	Designation	No. of meetings held	No. of meetings attended
Dilip Vishnu Acharekar	Chairman	1	1
Yerukalapudi Hari Priya	Member	1	1
Bhaskara Reddy Karna ^	Member	0	0
Gaddam Venkata Ramana #	Member	1	0

^ Resigned w.e.f 14-11-2024.

Member w.e.f 14-11-2024.

(c) Name and designation of Compliance Officer

Designation - Company Secretary and Compliance Officer Email id for investor grievances - grievance@vineetlabs.co.in / investorcomplaints@vineetlabs.co.in
Name: Ramesh Kumar Bandari

(d) Complaints of shareholders

Number of complaints received during 2024-25	0
Number of complaints not solved to the satisfaction of shareholders	0
Number of pending complaints	0

6) Senior Management

Name	Designation
B V Ramakrishna	Senior Manager - Finance & Accounts
Pavani Srinivasa Rao	Manager - HR
Ponnamanda Anjaneya Raju	Senior Manager - QA
Alluri Srinivasa Raju	Senior Manager - Purchase
Alluri Prabhakar Raju	Senior Manager - Warehouse
Pattabhi Ramu	In charge - Plant
Gadde Ravi Kumar	In charge - Maintenance
J. Venkata Ramana Reddy	In charge - Electrical Maintenance

7) Remuneration of Directors

There are no pecuniary transactions with any non-executive director of the Company.

Non-Executive Directors are paid sitting fee for attending the Board and Committee meetings.

- Criteria of making payments to non-executive directors is displayed on the website at <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/criteria-for-makingpayment-to-NEDs.pdf>
- The details of sitting fee paid to the Independent Directors during the financial year 2024-25 are as follows

Name of the Director	Amount (Rs.)
Yerukalapudi Hari Priya	1,00,000
Dilip Vishnu Acharekar	1,00,000
Bhaskara Reddy Karna	75,000

- The details of remuneration paid to Executive and Non-Executive Directors during the year are as follows:

Name of the Director and Designation	Salary in Rs	Benefits	Bonus	Commission	Service Contracts	Notice Period
Gaddam Venkata Ramana, Managing Director	51,00,000	-	-	-	Re-appointed as Managing Director for a period of 3 years w.e.f January 01, 2024 to December 31, 2026.	As per the Company Rules
Satyanarayana Raju Bhupathiraju, CFO & Whole-Time Director	39,00,000	-	-	-	Re-appointed as the Whole - Time Director for	As per the Company Rules

					a period of 3 years w.e.f January 01, 2024 to December 31, 2026.	
Satish Pandurang Samant CEO & Executive Director	12,00,000	-	-	-	Appointed as an Executive Director for a period of 3 years w.e.f October 16, 2023 to October 15, 2026 but Resigned w.e.f. May 29, 2024	As per the Company Rules
Alluri Ranga Raju Non-Executive Director	-	75,000 (Sitting Fee)	-	-	Appointed as a Non-Executive Director of the company in the AGM held on September 28, 2023.	As per the Company Rules

There were no severance fees, stock option plan or performance linked incentive for Executive / Non-Executive Directors.

8) General Body Meetings.

(a) Location and time, where last three AGMs held:

The following are the details of the last three Annual General Meetings held:

Financial Year	Date	Time	Venue
2023-24	27-09-2024	9.00 AM	SY.No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana – 500 074 through VC / OAVM
2022-23	28-09-2023	9.30 AM	Minerva Coffee Shop, 3 rd Floor, Beside Sanjeevini Hospital, Kiran Nagar, Doctors' Colony, Kothapet, Hyderabad, Telangana 500 035
2021-22	28-09-2022	11.00 AM	Minerva Coffee Shop, 3 rd Floor, Beside Sanjeevini Hospital, Kiran Nagar, Doctors' Colony, Kothapet, Hyderabad, Telangana 500 035

(b) Special Resolutions passed in the previous three AGMs:

Financial Year	Special Resolution
2023-24	None
2022-23	<ul style="list-style-type: none"> Re-appoint and to fix remuneration of Gaddam Venkata Ramana (DIN: 00031873) as the Managing Director of the Company. Re-appoint and to fix remuneration of Satyanarayana Raju Bhupathiraju (DIN: 02697880) as the Whole-Time director of the company.
2021-22	<ul style="list-style-type: none"> Set out the borrowing limits of the company. Create charge on the movable and immovable properties of the company, both present and future, in respect of borrowings. Approve existing as well as new material related party transactions with Vineet Life Sciences Private Limited, Wohler Laboratories Private Limited, Vineet Chem Trade Private Limited. Appoint Hari Priya Yerukalapudi (DIN: 09690829) as an Independent Director of the company. Approve revision in the remuneration of Gaddam Venkata Ramana (DIN: 00031873), Managing Director of the company. Approve revision in the remuneration of Satyanarayana Raju Bhupathiraju (DIN: 02697880), Whole-Time Director of the company. Change the designation of Kandula Murali Mohan (DIN: 03313407) from Non-Executive Director to Whole Time Director of the company. Fix the remuneration of Kandula Murali Mohan (DIN: 03313407), Whole Time Director.

(c) Special Resolution passed last year through postal ballot – details of voting pattern

None

(d) Person who conducted the postal ballot exercise – Not Applicable**(e) Whether any special resolution is proposed to be conducted through postal ballot**

No such proposal as on the date of this report.

(f) Procedure for Postal Ballot

Since postal ballot was not conducted, no procedure was required to be followed for the same.

9) Means of Communication.**(a) Quarterly results:**

The quarterly results of the Company are published in accordance with the requirements of the Listing Regulations.

(b) Newspapers wherein results normally published:

Quarterly / Half Yearly / Annual Audited Results are generally published in widely circulated newspapers viz., Financial Express (English daily) and Nava Telangana (Regional Newspaper – Telugu Daily).

(c) Any website, where displayed:

Quarterly / Half Yearly / Annual Audited Results, Annual Reports, Announcements, Investor information, Policies etc. are displayed on the Company's website: <http://vineetlabs.co.in/financials2.html>

(d) Annual Report

Pursuant to the MCA circulars and SEBI Circulars, the Annual Report for FY 2024-25 containing the Notice of AGM will be sent through e-mails to all those Members whose e-mail IDs were registered with the Company/ Depository Participants. However, a letter providing the web-link, including the exact path, where complete details of the Annual Report is available to those shareholder(s) who have not registered their e-mail ids shall be despatched by the RTA.

(e) Whether it also displays official news releases: None

(f) Presentations made to institutions investors or to the analysts: No presentations were being made during the financial year

10) General Shareholder Information.

(a) Annual General Meeting: 25 September 2025, 11:00 A.M through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM")

(b) Financial Year: April 01, 2024 to March 31, 2025

(c) Record Date / Book Closure Date for the purpose of AGM: September 19, 2025 to September 25, 2025
(both days inclusive)

(d) Dividend Payment Date: Not Applicable

(e) Listing on Stock Exchanges: BSE Limited
P. J. Towers, Dalal Street, Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex
Bandra (East), Mumbai 400 051

The Company confirms that it has paid annual listing fees to the Stock Exchanges for the year 2024-2025.

(f) There was no suspension of trading in Securities of the Company during the year under review.

(g) Registrars and Share Transfer Agents:

Venture Capital and Corporate Investments Private Limited
"AURUM", D No.4-50/P-II/57/4F & 5F, 4th & 5th Floors, Plot No.57,
Jayabheri Enclave Phase – II, Gachibowli, Serilingampally,
Hyderabad – 500 032. Ranga Reddy Dist., Telangana
Phone: +91 – 40 -23818475
Fax: +91 – 40 - 23868024
E-mail Id: investor.relations@vccipl.com

(h) Share Transfer system

The Company has appointed Venture Capital and Corporate Investments Private Limited, Hyderabad as Registrar and Share Transfer Agents for the purpose of carrying on the work relating to share transfers - both physical and demat form. The requests received for transfer of shares from the shareholders are normally completed within prescribed time, subject to the documents being valid and complete in all respects.

As per the Listing Regulations, requests for effecting transfer of equity shares in physical form shall not be accepted by Venture Capital and Corporate Investments Private Limited, Registrars and Transfer Agents, w.e.f. 01.04.2019 unless the equity shares are held in the dematerialized form with a Depository. However, in order to facilitate ease of investing for investors and to secure the rights of investors in the securities which were purchased by them, SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025 has decided to open a special window only for re-lodgement of transfer deeds, which were lodged prior to the deadline of April 01, 2019 and rejected/returned/not attended to due to deficiency in the documents/process/or otherwise, for a period of six months from July 07, 2025 till January 06, 2026. This was communicated to the members who hold the shares in physical form. The shareholders need to convert the shares to demat form compulsorily, if they wish to effect any transfer. However, the restriction is not applicable to the requests received for transmission or transposition of physical shares. All the shareholders, who hold the shares in physical form, are requested to dematerialize the shares at the earliest to avoid inconvenience in future, for transferring the shares.

(i) Distribution of Shareholding

Distribution of Shareholding as on 31st March 2025:

Nominal Value	Holders		Amount	
	Number	% To Total	In Rs	% To Total
Upto - 5000	8,317	83	93,87,470	10
5001 - 10000	874	9	63,27,660	7
10001 - 20000	431	4	61,19,550	7
20001 - 30000	146	1	36,62,610	4
30001 - 40000	60	1	21,01,420	2
40001 - 50000	55	1	25,72,440	3
50001 - 100000	65	1	45,95,110	5
100001 and above	78	1	5,74,23,820	62
Total	10,026	100	9,21,90,080	100

Shareholding Pattern as on 31st March 2025:

S.No	Description	No of Equity Shares	% Equity
1	Promoter Individuals	33,04,587	35.85
2	Resident Individuals	54,08,657	58.67
3	Bodies Corporates	4,16,217	4.51
4	HUF	-	-
5	Non Resident Indians (NRIs)	87,475	0.95
6	NRI Non-Repatriation	-	-
7	Clearing Members	2,072	0.02
8	IEPF	-	-
9	Foreign Portfolio Investors	-	-
10	Alternative Investment Fund	-	-
11	Trusts	-	-
12	Banks	-	-
13	Directors and Relatives	-	-
14	Foreign Nationals	-	-
	Total	92,19,008	100

(j) Dematerialization of shares and liquidity

The process of conversion of shares from physical form to electronic form is known as dematerialization. For dematerializing the shares, the Shareholder has to open a demat account with a Depository Participant (DP). The Shareholder is required to fill in a Demat Request Form and submit the same along with the Share Certificate(s) to the DP. The DP will allocate a demat request number and shall forward the request physically and electronically, through NSDL/CDSL to the R&T Agent. On receipt of the demat request, both physically and electronically and after verification, the Shares are dematerialized, and an electronic credit of shares is given in the account of the Shareholder.

The Company has made necessary arrangements with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) for dematerialization facility. All the shares were in dematerialized form as on 31st March 2025. The ISIN No/Code for the Company's Equity Shares is INE505Y01010.

(k) Outstanding global depository receipts or American depository receipts or warrants or any convertible instruments, conversion date and likely impact on equity - Nil

(l) Commodity Price Risk or Foreign Exchange risk and hedging activities:

The Company is not carrying on any Commodity Business and has also not undertaken any hedging activities; hence same are not applicable to the Company.

(m) Plant Location

Sy.No.300, Malkapur Village, Choutuppal Mandal,
Yadadri bhuvangir Dist, - 508252 Telangana State

(n) Address for correspondence

Company:

The Company Secretary and Compliance Officer,
Sy. No. 11/A3, Saheb Nagar, Kurdu Vill,
Chintal Kunta, Eshwaramma Nilayam,
L B Nagar, Hyderabad, Telangana – 500 074
Phone: 040-24128833
E-mail Id: cs@vineetlabs.co.in

Registrar and Share Transfer Agents:

Venture Capital and Corporate Investments Private Limited
“AURUM”, D No.4-50/P-II/57/4F & 5F, 4th & 5th Floors, Plot No.57,
Jayabheri Enclave Phase – II, Gachibowli, Serilingampally,
Hyderabad – 500 032. Ranga Reddy Dist., Telangana.
Phone: +91 – 40 -23818475
Fax: +91 – 40 -23868024
E-mail Id: investor.relations@vccipl.com

(o) Corporate Identity Number: L24304TG2016PLC112888

(p) Credit rating along with revisions, if any: Not Applicable since the company neither issued any debt instruments nor commenced any fixed deposit programme / any scheme involving mobilization of funds, whether in India or abroad.

11) Disclosures.

(a) Disclosures on materially significant related party transactions that may have potential conflict with the interests of company at large.

During the year 2024-2025, there was no materially significant related party transaction which had potential conflict with the interests of the Company at large. The details of the related party transactions are disclosed in the notes on accounts forming part of the Annual Report. In terms of Regulation 23 of the Listing Regulations, the Board has formulated a Related Party Transaction Policy.

The Related Party Transaction Policy is uploaded on the website of the Company at <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/related-party-transactions-policy.pdf>

(b) Details of Non-Compliance and Penalties during the last three years - None

(c) Whistle Blower policy and affirmation that no personnel have been denied access to the Audit Committee.

The Company has framed a Whistle Blower Policy with a view to provide a vigil mechanism for Directors and Employees of the Company to report genuine concerns about unethical behaviour, any wrongdoings, actual or suspected fraud or violation of the Company's Code of Conduct, legal or regulatory requirements and to provide direct access to the Chairperson of the "Audit Committee" in appropriate or exceptional cases, to provide adequate safeguards for protection of Employees and Directors from victimization or unfair treatment and ensure that frivolous accusations are not made.

The Audit Committee periodically reviews the functioning of the Whistle Blower Mechanism.

No personnel have been denied access to the Audit Committee. Whistle Blower Policy is uploaded on the website of the Company at <http://vineetlabs.co.in/images/pdf/policies-and-code-of-conduct/whistle%20blower-policy.pdf>

The Whistle Officer has not received any complaint for the financial year ended 31st March 2025.

(d) Details of compliance with mandatory requirements and adoption of the non-mandatory requirements

The Company has complied with all the mandatory requirements of the Listing Regulations entered into with the Stock Exchanges.

Extent of adoption of discretionary requirement as specified in Part E of Schedule II:

- Dilip Vishnu Acharekar, Independent Director is the Chairperson of the company and he maintained chairperson's office at the Company's expense and was also allowed reimbursement of expenses incurred in performance of his duties. Further, Gaddam Venkata Ramana is the Managing Director of the Company. The Chairperson and the Managing Director are not related to each other.
- The Company has one woman Independent Director – Hari Priya Yerukalapudi.
- The Company has been disclosing the financial performance on the website of the company for the knowledge of the shareholders.
- The Auditors expressed unmodified opinion on the financial statements of the company. Your Company continuously strives to adopt best practices to ensure regime of unqualified financial statements.
- The Internal Auditor reports directly to the Audit Committee.

(e) Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) – Not Applicable

(f) Policy for determining 'material subsidiaries' : The Company does not have any subsidiary

(g) SEBI Complaints Redress System (SCORES): The investors' complaints are also being processed through the centralized web base complaint Redressal system of SEBI. The salient features of SCORES are availability of centralized database of the complaints, uploading online action taken reports by the Company. Through SCORES the investors can view online, the action taken and current status of the complaints. SEBI vide its Circular dated March 26, 2018 and August 13, 2020, October 22, 2020, and September 20, 2023 have streamlined the process of filing investor grievances in the SCORES in order to ensure speedy and effective resolution of complaints filed therein. The said Circulars can be accessed on the website of SEBI at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=1&ssid=7&smid=0>.

- (h) A certificate (**Annexure VI**) has been received from M/s. P.S. Rao & Associates, Practicing Company Secretaries regarding compliance of conditions of corporate governance, which is annexed to the Board's Report.
- (i) A certificate (**Annexure VII**) has been received from M/s. P.S. Rao & Associates, Practicing Company Secretaries, that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such statutory authority.
- (j) The Board has accepted the recommendations of all the Committees during the year 2024-25.
- (k) NSVR & Associates LLP, Chartered Accountants, Registration No. 008801S/S2000600 have been appointed as the Statutory Auditors of the Company. The particulars of payment of Statutory Auditors' fees for FY 2024-25, on consolidated basis is given below:

Particulars	Rs.
Services as statutory auditors	4,00,000
Other matters (including quarterly audits)	2,00,000
Re-imburement of out-of-pocket expenses	-
Total	6,00,000

- (l) The Company has adopted a policy on prevention, prohibition and Redressal of Sexual harassment at workplace and has duly constituted an Internal Complaints Committee in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. During FY 2024-25, the Company has not received any complaints pertaining to Sexual Harassment. Further there were no cases / complaints pending disposal as at the end of the financial year.
- (m) Disclosure by listed entity and its subsidiaries of 'Loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount'- No such transactions during the year under review.
- (n) Details of material subsidiaries of the listed entity; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries - The Company does not have any subsidiary.
- (o) As required under Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard 2 on General Meetings, particulars of Directors seeking appointment / re-appointment at this AGM are given in the Annexure to the Notice of this AGM.
- (p) Disclosure of Accounting Treatment in preparation of Financial Statements:

The Company has followed the Indian Accounting Standards and Accounting Principles Generally Accepted in India in preparation of its Financial Statements.

- (q) Code for Prevention of Insider Trading Practices

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has formulated a Code of Fair Disclosure and Code of Conduct to Regulate, Monitor and Report Trading by Insiders. The Code has been formulated to regulate, monitor and ensure reporting of trading by the Employees and Connected Persons designated on the basis of their functional role in the Company towards achieving compliance with the Regulations and is designed to maintain the highest ethical standards of trading in Securities of the Company by persons to whom it is applicable.

The Code of Conduct for prohibition of insider trading, and to regulate, monitor and report trading by designated person is posted on the website of the Company at <https://vineetlabs.co.in/images/pdf/2025.06.10code-conduct-forprohibition-insider-trading.pdf>

The Code of practices and procedures for fair disclosure of UPSI is posted on the website of the Company at https://vineetlabs.co.in/images/pdf/2025.06.10code-practices-procedures-fair-disclosure-UPSI-VLL_F.pdf

(r) Management Discussion and Analysis Report

The Report on Management Discussion and Analysis is annexed to the Directors' Report and forms part of this Annual Report.

(s) Proceeds from public issues, rights issue, preferential issues, etc. - Nil

(t) Disclosures in respect of demat suspense account/unclaimed suspense account as on 31.03.2025

Aggregate number of shareholders and the outstanding shares in the suspense account lying at the beginning of the year	211 shareholders holding in aggregate 92,563 shares in the suspense account lying at the beginning of the year
Number of shareholders who approached listed entity for transfer of shares from suspense account during the year;	None
Number of shareholders to whom shares were transferred from suspense account during the year.	None
Aggregate number of shareholders and the outstanding shares in the suspense account lying at the end of the year	211 shareholders holding in aggregate 92,563 shares in the suspense account lying at the end of the year
That the voting rights on these shares shall remain frozen till the rightful owner of such shares claims the shares.	

(u) No Agreements were entered into by the shareholders, promoters, promoter group entities, related parties, directors, key managerial personnel, employees of the listed entity, among themselves or with the listed entity or with a third party, solely or jointly, which, either directly or indirectly or potentially or whose purpose and effect is to, impact the management or control of the listed entity or impose any restriction or create any liability upon the listed entity. Consequently, there was no rescission, amendment or alteration of such agreements thereto, whether or not the listed entity is a party to such agreements.

Annexure VI

CERTIFICATE ON CORPORATE GOVERNANCE BY PRACTICING COMPANY SECRETARIES

[Pursuant to Regulation 34(3) read with Para E of Schedule V to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Members,
Vineet Laboratories Limited,
SY.No. 11/A3, Saheb Nagar, Kurdu Vill,
Chintal Kunta, Eshwaramma Nilayam,
L B Nagar Hyderabad, Telangana- 500 074.

We have examined the compliance of the conditions of Corporate Governance by Vineet Laboratories Limited (hereinafter referred to as "the Company") for the year ended March 31, 2025, as stipulated in Chapter IV of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

The compliance of the conditions of Corporate Governance is the responsibility of the management. Our examination was limited to a review of the procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

We conducted our examination of the Corporate Governance Report in accordance with the established systems and procedures selected by us depending on our judgement, including assessment of the risks associated in compliance of the Corporate Governance Report with the applicable criteria. The procedures include, but are not limited to, verification of secretarial records and other information of the Company, as we deem necessary to arrive at an opinion.

Based on the procedures performed by us as mentioned above and according to the information and explanations provided to us, we are of the opinion that the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Regulations as applicable for the year ended March 31, 2025.

We further state that such compliance is neither an assurance as to the financial viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For P.S. Rao & Associates
Company Secretaries

Place: Hyderabad
Date: May 12, 2025

P.S. Rao
Senior Partner
FCS No.: 10322
CP. No.: 3829
P R. No: 6678/2025
UDIN: F010322G000316793

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) read with clause (10)(i) of Para C of Schedule V to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Members,
Vineet Laboratories Limited,
SY.No. 11/A3, Saheb Nagar, Kurdu Vill,
Chintal Kunta, Eshwaramma Nilayam,
L B Nagar Hyderabad, Telangana- 500 074.

We have examined the relevant registers, records, forms, returns and disclosures received from the directors of Vineet Laboratories Limited having CIN: L24304TG2016PLC112888 and registered office at SY.No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad 500 074 (hereinafter referred to as "the Company"), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Clause 10(i) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Director Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the directors on the Board of the Company as stated below, for the financial year ending on 31st March, 2025, have been debarred or disqualified from being appointed or continuing as directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such statutory authority.

Name of Director	Nature/Category of Directorship	Director Identification Number (DIN)
Gaddam Venkata Ramana	Managing Director	00031873
Satyanarayana Raju Bhupathiraju	CFO & Whole-time Director	02697880
Alluri Ranga Raju	Non-Executive Director	10044882
Satish Pandurang Samant [^]	Executive Director and CEO	10294920
Yerukalapudi Hari Priya	Independent Director	09690829
Dilip Vishnu Acharekar	Chairman & Independent Director	08849689
Bhaskara Reddy Karna*	Independent Director	08961904

[^] Resigned w.e.f May 29, 2024

* Resigned w.e.f. November 14, 2024

Ensuring eligibility for the appointment / continuity of every director on the Board is the responsibility of the management of the Company.

Our responsibility is to express an opinion on the above based on our verification. This certificate is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For P.S. Rao & Associates
Company Secretaries

Place: Hyderabad

Date: May 12, 2025

P.S. Rao
Senior Partner
FCS No.: 10322
CP. No.: 3829
PR. No: 6678/2025
UDIN: F010322G000316771

Annexure VIII

DECLARATION BY THE CHAIRMAN AND THE MANAGING DIRECTOR UNDER SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To
The Members of Vineet Laboratories Limited

We, Dilip Vishnu Acharekar (DIN: 08849689), Chairman and Gaddam Venkata Ramana (DIN: 00031873), Managing Director of Vineet Laboratories Limited declare that all the Board Members and the Senior Management personnel have affirmed in writing their adherence to the Code of Conduct adopted by the Company for the financial year ended on 31st March 2025.

For Vineet Laboratories Limited

Place: Hyderabad

Date : May 12, 2025

Dilip Vishnu Acharekar
Chairman
DIN: 08849689

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

**COMPLIANCE CERTIFICATE
CERTIFICATION BY MANAGING DIRECTOR AND CHIEF FINANCIAL OFFICER**

We, the Managing Director and the Chief Financial Officer of Vineet Laboratories Limited, certify that:

1. We have reviewed the financial statement and the cash flow statement of the company for the financial year ended on 31st March 2025 and that to the best of our knowledge and belief:
 - These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
 - These statements together present a true and fair view of Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
2. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year, which are fraudulent, illegal or in violation of Company's Code of Conduct.
3. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
4. We have indicated to the Auditors and Audit Committee:
 - (i) Significant changes in internal control over financial reporting during the year.
 - (ii) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements and
 - (iii) That there have been no instances of significant fraud of which we have become aware, involving of the management or an employee having a significant role in the Company's internal control system over financial reporting.

For Vineet Laboratories Limited

Place: Hyderabad
Date : May 12, 2025

Gaddam Venkata Ramana
Managing Director
DIN: 00031873

Satyanarayana Raju Bhupathiraju
Whole-time Director & CFO
DIN: 02697880

INDEPENDENT AUDITOR'S REPORT

To the members of
Vineet Laboratories Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Vineet Laboratories Limited ("the Company"), which comprise the Balance Sheet as at 31 March 2025, and the Statement of Profit and Loss (including Other Comprehensive Income), and the Statement of Cash Flows and the Statement of changes in equity for the year ended on that date, and notes to the financial statements, including a summary of the material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("The Act") in the manner so required and give a true and fair view in conformity with Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended, (Ind AS) and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and its profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SA's) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as the Key audit matters to be communicated in our report.

Key audit matter	How the matter was addressed in our audit
<p data-bbox="370 243 716 275">1. Revenue recognition:</p> <p data-bbox="212 342 862 562">Revenue from the sale of products is recognized when control over goods is transferred to a customer. The actual point in time when revenue is recognized varies depending on the specific terms and conditions of the sales contracts entered with customers.</p> <p data-bbox="212 636 862 821">The Company has many customers operating in various geographies and sales contracts with customers have distinct terms relating to the recognition of revenue, the right of return and price adjustments.</p> <p data-bbox="212 972 862 1041">We identified the recognition of revenue from sale of products as a key audit matter considering:</p> <p data-bbox="212 1182 862 1556">Revenue is a key performance indicator for the Company. Accordingly, there could be pressure to meet the expectations of investors/ other stakeholders and/ or to meet revenue targets stipulated in performance incentive schemes for a reporting period. We have considered that there is a risk of fraud related to revenue being overstated by recognition in the wrong period or before control has passed during the year and at period end.</p> <p data-bbox="212 1612 862 1795">Company's assessment of accrual towards rebates, discounts, returns, service level penalties and allowances require estimates and judgement and change in these estimates can have a significant financial impact.</p>	<p data-bbox="889 285 1468 470">To obtain sufficient and appropriate audit evidence, our principal audit procedures and procedures performed by component auditors, amongst others, include the following:</p> <ul data-bbox="943 478 1468 1717" style="list-style-type: none"> <li data-bbox="943 478 1468 625">• Compared the accounting policies in respect of revenue recognition with applicable accounting standards to test for compliance. <li data-bbox="943 657 1468 804">• Performed substantive testing of selected samples of revenue transactions recorded during the year. <li data-bbox="943 835 1468 1178">• For a sample of year-end sales, we verified contractual terms of sales invoices/ contracts, shipping documents and acknowledged delivery receipts for those transactions including management assessment and quantification of any sales reversal for undelivered goods. <li data-bbox="943 1276 1468 1461">• Verified Company's assessment of accruals of rebates, discounts, returns, service level penalties and allowances in line with the past practices to identify bias. <li data-bbox="943 1612 1468 1717">• Tested any unusual non-standard journal entries that impacted revenue recognized during the year.

Emphasis of Matter Paragraph

We draw attention to Note no 7.1 & 22.1 of the financial statement, which describes that during the course of physical verification, the management identified slow moving and obsolete inventory amounting to Rs. 7.12 crores. This amount appears in the profit and loss account under raw materials and change in inventory. Our audit opinion is not modified in respect of this matter.

Information other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexure to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report there on.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statement

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive Income, cash flows and statement of changes of equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) referred to in Section 133 of Companies Act 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication

Report on Other Legal and Regulatory Requirements

1. As required by section 143(3) of the Companies Act 2013, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- b) In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.
- c) The Balance Sheet and Statement of Profit and Loss including Other Comprehensive Income, the Cash flow Statement and the statement of changes in equity dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financials comply with the Accounting Standards specified under of Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of written representations received from the directors as on March 31, 2025, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025, from being appointed as a director in terms of sub section (2) of section 164 of the Companies Act, 2013.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "**Annexure A**"; Our report expresses an unmodified opinion on the adequacy and operating effectiveness on the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The company has disclosed the impact of pending litigation on its financial position in its financial statements.
 - ii. The Company does not have any derivatives contracts. Further there are no long term contracts for which provisions for any material foreseeable losses is required to be made.
 - iii. There are no amounts pending that are required to be transferred to Investor Education and Protection Fund.
 - iv. (a) The management has represented, to the best of their knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, to the best of their knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on the audit procedures performed by us, which has considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of rule 11(e) as provided under (a) and (b), contain any material mis-statement.
- v) The amount of dividend is in accordance with the section 123 of the Act.
- (a) The final dividend paid by the company during the year in respect of previous year is in accordance with Section 123 of the Act, to the extent it applies to payment of dividend.
 - (b) The Board of Directors of the Company have not proposed any dividend for the year and hence provisions of section 123 in respect of approval of dividend by the members at the ensuing Annual General Meeting is not applicable.

vi) Based on our examination which included test checks, the Company has used accounting software for maintaining its books of accounts for the financial year ended March 31, 2025, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2025.

2. As required by the Companies (Auditor's Report) Order, 2020, issued by the department of company affairs, in terms of section 143 (11) of the companies Act, 2013, we give in the "**Annexure B**" a statement on the matters specified in paragraph 3 and 4 of the Order, to the extent applicable.

For NSVR & ASSOCIATES LLP,
Chartered Accountants
FRN No.008801S/S200060

V Gangadhara Rao N
Partner
Membership Number: 219486
UDIN: 25219486BMIRWX3703

Date: 12 May 2025
Place: Hyderabad

ANNEXURE “A” TO THE INDEPENDENT AUDITOR’S REPORT

(Referred to paragraph 1(f) under „Report on Other Legal and Regulatory Requirements“ section of our report even date

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls with reference to financial statements of Vineet Laboratories Limited (“the Company”) as of 31 March 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standard on Auditing prescribed under Section 143(10) of the Companies Act 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedure selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls with reference to financial statements.

Meaning of internal financial Controls over Financial reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principles. A company's internal financial controls over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and(3)provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For NSVR & ASSOCIATES LLP,

Chartered Accountants

FRN No.008801S/S200060

V Gangadhara Rao N

Partner

Membership Number: 219486

UDIN: 25219486BMIRWX3703

Date: 12 May 2025

Place: Hyderabad

ANNEXURE „B“ TO THE INDEPENDENT AUDITOR’S REPORT

Referred to in paragraph 2 under „Report on Other Legal and Regulatory Requirements“ section of our report even date

- (i) a) A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
B) The company does not have intangible assets and hence reporting under clause(i)(a)(B) of the order is not applicable.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of 3 years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.
- c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the financial statements are held in the name of the Company.
- d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment during the year.
- e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company as at 31 March 2025 for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- ii) a) The inventories (except for goods-in-transit and stocks held with third parties), were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on such physical verification. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. For stocks held with third parties at the year-end, written confirmations have been obtained and in respect of goods in transit, the goods have been received subsequent to the year-end. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories/alternate procedures performed as applicable, when compared with books of account.

- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion and according to the information and explanations given to us, the quarterly returns or statements comprising of value of closing stock of inventory, receivables and payables filed by the Company with such bank are in agreement with the audited books of account of the Company of the respective quarters (quarter ended 30 June, 2024, 30 September 2024, 31 December 2024 and 31 March 2025). The Company has not been sanctioned any working capital limit from the financial institutions.
- (iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments, provided guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year. Hence reporting under clause (iii)(a) to (iii)(f) of the Order is not applicable.
- (iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, the Company has neither made any investments nor has it given loans or provided guarantee or security and therefore the relevant provisions of Sections 185 and 186 of the Companies Act, 2013 ("the Act") are not applicable to the Company. Hence, reporting under clause (iv) of the Order is not applicable.
- (v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Hence, reporting under clause (v) of the Order is not applicable.
- (vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Act. We have broadly reviewed the cost records maintained during the year by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended and prescribed by the Central Government under sub-section (1) of Section 148 of the Act, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii) a) According to the information and explanations given to us and on the basis of our examination of the records, there are certain delays in depositing undisputed statutory dues including provident fund, employees state insurance, income tax, sales tax, service tax, Goods and Services Tax, duty of customs, duty of excise, cess and other material statutory dues as applicable to the appropriate authorities.

Statement of arrears of statutory dues outstanding for more than six months

Name of the Statute	Nature of the due	Amount (Rupees in Lakhs)	Period to which the amount relates	Due date	Date of payment	Remarks if any
Income Tax	Tax deducted at source (TDS)	12.06	Financial year 2024-25	7 th day of following month in respect of previous month	-	The company has not paid the outstanding liability of TDS till now

- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues, which have not been deposited with the appropriate authorities on account of any dispute.
- (viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961, as income during the year.
- (ix) a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.
- b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a willful defaulter by any bank or financial institution or government or government authority
- c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained. there are no unutilized term loans at the beginning of the year.
- d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long term purposes by the Company.
- e) On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.
- f) The company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies (as defined under the Act).

- (x) a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) and hence reporting under clause (x)(a) of the Order is not applicable.
- b) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year) and hence reporting under clause (x)(b) of the Order is not applicable.
- (xi) a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no material fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- c) We have taken into consideration, the whistle blower complaints received by the Company during the year and up to the date of this report and provided to us, when performing our audit.
- (xii) According to the information and explanations given to us, the Company is not a Nidhi Company) and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) In respect of internal audit
 - a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
 - b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- (xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- (xvi) a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934 and hence reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.
- d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended) and hence reporting under clause (xvi)(d) of the Order is not applicable.

- (xvii) The Company has incurred cash losses amounting to ₹1830.28 Lakhs in the current financial year, whereas no cash losses were incurred in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) (a) According to the information and explanations given to us and based on our examination of the records of the Company, the provisions of Corporate Social Responsibility (CSR) are not applicable to the Company. Accordingly, clause (xx)(a) of the Order is not applicable for the year.
- (b) According to the information and explanations given to us and based on our examination of the records of the Company the provisions of Corporate Social Responsibility (CSR) are not applicable to the Company. Accordingly, clause (xx)(b) of the Order is not applicable

For NSVR & ASSOCIATES LLP.,
Chartered Accountants
(FRN No.008801S/S200060)

V Gangadhara Rao N
Partner
Membership Number: 219486
UDIN: 25219486BMIRWX3703

Date: 12 May 2025
Place: Hyderabad

1. NOTES TO FINANCIAL STATEMENTS

Summary of material accounting policies and other explanatory information

(All amounts are in INR Lakhs except share data or unless otherwise stated)

1.1. Company Information

VINEET LABORATORIES LIMITED (Formerly Known as Ortin Laboratories Limited, Unit-II) is incorporated under the provisions of Companies Act, 2013 on 10 November 2016 having its registered office at SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana -500074, India. The company is engaged in the manufacture of Drug Intermediates & Bulk Drugs.

Vineet Laboratories Limited is specialized in pharmaceutical intermediates & fine chemicals. Vineet Laboratories Limited is widely acknowledged for its abilities in product development & process technology and therefore is the preferred source for many multinational companies for their outsourcing requirements. Our infrastructure is very versatile & is specially designed to address the requirements of carrying out complex and hazardous chemical process safely and efficiently. Our personnel are highly skilled at handling different kinds of process chemistry.

The shares of the company are listed in Bombay Stock Exchange and National Stock Exchange

1.2 Basis of preparation and presentation

a) Statement of Compliance

The financial statements of Vineet Laboratories Limited (Formerly Known as Ortin Laboratories Limited, Unit-II) have been prepared and presented in accordance with and in compliance in all material aspects, with the Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 (the "Act") read along with the Companies (Indian Accounting Standards) Rules 2015, and presentation requirements of Division II of Schedule III to the Companies Act, 2013, and as amended from time to time together with the comparative period data as at and for the year ended 31 March 2024.

These financial statements have been prepared by the Company as a going concern on the basis of relevant Ind AS that are effective at the Company's annual reporting date, 31 March 2025. These financial statements for the year ended 31 March 2025 were approved by the Company's Board of Directors on 12 May 2025.

b) Basis of measurement

The financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i) Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);

- ii) Employee defined benefit assets/(liability) are recognized as the net total of the fair value of plan assets, plus actuarial losses, less actuarial gains and the present value of the defined benefit obligation, and
- iii) Long-term borrowings are measured at amortized cost using the effective interest rate method.

c) Functional and presentation currency

These financial statements are presented in Indian rupees, which is also the functional currency of the company. All the financial information presented in Indian rupees has been rounded to the nearest Lakhs.

d) Significant accounting judgements, estimates, and assumption

The preparation of the financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates and associated assumptions are based on historical experiences and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, the areas involving critical estimates or Judgment are:

Property, plant and equipment

The depreciation of property, plant and equipment is derived on determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The residual values of the Company's assets are determined by management at the time of acquisition of asset and are reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life.

Impairment of financial and non-financial assets

Significant management judgement is required to determine the amounts of impairment loss on the financial and non-financial assets. The calculations of impairment loss are sensitive to underlying assumptions.

Tax provisions and contingencies

Significant management judgement is required to determine the amounts of tax provisions and contingencies. Deferred tax assets are recognized for unused tax losses and MAT credit entitlements to the extent it is probable that taxable profit will be available against which these losses and credit entitlements can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies.

Defined benefit plans

The cost of the defined benefit plan and the present value of the obligation are determined using actuarial valuation. An actuarial valuation involves various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary

increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation.

The mortality rate is based on publicly available mortality tables. Those mortality tables tend to change only at intervals in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates.

Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using internal valuation techniques. The inputs into these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

e) Current and noncurrent classification

The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.

All the assets and liabilities have been classified as current or noncurrent as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013 and Ind AS 1, presentation of financial statements.

An asset is classified as current when it satisfies any of the following criteria:

- i) It is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle.
- ii) It is held primarily for the purpose of being traded.
- iii) It is expected to be realized within twelve months after the reporting date; or
- iv) It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any of the following criteria:

- i) It is expected to be settled in the Company's normal operating cycle.
- ii) It is held primarily for the purpose of being traded.
- iii) It is due to be settled within twelve months after the reporting date; or
- iv) The Company does not have an unconditional right to defer settlement of liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification

The Company classifies all other liabilities as non-current.

Current assets/ liabilities include the current portion of noncurrent assets/ liabilities respectively. Deferred tax assets and liabilities are always disclosed as non-current.

The operating cycle is the time between the acquisition of assets for processing and their realization in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

f) Fair value measurement

The Company measures financial instruments, such as derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer liability takes place either:

- in the principal market for the asset or liability, or
- in the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset considers a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data is available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Ind AS financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

For assets and liabilities that are recognised in the Ind AS financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

The Company's management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for sale in discontinued operations.

External valuers are involved, wherever considered necessary. For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy, as explained above.

This note summarizes accounting policy for fair value. Other fair value-related disclosures are given in the relevant notes.

2. Summary of significant accounting policies

2.1 Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded by the Company at their respective functional currency spot rates at the date, the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date. Exchange differences arising on settlement or translation of monetary items are recognised in the statement of profit and loss.

Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the initial transaction.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.

The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in other comprehensive income ("OCI") or profit or loss are also recognised in OCI or profit or loss, respectively).

2.2 Property plant and equipment

The cost of an item of property, plant and equipment are recognized as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

Items of property, plant and equipment (including capital-work-in progress) are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.

Cost includes expenditures that are directly attributable to the acquisition of the asset i.e., freight, non-refundable duties and taxes applicable, and other expenses related to acquisition and installation.

The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the company and the cost of the item can be measured reliably.

Depreciation

Depreciation on items of PPE is provided on straight line basis, computed on the basis of useful lives as mentioned in Schedule II to the Companies Act, 2013. Depreciation on additions / disposals is provided on a pro-rata basis i.e. from / up to the date on which asset is ready for use / disposed off.

The estimated useful lives are as follows:

Type of Asset	Useful life in years
Land	Non depreciable asset
Factory Building	30
Plant & Machinery	20
Testing Equipment	20
Furniture & Fixtures	10
Electrical Fittings	10
Motor Vehicles	8
Computers	3
Office equipment	20
Air Conditioner	15

The residual values, useful lives and method of depreciation are reviewed at each financial year end and adjusted prospectively, if appropriate.

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The carrying amount of the replaced part will be derecognized. The costs of repairs and maintenance are recognized in the statement of profit and loss as incurred.

Items of stores and spares that meet the definition of Property, plant and equipment are capitalized at cost, otherwise, such items are classified as inventories.

Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date is disclosed as capital advances under other assets. The cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress.

2.3 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

a. Financial assets

Initial recognition and measurement

All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the marketplace (regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the assets.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Debt instruments at amortized cost.
- Debt instruments at fair value through other comprehensive income (FVTOCI).
- Debt instruments, derivatives and equity instruments at fair value through profit or loss (FVTPL).
- Equity instruments measured at fair value through other comprehensive income (FVTOCI)

Debt instruments at amortized cost

A “debt instrument” is measured at the amortized cost, if both of the following conditions are met: (i) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and (ii) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate (EIR) method. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortization is included in finance income in the statement of profit and loss. The losses arising from impairment are recognized in the statement of profit and loss. This category generally applies to trade and other receivables.

Debt instrument at FVTOCI

A „debt instrument“ is classified as FVTOCI, if both of the following criteria are met: (i) The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and (ii) The asset’s contractual cash flows represent SPPI.

Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in OCI. However, the Company recognizes interest income, impairment losses and foreign exchange gain or loss in the statement of profit and loss. On de-recognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from the equity to statement of profit and loss.

Interest earned whilst holding FVTOCI debt instrument is reported as interest income using the EIR method.

Debt instrument at FVTPL

FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as FVTPL. Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Equity Instruments

All equity investments in the scope of Ind AS 109 are measured at fair value. Equity instruments which are held for trading are classified as FVTPL. If the Company decides to classify an equity instrument as FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to statement of profit and loss. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the statement of profit and loss.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company's balance sheet) when:

- a) The rights to receive cash flows from the asset have expired, or
- b) The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a „pass-through“ arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred assets and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Impairment of Financial Assets

The company assesses at each balance sheet date whether a financial asset or a group of financial assets is impaired.

In accordance with Ind AS 109, the company uses “Expected Credit Loss” (ECL) model, for evaluating impairment of Financial Assets other than those measured at Fair Value Through Profit and Loss (FVTPL).

Expected credit losses are measured through a loss allowance at an amount equal to:

- The 12 months expected credit losses (expected credit losses that result from those default events on the financial instrument that are possible within 12 months after the reporting date);
- Full lifetime expected credit losses (expected credit losses that result from all possible default events over the life of the financial instrument)

The company follows a simplified approach for recognition of impairment loss allowance on trade receivables and under the simplified approach, the company does not track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECL at each reporting date right from its initial recognition. The company uses a provision matrix to determine impairment loss allowance on trade receivables. The provision matrix is based on its historically observed default rates over the expected life of trade receivable and is adjusted for forward looking estimates. At every reporting date, the historically observed default rates are updated

For other assets, the company uses 12-month ECL to provide for impairment loss where there is no significant increase in credit risk. If there is a significant increase in credit risk full lifetime ECL is used.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value i.e., loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts, financial guarantee contracts.

Subsequent measurement

The measurement of financial liabilities depends on their classification.

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as fair value through profit or loss. Financial liabilities are classified as being held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading, unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognised in the statement of profit and loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied. For liabilities designated as FVTPL, fair value gains/losses attributable to changes in

own credit risk are recognized in OCI. These gains/ losses are not subsequently transferred to the statement of profit and loss.

However, the Company may transfer the cumulative gain or loss within equity. All other changes in the fair value of such liability are recognised in the statement of profit and loss.

Loans and borrowings

After initial recognition, interest-bearing borrowings are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in the statement of profit and loss when the liabilities are derecognised as well as through the EIR amortization process. Amortized cost is calculated by considering any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

De-recognition

Financial liability is derecognized when the obligation under the liability is discharged or cancelled or expired. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Reclassification of financial assets and liabilities

The Company determines classification of financial assets and liabilities on initial recognition. After initial recognition, no re-classification is made for financial assets which are equity instruments and financial liabilities. For financial assets, which are debt instruments, a re-classification is made only if there is a change in the business model for managing those assets. A change in the business model occurs when the Company either begins or ceases to perform an activity that is significant to its operations. If the Company reclassifies financial assets, it applies the re-classification prospectively from the re-classification date, which is the first day of the immediately next reporting period following the change in business model. The Company does not restate any previously recognised gains, losses (including impairment gains or losses) or interest.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet, if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

2.4 Cash & Cash Equivalents

Cash and bank balances comprise of cash balance in hand, in current accounts with banks, and other short-term deposits. For this purpose, "short-term" means investments having maturity of three months or less from the date of investment, and which are subject to an insignificant risk of change in value. Bank overdrafts that are repayable on demand and form an integral part of our cash management are included as a component of cash and cash equivalents for the purpose of the statement of cash flows.

2.5 Inventories

Inventories of all procured raw materials, spares and stores, consumables, supplies and loose tools are valued at the lower cost (on FIFO basis) and the net realisable value after providing for obsolescence and other losses, where considered necessary. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

The cost of raw material and packing materials includes all charges in bringing the goods to their present location and condition, including non-creditable taxes and other levies, transit insurance and receiving charges. However, these items are considered to be realisable at cost if the finished products, in which they will be used, are expected to be sold at or above cost.

The cost of finished goods and work-in-progress includes the cost of raw materials, packing materials, an appropriate share of fixed and variable production overheads, non-creditable duties and taxes as applicable and other costs incurred in bringing the inventories to their present location and condition. Fixed production overheads are allocated on the basis of normal capacity of production facilities.

2.6 Impairment of non-financial assets

The carrying amounts of the Company's non-financial assets, other than biological assets, investment property, inventories, contract assets and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment.

If any such indication exists, then the asset's recoverable amount is estimated.

For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year on March 31.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value for money and the risks specific to the asset or the cash-generating unit.

For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflow of other assets or groups of assets (the "cash-generating unit").

The Company bases its impairment calculations on detailed budgets and forecasts calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. These budgets and forecast calculations generally cover a period of five years. For longer periods, a long-term growth rate is calculated and applied to project future cash flow after the fifth year. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Company extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country in which the entity operates, or for the market in which the asset is used.

An impairment loss is recognized in the statement of profit and loss if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.

Reversal of Impairment of Assets

An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

2.7 Employee benefits

Short term employee benefits

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

Defined contribution plans

The Company's contributions to defined contribution plans are charged to the statement of profit and loss as and when the services are received from the employees.

Defined benefit plans

The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the statement of profit and loss in employee benefit expense, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the statement of profit and loss.

The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise. When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past

service or the gain or loss on curtailment is recognized immediately in the statement of profit and loss. The Company recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.

Termination benefits

Termination benefits are recognized as an expense in the statement of profit and loss when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the statement of profit and loss if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.

Other long-term employee benefits

The Company's net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognised in the statement of profit and loss in the period in which they arise.

Compensated absences

The Company's current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilised compensated absences and utilise them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary.

2.8 Provisions, contingent liabilities and contingent assets

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Expected future operating losses are not provided for.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to liability.

Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Contingent liabilities and contingent assets

A disclosure for contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of an outflow of resources is remote, no provision or disclosure is made.

Contingent assets are not recognized in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

Onerous contracts

A provision for onerous contracts is recognised in the statement of profit and loss when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognises any impairment loss on the assets associated with that contract.

Reimbursement rights

Expected reimbursements for expenditures required to settle a provision are recognised in the statement of profit and loss only when receipt of such reimbursements is virtually certain. Such reimbursements are recognised as a separate asset in the balance sheet, with corresponding credit to the specific expense for which the provision has been made.

2.9 Revenue recognition

Revenue from contracts with customers is recognised when control of the goods or services is transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

For contracts that permit the customer to return an item, revenue is recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur.

Therefore, the amount of revenue recognised is adjusted for expected returns, which are estimated based on the historical data. In these circumstances, a refund liability and a right to recover returned goods are recognised.

Revenue from the sale of goods is measured at the transaction price which is consideration received or receivable, net of returns, Goods and Service Tax (GST) and applicable trade discounts, allowances and chargeback. Revenue includes shipping and handling costs billed to the customer.

Services Income

Revenue is measured based on the consideration specified in a contract with a customer. Revenue is recognised at a point in time when the Company satisfies performance obligations by transferring the promised services to its customers.

2.10 Interest Income

Interest Income mainly comprises of interest on Margin money deposit with banks relating to bank guarantee and term deposits.

Interest income or expense is recognised using the effective interest method (EIR).

Interest is recognized using the time-proportion method, based on rates implicit in the transactions.

2.11 Tax Expenses

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in Other comprehensive income.

The Company has determined that interest and penalties related to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under Ind AS 37 Provisions, Contingent Liabilities and Contingent Assets.

Current tax

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction). Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions, where appropriate.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities and assets are recognized for all taxable temporary differences and deductible temporary differences.

Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax assets to be utilised.

Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside the statement of profit and loss is recognised outside the statement of profit and loss (either in OCI or in equity in correlation to the underlying transaction).

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum alternate tax (MAT) paid in a year is charged to the statement of profit and loss as current tax for the year. The deferred tax asset is recognised for MAT credit available only to the extent that it is probable that the Company will pay normal income tax during the specified year, i.e., the year for which MAT credit is allowed to be carried forward. In the year in which the Company recognizes MAT credit as an asset, it is created by way of credit to the statement of profit and loss and shown as part of deferred tax asset. The Company reviews the "MAT credit entitlement" asset at each reporting date and writes down the asset to the extent that it is no longer probable that it will pay normal tax during the specified period.

Goods and Service Tax (GST) paid on acquisition of assets or on incurring expenses

When the tax incurred on purchase of assets or services is not recoverable from the taxation authority, the tax paid is recognised as part of the cost of acquisition of the asset or as part of the expense item, as applicable. Otherwise, expenses and assets are recognized net of the amount of taxes paid. The net amount of tax recoverable from, or payable to, the taxation authority is included as part of receivables or payables in the balance sheet.

2.12 Earnings Per Share

Basic earnings per share

Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders (after deducting preference dividends and attributable taxes) by the weighted average number of equity shares outstanding during the year.

The weighted average number of equity shares outstanding during the year is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

Diluted earnings per share

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per share) after considering the effect of interest and other financing costs or income (net of attributable taxes) associated with dilutive potential equity shares by the weighted average number of equity shares considered for deriving basic earnings per share adjusted for the weighted average number of equity shares that would have been issued upon conversion of all dilutive potential equity shares.

2.13 Segment reporting

The Company is engaged in the " manufacture of Drug Intermediates & Bulk Dugs " and the same constitutes a single reportable business segment as per Ind AS 108. And hence segment reporting specified as per IND AS 108 is not applicable.

2.14 Share capital

Incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

2.15 Determination of fair values

The Company's accounting policies and disclosures require the determination of fair value, for certain financial and non-financial assets and liabilities. Fair values have been determined for

measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Property, plant and equipment

Property, plant and equipment, if acquired in a business combination or through an exchange of non-monetary assets, is measured at fair value on the acquisition date. For this purpose, fair value is based on appraised market values and replacement cost.

Inventories

The fair value of inventories acquired in a business combination is determined based on its estimated selling price in the ordinary course of business less the estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories.

Investments in equity and debt securities and units of mutual funds

The fair value of marketable equity and debt securities is determined by reference to their quoted market price at the reporting date. For debt securities where quoted market prices are not available, fair value is determined using pricing techniques such as discounted cash flow analysis. In respect of investments in mutual funds, the fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors. Accordingly, such net asset values are analogous to fair market value with respect to these investments, as transactions of these mutual funds are carried out at such prices between investors and the issuers of these units of mutual funds.

2.16 New standards adopted by the company

Ind AS 1 – Presentation of financial information

The amendments require companies to disclose their material accounting policies rather than their significant accounting policies. Accounting policy information, together with other information, is material when it can reasonably be expected to influence decisions of primary users of general purpose financial statements. The Company does not expect this amendment to have any significant impact in its financial statement.

Ind AS 12 – Income Taxes

The amendments clarify how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments narrowed the scope of the recognition exemption in paragraphs 15 and 24 of Ind AS 12 (recognition exemption) so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences. The Company does not expect this amendment to have any significant impact in its financial statements.

Ind AS 8 – Accounting Policies, Changes in Accounting Estimates and Errors

The amendments will help entities to distinguish between accounting policies and accounting estimates. The definition of a change in accounting estimates has been replaced with a definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty”. Entities develop accounting estimates if accounting policies require items in Restated financial information to be measured in a way that involves measurement uncertainty. The company does not expect this amendment to have any significant impact in its financial statements.

2.17 New Accounting pronouncements

Ministry of Corporate Affairs (“MCA”) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

VINEET LABORATORIES LIMITED

CIN:L24304TG2016PLC112888

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.

(All amounts are in INR Lakh except share data or unless otherwise stated)

Balance sheet as at March 31, 2025			
	Particulars	As at March 31, 2025(Audited)	As at March 31, 2024(Audited)
I	ASSETS		
	1 Non-current assets		
	(a) Property, plant and equipment	2,545.88	2,691.53
	(b) Financial assets		
	(i) Investments	20.63	18.16
	(ii) Others	80.69	141.95
	(c) Other non-current assets	67.43	16.74
		2,714.64	2,868.38
	2 Current assets		
	(a) Inventories	4,997.06	4,939.37
	(b) Financial assets		
	(i) Trade receivables	1,324.71	3,160.39
	(ii) Cash and cash equivalents	30.68	22.78
	(iii) Other bank balances	36.23	21.23
	(iv) Other financial assets	-	5.86
	(c) Other current assets	350.71	669.18
		6,739.38	8,818.81
	Total assets	9,454.01	11,687.19
II	EQUITY AND LIABILITIES		
	1 Equity		
	(a) Equity share capital	921.90	921.90
	(b) Other equity	542.86	2,550.53
		1,464.76	3,472.43
	2 Liabilities		
(i)	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	378.59	388.57
	(b) Provisions	80.43	80.62
	(c) Deferred tax liabilities (Net)	91.34	145.94
		550.36	615.13
(ii)	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	3,626.12	4,041.39
	(ii) Trade payables		
	- total outstanding dues of micro and small enterprises;	621.99	1,450.47
	- total outstanding dues of creditors other than micro and small enterprises	2,739.22	1,775.30
	(iii) Other financial liabilities	5.22	40.81
	(b) Other current liabilities	402.56	232.97
	(c) Provisions	43.78	46.46
	(d) Current tax liabilities (net)	-	12.23
		7,438.89	7,599.63
	Total liabilities	7,989.25	8,214.77
	Total equity and liabilities	9,454.01	11,687.19

The accompanying notes form an integral part of these financial statements.

This is the Statement of Changes in Equity referred to in our report of even date.

for NSVR & Associates LLP

Chartered Accountants

Firm Regn No:008801S/S200060

V Gangadhara Rao N

Partner

Membership Number: 219486

UDIN: 25219486BMIRWX3703

Place: Hyderabad

Date: 12-05-2025

For and on behalf of the Board of Directors of

Vineet Laboratories Limited**G. Venkata Ramana**

Managing Director

DIN: 00031873

B. Satyanarayana Raju

Whole-time Director and CFO

DIN: 02697880

Ramesh Kumar Bandari

Company Secretary & Compliance Officer

M.No : A24519

Vineet Laboratories Limited
CIN:L24304TG2016PLC112888

Statement of Profit and Loss for the year ended 31 March 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

Particulars	Notes	For the year ended	
		Monday, March 31, 2025	Sunday, March 31, 2024
Income			
Revenue from operations	20	7,499.50	15,059.13
Other income	21	198.68	46.32
Total income		7,698.18	15,105.44
Expenses			
Cost of material consumed	22	6,376.84	13,170.41
Changes in inventories of stock-in-trade	23	647.00	(1778.50)
Employee benefits expense	24	533.58	638.47
Finance costs	25	397.76	478.10
Depreciation and amortisation expense	26	250.16	251.90
Other expenses	27	1,570.39	2,308.72
Total expenses		9,775.73	15,069.11
Profit Before Tax		(2077.55)	36.34
Tax expenses			
Current tax expense	28	-	12.23
Deferred tax expense		(58.45)	(59.89)
Taxes in respect of prior periods		-	(18.71)
Total tax expenses		(58.45)	(66.37)
Profit for the year		(2019.10)	102.71
Other Comprehensive Income ('OCI')			
(i) Items that will not be reclassified subsequently to profit or loss			
Re-measurement gains/(losses) on defined benefit plans		15.29	1.85
Income tax effect on the above		(3.85)	(0.47)
(ii) Items that will be reclassified subsequently to profit or loss			
Total other comprehensive income		11.44	1.38
Total comprehensive income for the year		(2007.67)	104.09
Earnings per equity share (EPES)			
Basic EPS	24	(21.90)	1.11
Diluted EPS		(21.90)	1.11
Nominal value per equity share		10.00	10.00

The accompanying notes form an integral part of these financial statements.
This is the Statement of Profit and Loss referred to in our report of even date

for NSVR & Associates LLP
Chartered Accountants
Firm Regn No:008801S/S200060

V Gangadhara Rao N
Partner
Membership Number: 219486
UDIN: 25219486BMIRWX3703

Place: Hyderabad
Date: 12-05-2025

For and on behalf of the Board of Directors of
Vineet Laboratories Limited

G. Venkata Ramana
Managing Director
DIN: 00031873

B. Satyanarayana Raju
Whole-time Director and CFO
DIN: 02697880

Ramesh Kumar Bandari
Company Secretary & Compliance Officer
M.No : A24519

Vineet Laboratories Limited
CIN:L24304TG2016PLC112888
Cash Flow Statement for the year ended 31 March 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

	For the year ended	
	31 March 2025	31 March 2024
Cash flows from operating activities		
Profit before tax	(2,077.55)	36.34
Adjustments:		
Finance costs	397.76	478.10
Interest income	198.68	(46.32)
Change in fair value of financial assets at FVTPL	(2.47)	(4.81)
Depreciation and amortisation expenses	250.16	251.90
Foreign exchange (gain)/loss, net	(0.42)	(0.68)
Operating profit before working capital changes	(1,233.84)	714.52
Movements in working capital:		
Trade receivables	1,835.68	355.92
Inventories	(57.69)	(321.99)
Other current assets	318.47	(154.20)
Other non current assets	-50.69	13.87
Other financial assets	67.12	(14.77)
Trade payables	135.86	(262.99)
Provisions	12.41	19.45
Other liabilities	169.59	(999.76)
Other financial liabilities	(35.59)	14.12
Cash flows generated from operating activities	1,161.32	(635.81)
Income-taxes paid	(12.23)	(25.28)
Net cash flows generated from operating activities	1,149.09	(661.09)
Cash flows from investing activities		
Purchase of property, plant and equipment	(104.51)	(278.87)
Interest received	(198.68)	46.32
Movement in other bank balances	(15.00)	10.37
Net cash used in investing activities	(318.19)	(222.18)
Cash flows from financing activities		
Proceeds from long-tem borrowings	20.00	518.80
Repayment of long-tem borrowings	(63.39)	(587.33)
Proceeds from short-tem borrowings	(381.85)	1,389.61
Interest paid	(397.76)	(478.10)
Net cash used in financing activities	(823.01)	842.98
Net change in cash and cash equivalents	7.90	(40.29)
Cash and cash equivalents at the beginning of the year	22.78	63.07
Cash and cash equivalents at the end of the year	30.68	22.78
	As at	
	31 March 2025	31 March 2024
Cash and cash equivalents includes:		
Cash on hand	9.58	9.98
Balances with banks in current accounts	21.09	12.80
Cash and cash equivalents at end of the year	30.68	22.78

The accompanying notes form an integral part of these financial statements.

This is the Cash Flow Statement referred to in our report of even date.

for NSVR & Associates LLP
Chartered Accountants
Firm Regn No:008801S/S200060

V Gangadhara Rao N
Partner
Membership Number: 219486
UDIN: 25219486BMIRWX3703

Place: Hyderabad
Date: 12-05-2025

For and on behalf of the Board of Directors of
Vineet Laboratories Limited

G. Venkata Ramana
Managing Director
DIN: 00031873

B. Satyanarayana Raju
Whole-time Director and CFO
DIN: 02697880

Ramesh Kumar Bandari
Company Secretary & Compliance Officer
M.No : A24519

Vineet Laboratories Limited**Statement of Changes in Equity for the year ended 31 March 2025**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

A Equity share capital

	Notes	No. of shares	Amount
As at 01 April 2023		10,810,000	921.90
Changes in equity share capital	11	-	-
As at 31 March 2024		10,810,000	921.90
Changes in equity share capital	11	-	-
As at 31 March 2025		10,810,000	921.90

B Other equity

	Reserves and surplus		Other comprehensive income ("OCI")	Total
	Retained Earnings	Capital Reserve	Re-measurement gains/ (losses) on defined benefit plans net of tax	
As at 01 April 2023	1,324.03	1,108.95	13.46	2,446.44
Profit for the year	102.71	-	-	102.71
Less: Dividend paid	-	-	-	-
Other comprehensive income, net of taxes	-	-	1.38	1.38
As at 31 March 2024	1,426.73	1,108.95	14.84	2,550.54
Profit for the year	(2,019.10)	-	-	(2,019.10)
Other comprehensive income, net of taxes	-	-	11.44	11.44
As at 31 March 2025	(592.37)	1,108.95	26.28	542.87

The accompanying notes form an integral part of these financial statements.

This is the Statement of Changes in Equity referred to in our report of even date.

for NSVR & Associates LLP

Chartered Accountants

Firm Regn No:008801S/S200060

V Gangadhara Rao N

Partner

Membership Number: 219486

UDIN: 25219486BMIRWX3703

Place: Hyderabad

Date: 12-05-2025

For and on behalf of the Board of Directors of

Vineet Laboratories Limited**G. Venkata Ramana**

Managing Director

DIN: 00031873

B. Satyanarayana Raju

Whole-time Director and CFO

DIN: 02697880

Ramesh Kumar Bandari

Company Secretary & Compliance Officer

M.No : A24519

Vineet Laboratories Limited
Summary of material accounting policies and other explanatory information
 (All amounts are in INR Lakhs except share data or unless otherwise stated)

3 Property, plant and equipment

Particulars	Land	Factory building	Plant & machinery	Testing equipment	Furniture & fixtures	Electrical fittings	Vehicles	Office equipment	Computer	Air conditioner	Total
Balance as at 01 April 2023	12.25	459.50	3,573.71	84.16	32.44	95.86	381.26	14.24	30.32	1.47	4,685.21
Additions during the year	-	17.51	234.68	1.04	-	-	24.98	-	0.30	0.37	278.87
Disposals / adjustments during the year	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2024	12.25	477.01	3,808.39	85.20	32.44	95.86	406.24	14.24	30.62	1.84	4,964.08
Additions during the year	-	-	86.73	-	-	-	17.78	-	-	-	104.51
Disposals / adjustments during the year	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2025	12.25	477.01	3,895.12	85.20	32.44	95.86	424.02	14.24	30.62	1.84	5,068.59
Accumulated depreciation											
Up to 01 April 2023	-	152.76	1,503.60	48.23	16.93	81.72	181.72	8.76	26.16	0.76	2,020.64
Charge for the year	-	13.34	184.06	4.32	2.80	1.84	41.13	0.72	3.59	0.12	251.90
Deletions/Disposals	-	-	-	-	-	-	-	-	-	-	-
Up to 31 March 2024	-	166.09	1,687.66	52.55	19.72	83.56	222.85	9.48	29.74	0.88	2,272.54
Charge for the year	-	13.34	186.41	4.32	2.80	1.84	39.91	0.72	0.72	0.12	250.16
Deletions/Disposals	-	-	-	-	-	-	-	-	-	-	-
Up to 31 March 2024	-	179.43	1,874.07	56.87	22.52	85.40	262.76	10.20	30.46	0.99	2,522.71
Net book value											
As at 31 March 2024	12.25	310.91	2,120.73	32.65	12.71	12.30	183.39	4.76	0.87	0.96	2,691.53
As at 31 March 2025	12.25	297.58	2,021.05	28.33	9.92	10.45	161.26	4.04	0.15	0.84	2,545.88

Notes:

- (i) Title Deeds of immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) are held in the name of the Company.
 (ii) The Company has not revalued its Property, Plant and Equipment.

The accompanying notes form an integral part of these financial statements.

This is the Statement of Changes in Equity referred to in our report of even date.

for NSVR & Associates LLP

Chartered Accountants

Firm Regn No:008801S/S2000060

V Gangadhara Rao N

Partner

Membership Number: 219486

UDIN: 25219486BMIRWX3703

Place: Hyderabad

Date: 12-05-2025

For and on behalf of the Board of Directors of
Vineet Laboratories Limited

G. Venkata Ramana

Managing Director

DIN: 00031873

B. Satyanarayana Raju

Whole-time Director and CFO

DIN: 02697880

Ramesh Kumar Bandari

Company Secretary & Compliance Officer

M.No : A24519

Vineet Laboratories Limited

Notes to financial statements for the year ended 31 March 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
4 Investments		
Non-current		
In Quoted Mutual Funds	20.63	18.16
In other companies (quoted, traded) - measured at fair value through Profit or loss		
(21,469 units of Flexi cap mutual funds(regular) at the rate of Rs.96.10 each per units and Rs. 84.60 at 31 March 2024)		
	20.63	18.16
Aggregate value of quoted investments	20.63	18.16

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
5 Other financial assets		
(i) Non-current		
Unsecured, considered good		
Deposits with government and other agencies	80.69	141.95
	80.69	141.95
(ii) Current		
Unsecured, considered good		
Interest receivable	-	3.16
Other receivable	-	2.70
	-	5.86

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
6 Other assets		
(i) Non-current		
Unsecured and considered good		
Advances other than capital advances	6.32	16.74
Deposits with government and other agencies	61.11	
	67.43	16.74
(ii) Current		
Unsecured and considered good		
Advances to suppliers	24.52	262.91
Advances-others	154.30	139.46
Balances with statutory authorities	155.26	250.20
Preliminary expenses	16.61	16.61
	350.71	669.18

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
7 Inventories		
Raw material	2,321.64	1,616.95
Work in process	2,675.42	3,322.42
	4,997.06	4,939.37

7.1 Inventory includes slow-moving and obsolete inventory amounting to Rs. 7.12 crores in raw materials & work in progress.

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
8 Trade receivables		
Unsecured, considered good	1,324.71	3,160.39
Less: Allowance for expected credit loss	-	-
	1,324.71	3,160.39

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
(a) Trade receivables ageing:		
<i>Undisputed outstanding for following periods from due date of payment</i>		
(i) Not due	-	-
(ii) Less than 6 months	1,289.35	3,087.95
(iii) 6 months - 1 year	24.26	72.44
(iv) 1 - 2 years	11.09	-
(v) 2 - 3 years	-	-
(vi) More than 3 years	-	-
	1,324.71	3,160.39

There are no disputed receivables outstanding as at 31 March 2025 and 31 March 2024.

Vineet Laboratories Limited

Notes to financial statements for the year ended 31 March 2025

(All amounts are in INR Lakhs except share data or unless otherwise stated)

(b) Movement in the allowance for trade receivables for the period ended 31 March 2025 and 31 March 2024 is as follows:

	Monday, March 31, 2025	Sunday, March 31, 2024
Opening balance at beginning of the year	-	-
Provision made during the year	-	-
Bad debts written off during the year	-	-
Closing balance at end of the year	-	-

9 Cash and cash equivalents

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
Cash on hand	9.58	9.98
Balances with banks		
In current accounts	21.09	12.80
	30.68	22.78

10 Bank balances other than cash and cash equivalents

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
Margin money deposits with maturity more than 3 months but less than 12 months	36.23	21.23

11 (a) Equity share capital

	Monday, March 31, 2025		31 March 2024	
	Number	Amount	Number	Amount
Authorised share capital				
Equity shares of ₹10 each (31 March 2024: Equity shares of ₹10 each)	10,810,000	1,081.00	10,810,000	1,081.00
Issued share capital				
Equity shares of ₹10 each (31 March 2024: Equity shares of ₹10 each)	10,810,000	1,081.00	10,810,000	1,081.00
Subscribed and fully paid up				
Equity shares of ₹10 each (31 March 2024: Equity shares of ₹10 each)	9,219,008	921.90	9,219,008	921.90
	9,219,008	921.90	9,219,008	921.90

(i) Reconciliation of the number of equity shares outstanding at the beginning and at the end of the year:

	Monday, March 31, 2025		31 March 2024	
	Number	Amount	Number	Amount
Equity shares of ₹10 each (31 March 2024: Equity shares of ₹10 each)				
Balance at the beginning of the year	9,219,008	921.90	9,219,008	921.90
Add: Shares issued during the year	-	-	-	-
Balance at the end of the year	9,219,008	921.90	9,219,008	921.90

(ii) Rights, preferences and restrictions attached to equity shares:

The Company has only one class of issued, subscribed and paid up equity shares having a par value of ₹10 each per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividend in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the Annual General Meeting, except in case of interim dividend. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(iii) Details of shareholders holding more than 5% shares in the Company:

Name of the equity shareholders	Monday, March 31, 2025		31 March 2024	
	Number	% holding	Number	% holding
Venkata Ramana Gaddam	1,378,168	14.95%	1,378,168	14.95%
Satyanarayana Raju Bhupathiraju	519,487	5.63%	519,487	5.63%

(iv) Details of shareholding of promoters:

Name of promoter *	Monday, March 31, 2025		31 March 2024	
	Number	% holding	Number	% holding
Satyanarayana Raju Bhupathiraju	519,487	5.63%	519,487	5.63%
V Varaprasada Rao	162,083	0.20%	162,083	1.76%
A Srinivasa Raju	254,972	2.77%	254,972	2.77%
A Ranga Raju	192,093	2.08%	192,093	2.08%
A Prabhakar Raju	357,205	3.87%	357,205	3.87%
Alluri Maithili	204,521	2.22%	204,521	2.22%
Venkata Ramana Gaddam	1,378,168	14.95%	1,378,168	14.95%
Alluri Anantha Laxmi	165,891	1.80%	165,891	1.80%
Murali Mohan Kandula	115,746	0.01%	115,746	1.26%
Penmetsa Venkata Krishnam Raju	85,988	0.93%	85,988	0.93%
P Kishore Raju	74,312	0.81%	74,312	0.81%
Gaddam Srinivasarao	36,233	0.39%	36,233	0.39%
Gaddam Balaji	16,993	0.18%	16,993	0.18%

* Details of promoters are identified based on information submitted in the Annual Returns, filed in accordance with the provisions of Section 92 of the Companies Act, 2013.

(v) The Company has neither bought back any shares nor issued any bonus shares or shares for consideration other than cash during the period of five years immediately preceding the reporting date.

Vineet Laboratories Limited

Summary of significant accounting policies and other explanatory information

(All amounts are in INR Lakhs except share data or unless otherwise stated)

12 Other equity

	As at	
	31 March 2025	31 March 2024
Reserve and surplus		
Opening balance	1,426.73	1,324.03
Profit for the year	(2,019.10)	102.71
Less: Dividend paid	-	-
Closing balance	(592.37)	1,426.73
Capital reserve		
Balance as at the beginning of the year	1,108.95	1,108.95
Addition during the year	-	-
Closing balance	1,108.95	1,108.95
Other items of OCI		
Balance as at the beginning of the year	14.84	13.46
Re-measurement gains/ (losses) on defined benefit plans net of tax	11.44	1.38
Closing balance	26.28	14.84
	542.86	2,550.53

Retained earnings

Retained earnings are the profits that the Company has earned till date, less any dividends or other distribution to the shareholders.

Capital Reserve

The company recognise the profit on demerger from Ortin laboratories Limited to capital reserve.

Re-measurement gains/ (losses) on defined benefit plans

Remeasurements of the net defined benefits plan reserve comprises the cumulative net gains/ losses on actuarial valuation of post-employment obligations.

Notes to financial statements for the year ended 31 March 2025
(All amounts are in INR Lakhs except share data or unless otherwise stated)

13 Borrowings**(i) Non-Current****Secured**

Term loans from Banks
Vehicle loans from banks

Unsecured

Loans from directors

(ii) Current**Secured**

Loans repayable on demand from banks
Current maturities of non current borrowings

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
	278.74	315.95
	29.31	37.38
	-	-
	70.54	35.24
	378.59	388.57
	3,527.54	3,909.39
	98.58	132.00
	3,626.12	4,041.39

13.1 Terms of loans from bank

Bank	Sanctioned Amount	Rate of Interest (per annum)	Security	Repayment	Amount Outstanding as at 31 March 2025
HDFC Bank- Bus	17.80	8.02	Hypothecation of Motor Vehicle	Repayable in 48 monthly installments of Rs. 0.43 Lakh in each installment (Starts from August 05, 2021 to July 05, 2025)	1.71
HDFC Bank- DCM Eicher	16.00	8.01	Hypothecation of Motor Vehicle	Repayable in 48 equal monthly installments of Rs. 0.39 Lakh (Starts from June 15, 2022 to May 15, 2026)	5.20
Yes bank- Volvo	56.00	7.83	Hypothecation of Motor Vehicle	Repayable in 60 equal monthly installments of Rs. 1.13 lakh each (Starts from January 15, 2021 to December 15, 2025)	9.84
HDFC Bank - Term loan	499.97	7.55%	Hypothecation of Plant & Machineries, Debtors, Stock, Capex LC Margin	Repayable in 84 monthly installments of Rs. 7.79 lakh each (Starts from September 07, 2022 to August 07, 2029)	346.96
HDFC Bank- CRETA	17.78	7.25%	Hypothecation of Motor Vehicle	Repayable in 48 monthly installments of Rs. 0.43 lakh each (Starts from February 05, 2022 to January 05, 2026)	4.14
HDFC Bank- DCM Ashok layland	28.80	801.00%	Hypothecation of Motor Vehicle	Repayable in 58 equal monthly installments of Rs. 0.61 Lakh (Starts from November 05, 2023 to August 05, 2028)	21.61
HDFC Bank - Bus Loan	20.00	4.72%	Hypothecation of Plant & Machineries, Debtors, Stock, Capex LC Margin	Repayable in 48 equal monthly installments of Rs. 0.50 Lakh (Starts from August 15, 2024 to July 15, 2028)	17.17

13.2 The Company has been sanctioned a working capital limit in excess of ₹50 million, by a bank on the basis of security of current assets. Pursuant to the terms of the sanction letter and its subsequent revisions, the Company was required to furnish a statement till quarter ended 31 March 2025.

- (a) Loan from directors and other related parties are interest free, unsecured and are repayable on demand.
- (b) Changes in liabilities arising from financing activities:

	As at	Cashflows	Others	As at
	Monday, April 1, 2024			Monday, March 31, 2025
Term loans from Banks (including current maturities)	485.33	(78.69)	-	406.64
Loans from directors	35.24	35.30	-	70.54
Loans repayable on demand from banks	3,909.39	(381.85)	-	3,527.54
	4,429.96	(425.25)	-	4,004.71
	As at	Cashflows	Others	As at
	Saturday, April 1, 2023			Sunday, March 31, 2024
Term loans from Banks (including current maturities)	562.86	(77.53)	-	485.33
Loans from directors	26.24	9.00	-	35.24
Loans repayable on demand from banks	2,519.78	1,389.61	-	3,909.39
	3,108.88	1,321.08	-	4,429.96

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

	As at	
	Monday, March 31, 2025	Sunday, March 31, 2024
17 Other financial liabilities		
Electricity charges payable	5.07	31.69
Expenses payable	0.15	9.13
	5.22	40.81
18 Other current liabilities		
Advances from customers	101.00	19.55
Statutory dues payables	130.14	113.23
Salaries and wages payable	122.20	78.90
Directors remuneration payable	49.22	21.29
	402.56	232.97
19 Current tax liabilities (net)		
Provision for tax, net of advance taxes	-	12.23
	-	12.23
20 Revenue from operations	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Sale of manufactured goods		
Domestic	6,977.01	14,719.42
Sale of Services	522.49	339.71
	7,499.50	15,059.13
21 Other Income	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Interest income	-	3.54
Foreign exchange gain, net	0.42	0.68
Gain on Remeasurement of investments at FVTPL	2.47	4.81
Sale of Engineering materials	190.03	36.06
Other miscellaneous income	5.75	1.23
	198.68	46.32
22 Cost of Material Consumed	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Raw Material Consumed		
Raw materials at the beginning of the year	1,616.95	3,073.46
Add: Purchases During the year	7,081.52	11,713.90
Less: Raw materials at the end of the year	(2321.64)	(1616.95)
	6,376.84	13,170.41
22.1	The cost of material consumed includes a write-down of Rs. 7.12 crores on account of obsolete and slow-moving inventory identified during physical verification.	
23 Changes in inventories of work-in-progress	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Opening stock	3,322.42	1,543.91
Less: Closing stock	(2675.42)	(3322.42)
	647.00	-1,778.50
24 Employee benefits expense	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Salaries and wages	463.69	541.38
Contribution to provident fund and others	25.27	31.33
Gratuity expenses	15.34	16.00
Leave encashment expenses	(2.93)	3.45
Staff welfare expenses	32.20	46.31
	533.58	638.47

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

24.1 An excess provision made towards leave encashment expenses in the FY 2023-24 has been reversed during the year. As a result, the current FY 2024-25 leave encashment expenses show a negative balance of ₹2.93 lakhs.

25 Finance costs

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Interest on term loans	48.28	71.14
Interest on working capital loan	334.79	313.78
Other borrowing cost	14.69	93.18
	397.76	478.10

26 Depreciation and amortisation expense

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Depreciation on property, plant and equipment	250.16	251.90
	250.16	251.90

27 Other expenses

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Power and fuel	399.47	629.58
Labour wages	371.76	452.23
Repairs and maintenance	283.76	413.71
Freight & transportation	158.56	246.64
Jobwork charges	100.75	277.54
Security charges	68.69	76.75
Consumption of stores	66.77	19.04
Pollution & Prevention Charges	27.16	8.33
Insurance	21.34	28.19
Legal & professional charges	21.19	56.34
Telephone & communication expenses	8.40	5.84
Travelling & conveyance expenses	7.52	15.91
Rates and taxes	6.77	14.32
Audit fees	6.00	6.00
Printing & stationery	4.24	11.93
Director sitting fees	3.75	4.50
Rent	3.45	3.94
Subscriptions & renewables	2.56	2.33
Farmers Compensation - Malkapur	0.70	23.20
Sales & business promotion	0.49	5.91
Miscellaneous expenses	7.07	6.49
	1,570.39	2,308.72

(i) Details of payments to auditors:

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
As auditor:		
-Statutory audit fees	4.00	4.00
- Tax audit fee	2.00	2.00

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

28 Tax expense

The Company has elected the option provided under Section 115BAA of the Income-tax Act, 1961 for measurement of its income tax expense for the period ended 31 March 2025 and 31 March 2024 and has accordingly recognised the income tax expense at the prescribed domestic effective tax rate of 25.17% (31 March 2023 : 25.17%). The major components of income tax expense and the reconciliation between expected tax expense based on the domestic effective tax rate and the reported tax expense in the statement of profit and loss is as follows:

(i) Income tax expense reported in the Standalone Statement of Profit and Loss

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Current tax expense	-	12.23
Deferred tax expense	(58.45)	(59.89)
Taxes in respect of prior periods	-	(18.71)
	(58.45)	(66.37)

(ii) Reconciliation of effective tax rate :

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Profit before tax	(2,077.55)	36.34
Statutory income tax rate	25.17%	25.17%
Expected tax expense	-	9.15
<i>Tax effect of amounts which are not deductible / taxable in calculating taxable income:</i>		
Effect of expenses not deductible under the IT Act, 1961	12.41	23.94
Effect of expenses relating to origination and reversal of temporary differences under the IT Act, 1961	-	-
Adjustment for current tax in respect of prior periods	-	(18.71)
Other adjustments	(70.86)	(80.74)
Income tax expense	(58.45)	(66.37)

29 Earnings per equity share (EPES)

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
Profit for the year	(2,019.10)	102.71
Weighted average number of equity shares outstanding during the year	9,219,008	9,219,008
Earnings per equity share (in absolute ₹ terms):		
Basic and Diluted EPES	(21.90)	1.11
Nominal value per equity share	10.00	10.00

30 Related party disclosures**(a) Names of the related parties and nature of relationship**

Names of related parties	Nature of relationship
Satyanarayana Raju Bhupathiraju V Varaprasada Rao A Srinivasa Raju A Ranga Raju A Prabhakar Raju Alluri Maitihili Venkata Ramana Gaddam Murali Mohan Kandula Penmetsa Venkata Krishnam Raju Gaddam Srinivasarao Gaddam Balaji	Promoters
Gaddam Venkata Ramana Satyanarayana Bhupathiraju Kandula Murali Mohan Ramesh Kumar Bandari (With effective from 10th November, 2023) Nirosha Ravikanti (Effective till 28th October, 2023) Dilip Vishnu Achrekar Bhaskar Reddy Karna Hari Priya Yerukalapudi Dr. Satish Panduranga Samant A. Ranga Raju Thotakura Uma Sangeetha	Key Managerial Personnel ("KMP")
Wohler Laboratories Private Limited Vineet Life sciences Private Limited Organo Metalics Private Limited Wohler Laboratories Private Limited Vineet Chem Trade Private Limited	Entities in which KMP's or their relatives exercises control / has significant influence

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

(b) Transactions with related parties

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
(i) Revenue from sale of products		
Vineet Life Sciences Private Limited	2,432.54	5,051.38
Vineet Chem Trade Private Limited	-	-
Organo Metalics Private Limited	1,325.18	1,440.76
(ii) Remuneration expense		
G. Venkata Ramana	51.00	51.00
K.Murali Mohan	-	-
Bh. Satyanarayana Raju	39.00	39.00
Nirosha Ravikanti	-	1.75
Dr.Satish Panduranga Samant	12.00	33.10
Ramesh Kumar Bandari	-	1.17
(iii) Sitting fee expense		
K. Bhaskar Reddy	0.75	1.25
T. Umasangeeta	-	-
Dilip Achrekar	1.00	1.25
Hari Priya Yerukalapudi	1.00	1.25
A.Ranga raju	1.00	0.75
(iii) Purchases		
Vineet Life Sciences Private Limited	1,791.35	4,145.29
Wohler Laboratories Private Limited	-	213.89
Organo Metalics Private Limited	2,355.87	997.51
Vineet Chem Trade Private Limited	-	-

30 Related party disclosures (cont'd)**(c) Balance receivable / (payable)**

	For the year ended	
	Monday, March 31, 2025	Sunday, March 31, 2024
(i) Trade receivables		
Vineet Chem Trade Private Limited	-	-
Vineet Life Sciences Private Limited	910.51	2,065.99
Organo Metalics Private Limited	697.05	102.23
Wohler Laboratories Private Limited	-	-
(ii) Trade payables		
Wohler Laboratories Private Limited	(0.15)	(0.85)
(iii) Remuneration payable		
G. Venkata Ramana	(22.48)	(4.60)
Bh. Satyanarayana Raju	(15.74)	(6.50)
Dr.Satish Panduranga Samant	(11.00)	(10.20)
Nirosha Ravikanth	-	-
Ramesh Kumar Bandari	-	(0.50)
(iv) Sitting fee payable		
K. Bhaskar Reddy	-	-
Dilip Achrekar	-	-
T. Uma Sangeeta	-	-

31 Defined benefit plans

The Company has a defined benefit gratuity plan, according to which every employee who has completed five periods or more of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed period of service (service of six months and above is rounded off as one period) after deduction of necessary taxes at the time of retirement / exit, in accordance with Payment of Gratuity Act, 1972. The following tables summarize the reconciliation of opening and closing balances of the present value and defined benefit obligation:

	Monday, March 31, 2025	Sunday, March 31, 2024
(i) Reconciliation of present value of defined benefit obligation		
Defined benefit obligation at the beginning of the year	98.42	84.27
Current service cost	8.22	9.67
Interest cost	7.12	6.33
Benefits paid	-	-
Actuarial loss/(gain) recognised during the year	-	-
- due to demographic assumption	-	-
- due to change in financial assumptions	1.97	1.43
- due to experience	(17.26)	(3.28)
Defined benefit obligation at the end of the year	98.47	98.42
(ii) Reconciliation of fair value of plan asset		
Fair value of plan assets, beginning of the year	-	-
Interest on plan assets	-	-
Return on plan assets excluding interest income	-	-
Employer contribution	-	-
Benefits paid	-	-
Remeasurement due to - actual return on plan assets less interest on plan assets	-	-
Fair value of plan assets, at the end of the year	-	-

Vineet Laboratories Limited
Summary of significant accounting policies and other explanatory information
 (All amounts are in INR Lakhs except share data or unless otherwise stated)

	Monday, March 31, 2025	Sunday, March 31, 2024
(iii) Reconciliation of present value of defined benefit obligation and fair value of plan assets		
Present value of defined benefit obligation	98.47	98.42
Fair value of plan assets	-	-
Liability recognised in the Balance Sheet	98.47	98.42
Non current	34.25	35.37
Current	64.22	63.06
(iii) Expenses recognised in the Statement of profit and loss / OCI		
Monday, March 31, 2025 Sunday, March 31, 2024		
Recognised in statement of profit and loss		
Current service cost	8.22	9.67
Interest cost	7.12	6.33
	15.34	16.00
Recognised in statement of other comprehensive income		
Actuarial loss/(gain)	(15.29)	(1.85)
	(15.29)	(1.85)
(iv) Key actuarial assumptions		
Monday, March 31, 2025 Sunday, March 31, 2024		
Discount rate	6.82%	7.23%
Retirement age	60 years	60 years
Salary escalation rate	5.00%	5.00%
Withdrawal rate	5.0% to 7.0%	5.0% to 7.0%
Mortality rate	100% of IALM 2012-14	
The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.		
(v) Maturity profile of defined benefit obligation:		
Monday, March 31, 2025 Sunday, March 31, 2024		
Within 1 year	35.26	36.48
2 to 5 years	35.65	36.21
6 to 10 years	84.87	94.06
(vi) Sensitivity analysis		
Monday, March 31, 2025 Sunday, March 31, 2024		
Discount rate (+ 1% movement)	93.84	93.55
Discount rate (- 1% movement)	103.74	103.99
Salary escalation (+ 1% movement)	103.24	103.43
Salary escalation (- 1% movement)	94.23	94.00
(vii) Weighted average remaining duration of defined benefit obligation is 6 years (31 March 2024: 6 years)		

Leave Encashment

The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was Rs.25.73 Lakhs as at 31 March 2025 (Rs.28.66 Lakhs as at 31 March 2024).

Vineet Laboratories Limited

Summary of significant accounting policies and other explanatory information

(All amounts are in INR Lakhs except share data or unless otherwise stated)

32 Segment information

The Company is engaged in the in " manufacture of Drug Intermediates & Bulk Dugs " and the same constitutes a single reportable business segment as per Ind AS 108. And hence segment reporting specified as per IND AS 108 is not applicable.

33 Categories of Financial instruments and their fair values

The carrying amount of all financial assets and financial liabilities appearing in the financial statements are reasonable approximation of their fair values.

Categories of financial instruments

	As at 31 March 2025		As at 31 March 2024	
	Carrying value	Fair value/ amortised cost	Carrying value	Fair value/ amortised cost
Financial assets				
Investments	20.63	20.63	18.16	18.16
Trade receivables	1,324.71	1,324.71	3,160.39	3,160.39
Cash and bank balances	30.68	30.68	22.78	22.78
Others	116.92	116.92	169.04	169.04
	1,492.93	1,492.93	3,370.37	3,370.37
Financial liabilities				
Borrowings	4,004.71	4,004.71	4,429.96	4,429.96
Trade payables	3,361.21	3,361.21	3,225.77	3,225.77
Other financial liabilities	5.22	5.22	40.81	40.81
	7,371.15	7,371.15	7,696.54	7,696.54

The fair value of the financial assets and financial liabilities are included at an amount at which the instruments could be exchanged in a current transaction between the willing parties, other than in a forced or liquidation sale.

34 Financial risk management objectives and policies**Financial Risk Management Framework**

The Company is exposed to financial risks arising from its operations and the use of financial instruments. The key financial risks include credit risk, market risk and liquidity risk. The Company's risk management policies are established to identify and analyse the risks faced by the Company and seek to, where appropriate, minimize potential impact of the risk and to control and monitor such risks. There has been no change to the Company's exposure to these financial risks or the manner in which it manages and measures the risks.

The following sections provide details regarding the Company's exposure to the financial risks associated with financial instruments held in the ordinary course of business and the objectives, policies and processes for management of these risks.

A. Credit risk**Financial assets that are neither past due nor impaired**

None of the Company's cash equivalents, loans and other financial assets were either past due or impaired as at the respective reporting period. The Company has diversified its portfolio of investment in cash and cash equivalents and term deposits with various banks which have secure credit ratings, hence the risk is reduced. Loans given to related parties and others are tested for impairment where there is an indicator and the assessed credit risk associated with such loans is relatively low. Other financial assets represent security deposits given to lessors and other assets. Credit risk associated with such deposits and other assets is relatively low.

The Company's credit period for trade receivables from its customers generally ranges from 30 - 180 days. The ageing of trade receivables is given below:

	31 March 2025	31 March 2024
Neither past due nor impaired	-	-
<i>Past due but not impaired:</i>		
Less than 180 days	1,289.35	3,087.95
More than 180 days	35.36	72.44
	1,324.71	3,160.39
Less: Allowance for credit losses	-	-
	1,324.71	3,160.39

Ind AS requires expected credit losses to be measured through a loss allowance. The Company assesses at each balance sheet date whether a financial asset or a group of financial assets are impaired. Expected credit losses are measured at an amount equal to the 12 month expected credit losses or at an amount equal to the life time expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. The Company has used a practical expedient by computing the expected credit loss allowance for trade receivables based on a provision matrix if they past due. The provision matrix takes into account historical credit loss experience and is adjusted for forward-looking information.

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

35 Financial risk management objectives and policies (cont'd)**B. Liquidity risk**

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company manages liquidity risk by maintaining cash and cash equivalents and the cash flows generated from operations.

The table below summarises the maturity profile of the Company's financial liabilities based on contractual undiscounted payments:

As at 31 March 2025	Up to 1 year	More than 1 year	Total
Borrowings	3,626.12	378.59	4,004.71
Trade payables	3,361.21	-	3,361.21
Other financial liabilities	5.22	-	5.22
	6,992.55	378.59	7,371.14

As at 31 March 2024	Up to 1 year	More than 1 year	Total
Borrowings	4,041.39	388.57	4,429.96
Trade payables	3,225.77	-	3,225.77
Other financial liabilities	40.81	-	40.81
	7,307.97	388.57	7,696.54

C. Market risk:

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates will affect the Company's income. Market risk is attributable to all market risk sensitive financial instruments including foreign currency receivables and payables. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

i. Foreign currency risk:

Foreign currency risk is the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. The majority of Company's revenue is generated in foreign currencies (primarily in United States Dollars), while a significant portion of its costs are in Indian rupees. As a result, as the rupee appreciates or depreciates against foreign currencies, the results of the entity's operations are impacted. The Company does not use financial derivatives such as foreign currency forward contracts.

- (a) Significant unhedged foreign currency risk exposure relating to financial assets and financial liabilities expressed in ₹ terms are as follows:

	31 March 2025	31 March 2024
USD		
Trade receivables	0.22	0.22
Trade payables	180.95	51.20

- (b) Foreign currency sensitivity:

The following table demonstrates the sensitivity to a reasonably possible change in foreign currencies ('FC'), with all other variables held constant:

Foreign currency	Impact on profit after tax / equity for the year ended			
	Appreciation in FC by 5%		Depreciation in FC by 5%	
	31 March 2025	31 March 2024	31 March 2025	31 March 2024
USD	-9.04	-2.57	9.04	2.57

ii Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Company and the Company's financial instruments will fluctuate because of changes in market interest rates. The Company's exposure to interest rate risk relates primarily to the floating interest rate borrowings. The Company's investment in deposits with banks and loans are fixed interest rates and therefore do not expose the Company to significant interest rate risk.

The Company's exposure to changes in interest rates relates primarily to the Company's outstanding floating rate borrowings. The exposure of the Company to variable rate borrowings at the end of the reporting period are as follows:

	31 March 2025	31 March 2024
Variable rate borrowings	3,934.17	4,394.72

Interest rate sensitivity

The Company noted that any reasonably possible change in interest rates on the variable rate instruments will not have any material impact on the Company's profit after tax and its equity.

iii Price risk

The fair value of some of the Company's investments measured at fair value through other comprehensive income exposes the Company to equity price risks. These investments are subject to changes in the market price of securities. The Company periodically monitors the sectors it has invested in, performance of the investee companies, measures mark- to- market gains/losses and reviews the same to manage the price risk.

Sensitivity analysis as at 31 March 2025

	Cost	Fair value	Sensitivity to fair value	
			10% increase	10% decrease
Investment in Flexi cap mutual funds	3.00	20.63	2.06	(2.06)

Sensitivity analysis as at 31 March 2024

	Cost	Fair value	Sensitivity to fair value	
			10% increase	10% decrease
Investment in Flexi cap mutual funds	3.00	18.16	1.82	(1.82)

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

36 Capital risk management

Capital includes equity capital and all reserves attributable to the equity holders of the Company. The primary objective of the capital management is to ensure that it maintain an efficient capital structure and healthy capital ratios in order to support its business and maximise shareholder's value. The Company manages its capital structure and make adjustments to it, in light of changes in economic conditions or its business requirements. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders return capital to shareholders or issue new shares.

The Company monitors capital using a debt to capital employed ratio which is debt divided by total capital plus debt. The Company's policy is to keep this ratio at an optimal level.

	31 March 2025	31 March 2024
Debt	4,004.71	4,429.96
Less: Cash and cash equivalents	(30.68)	(22.78)
Net debt	3,974.04	4,407.18
Total equity	1,464.76	3,472.43
Capital and net debt	5,438.80	7,879.61
Net debt to equity ratio (%)	73.07%	55.93%

37 Revenue from contracts with customers

Set out below is the disaggregation of the Company's revenue from contracts with customers and reconciliation to profit and loss account:

	31 March 2025	31 March 2024
(i) Revenue from contracts with customers comprises of:		
Sale of products		
Manufactured	6,977.01	14,719.42
Traded	-	-
Sale of services	522.49	339.71
	7,499.50	15,059.13
(ii) Geographical markets		
India	7,499.50	15,059.13
Outside India	-	-
	7,499.50	15,059.13
(iii) Reconciling the amount of revenue recognised in the statement of profit and loss with the contracted price		
Revenue as per contract	7,499.50	15,059.13
Less: Adjustment for contracts where Company acts as an agent	-	-
	7,499.50	15,059.13
(iv) Timing of revenue recognition		
Services rendered over a point of time	522.49	339.71
Products transferred at a point in time	6,977.01	14,719.42
	7,499.50	15,059.13
(v) Assets and liabilities related to contracts with customers		
	31 March 2025	31 March 2024
Trade receivables	1,324.71	3,160.39
Contract assets	-	-
Contract liabilities	-	-

38 Additional disclosures

- (i) No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
- (ii) The Company have not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (iii) No transactions are carried out with companies struck off under Section 248 of the Act or Section 560 of Companies Act, 1956.
- (iv) The Company has complied with the number of layers prescribed under the Companies Act, 2013.
- (v) The Company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.
- (vi) There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.
- (vii) The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.
- (viii) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- (ix) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Vineet Laboratories Limited**Summary of significant accounting policies and other explanatory information**

(All amounts are in INR Lakhs except share data or unless otherwise stated)

- (x) The Company has been sanctioned a working capital limit in excess of ₹50 million, by a bank on the basis of security of current assets. Pursuant to the terms of the sanction letter and its subsequent revisions, the Company was required to furnish a statement till quarter ended 31 March 2025. The statements filed are in agreement with the books of account of the Company, except for the below instances. The differences as reported is mainly attributed to use of information extracted from books prior to book closures. Management has taken necessary steps to minimise such differences.

	Quarter ended 31 March 2025			Quarter ended 31 December 2024		
	Amount as per Books	Amount as reported to the lender	Variance	Amount as per Books	Amount as reported to the lender	Variance
Trade receivables	1,324.71	991.64	333.07	1,404.16	1,554.12	-149.97
Inventories	4,997.06	4,997.06	-	4,996.41	4,996.41	-
Trade payables	3,346.96	1,202.79	-2,144.17	2,760.88	1,800.10	-960.78

	Quarter ended 30 September 2024			Quarter ended 30 June 2024		
	Amount as per Books	Amount as reported to the lender	Variance	Amount as per Books	Amount as reported to the lender	Variance
Trade receivables	2,486.88	2,585.80	-98.92	2,766.60	2,882.05	-115.45
Inventories	5,100.27	5,100.27	-	5,150.76	5,150.76	-
Trade payables	3,031.51	2,227.96	803.55	2,961.17	2,551.25	409.92

- (xi) There are no charges or satisfaction which are yet to be registered with the registrar of companies beyond the statutory period.
- 39 The Ministry of Corporate Affairs (MCA) has prescribed a new requirement for companies under the proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 inserted by the Companies (Accounts) Amendment Rules 2021 requiring companies, which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled.

The Company, in respect of financial year commencing on 1 April 2023 has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log).

Vineet Laboratories Limited
Summary of significant accounting policies and other explanatory information
 (All amounts are in INR Lakhs except share data or unless otherwise stated)

40 Ratios as per the Schedule III requirements

Particulars	Monday, March 31, 2025	Sunday, March 31, 2024	% Change	Note
Current Ratio	0.91	1.16	-21.93%	a.
Debt Equity Ratio	2.73	1.28	114.31%	b.
Debt Service Coverage Ratio	-0.24	1.28	-119.06%	c.
Return on Equity	-81.79%	3.00%	-2823.90%	d.
Inventory Turnover Ratio	1.41	2.38	-40.70%	e.
Trade Receivables turnover ratio	3.34	4.51	-25.87%	f.
Trade Payables turnover ratio	2.63	4.18	-37.10%	g.
Net Capital Turnover Ratio	-10.72	12.35	-186.80%	h.
Net profit ratio	-26.92%	0.68%	-4047.59%	i.
Return on Capital employed	-94.66%	11.52%	-921.95%	j.

a. Current Ratio = Current assets divided by Current liabilities

Particulars	Monday, March 31, 2025	31 March 2024
Current assets	6,739.38	8,818.81
Current liabilities	7,438.89	7,599.63
Ratio	0.91	1.16
% Change from previous year	-21.93%	

Reason for change more than 25%: NA

b. Debt Equity ratio = Total debt divided by Shareholder's Equity where total debt refers to sum of current & non current borrowings

Particulars	Monday, March 31, 2025	31 March 2024
Total debt	4,004.71	4,429.96
Shareholder's Equity	1,464.76	3,472.43
Ratio	2.73	1.28
% Change from previous year	114.31%	

Reason for change more than 25%: The Decrease in ratio is mainly attributable to significant decrease in shareholder's equity made during the year.

c. Debt Service Coverage Ratio = Earnings available for debt service divided by interest and lease payments + principal repayments

Particulars	Monday, March 31, 2025	31 March 2024
Net Profit after tax	(2,019.10)	102.71
Add: Non cash operating expenses and finance cost		
-Depreciation and amortizations	250.16	251.90
-Finance cost	397.76	478.10
Earnings available for debt service	(1,371.18)	832.71
Interest cost on borrowings	397.76	478.10
Principal repayments for long-term borrowings	(63.39)	587.33
Total Interest and principal repayments	334.37	1,065.43
Ratio	-0.24	1.28
% Change from previous year	-119.06%	

Reasons for change more than 25%: The decrease in ratio is due to negative earnings available for debt service in the current year, driven by a net loss and reduced principal repayments.

d. Return on Equity Ratio / Return on Investment Ratio = Net profit after taxes divided by average shareholder's equity

Particulars	Monday, March 31, 2025	31 March 2024
Net profit after taxes	(2019.10)	102.71
Less: Preference dividend	-	-
Earning available to equity shareholders	(2019.10)	102.71
Average Shareholder's Equity	2468.60	3,420.39
Ratio	-81.79%	3.00%
% Change from previous year	-2823.90%	

Reason for change more than 25%: The decrease in ratio is due to a loss in current year compared to a profit in previous year, while average shareholder's equity decreased only marginally

e. Inventory Turnover Ratio = Cost of goods sold divided by average inventory

Particulars	Monday, March 31, 2025	31 March 2024
Cost of Inventory consumed	7,023.83	11,391.91
Average Inventory	4,968.21	4,778.38
Inventory Turnover Ratio	1.41	2.38
% Change from previous year	-40.70%	

Reason for change more than 25%: The decrease in ratio is due to reduction in the cost of inventory consumed in the current year, while average inventory levels remained relatively stable

f. Trade Receivables turnover ratio = Revenue from operations divided by Average Trade Receivables

Particulars	Monday, March 31, 2025	31 March 2024
Net Credit Sales	7,499.50	15,059.13
Average Trade Receivables	2,242.55	3,338.35
Ratio	3.34	4.51
% Change from previous year	-25.87%	

Reason for change more than 25%: The decrease in ratio is due to a decrease in net credit sales.

g. Trade Payables turnover ratio = Purchases of stock-in-trade and other expenses divided by average Trade Payables

Particulars	Monday, March 31, 2025	31 March 2024
Purchase of stock-in-trade	7,081.52	11,713.90
Other expenses (excluding other adjustments like allowance for trade receivables etc)	1,570.39	2,308.72
Total	8,651.92	14,022.62
Average Trade payables and provision for expenses	3,293.49	3,357.61
Ratio	2.63	4.18
% Change from previous year	-37.10%	

Reason for change more than 25%: The decline in ratio is due to reduction in total purchases and expenses in the current year, while average trade payables remained nearly constant

Vineet Laboratories Limited

Summary of significant accounting policies and other explanatory information

(All amounts are in INR Lakhs except share data or unless otherwise stated)

h. **Net Capital Turnover Ratio = Sales divided by Working Capital where Working Capital = Current Assets - Current Liabilities**

Particulars	Monday, March 31, 2025	31 March 2024
Revenue from operations	7,499.50	15,059.13
Working capital	-699.51	1,219.18
Ratio	(10.72)	12.35
% Change from previous year	-186.80%	

Reason for change more than 25%: The decrease in ratio is due to a negative working capital in the current year and a 50% drop in revenue, reversing the ratio from positive to negative

i. **Net profit ratio = Net profit after taxes divided by Net Sales**

Particulars	Monday, March 31, 2025	31 March 2024
Net profit after taxes	(2019.10)	102.71
Net Sales	7,499.50	15,059.13
Ratio	-26.92%	0.68%
% Change from previous year	-4047.59%	

Reason for change more than 25%: The decrease in ratio is due to a net loss in the current year compared to a profit in previous year, along with a 50% drop in net sales, significantly impacting profitability

j. **Return on Capital employed (pre cash)=Earnings Before Interest and Taxes (EBIT) divided by Capital Employed**

Particulars	Monday, March 31, 2025	31 March 2024
Profit before tax (A)	(2077.55)	36.34
Finance costs (B)	397.76	478.10
Other income (C)	198.68	46.32
EBIT (D) = (A)+(B)-(C)	(1878.47)	468.12
Capital Employed (Pre Cash) (J)= (E)-(F)-(G)	1,984.45	4,064.78
Total Assets (E)	9,454.01	11,687.19
Current liabilities (F)	7,438.89	7,599.63
Cash and Cash equivalents (G)	30.68	22.78
Ratio (D)/(J)	-94.66%	11.52%
% Change from previous year	-921.95%	

Reason for change more than 25%: The decrease in ratio is due to a significant negative EBIT in the current year, resulting from a substantial drop in profit before tax, coupled with reduction in capital employed

This is the notes to financial statements referred to in our report of even date.

for NSVR & Associates LLP

Chartered Accountants

Firm Regn No:008801S/S200060

V Gangadhara Rao N

Partner

Membership Number: 219486

UDIN: 25219486BMIRWX3703

Place: Hyderabad

Date: 12-05-2025

For and on behalf of the Board of Directors of

Vineet Laboratories Limited**G. Venkata Ramana**

Managing Director

DIN: 00031873

B. Satyanarayana Raju

Whole-time Director and CFO

DIN: 02697880

Ramesh Kumar Bandari

Company Secretary & Compliance Officer

M.No : A24519